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Environmental and dietary exposures alter disease risk 
Adult chronic illnesses, such as cancer, cardiovascular diseases and respiratory diseases 
account for the majority of deaths worldwide (1). Since the complete sequencing of the 
human genome, genes involved in disease susceptibility have been and will be 
distinguished, resulting in the improvement of predicting an individual’s risk on disease 
(2). Cancer affects millions of people worldwide and represents a major burden of disease. 
However, only 5-10 % of all cancers are caused by genetic defects, while 90-95 % is caused 
by environmental factors of which the diet is the most important one (30-35 %) (3). 
Throughout their life humans are constantly exposed to drugs and other foreign 
compounds. To prevent that these substances cause any damage, they are neutralized 
and excreted. Environmental genotoxicants and mutagens cause about 80 % of human 
malignancies (4). One important group of environmental contaminants are the polycyclic 
aromatic hydrocarbons (PAHs), which we are exposed to through inhalation of smoke 
from coal, wood, diesel fuel and tobacco; but also through ingestion of roasted, smoked or 
charbroiled foods. PAH can be metabolically activated to derivates that can damage our 
DNA, which is an important initiating event in carcinogenesis.  
Another important source of DNA damaging compounds are the so-called reactive oxygen 
species (ROS). Enhanced exposure to ROS is linked to the onset and propagation of 
different diseases, for instance neurodegenerative diseases (5-9), cardiovascular diseases 
(10, 11), diabetes (12) and cancer (13-15), but are also believed to contribute to aging 
(16). They are regularly produced by mitochondria as a consequence of the aerobic 
metabolism. For instance 1-5 % of total oxygen consumed in aerobic metabolism gives rise 
to superoxide anion radicals (O2
-•) (17, 18). However, ROS are also formed by microsomal 
CYP450, flavoprotein oxidase and peroxisomal enzymes involved in fatty acid metabolism. 
Besides, they play a crucial role as signal transducers to regulate cell proliferation and they 
are also involved in the destruction of invading pathogens (18). The negative outcomes of 
ROS are thought to be the result of an imbalance between the amount of antioxidants and 
ROS, termed oxidative stress (17). 
How can we protect ourselves against environmental exposure? Role of 
flavonoid supplementation 
It is well known that a healthy diet contributes to our protection against chronic diseases. 
One major dietary group of components that receives a lot of attention in the scientific 
literature, because of their potential protective effects, are the flavonoids. Dietary 
flavonoids comprise a large group of polyphenolic compounds widely distributed 
throughout the diet as they play a role in plant’s pigmentation and flavor (19). They have a 
common structure consisting of 3 phenolic rings defined as the A, B and C ring (Figure 1A). 
Depending on the oxidation level of the C ring flavonoids can be divided into 6 subclasses, 
namely flavones (apegenin, luteolin), flavonols (quercetin, kaempferol), flavanones 
(naringenin, hesperedin), flavanols (epicatechin, gallocatechin), anthocyanidins (malvidin, 
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cyanidin) and isoflavones (genistein, daidzein) (19-21). The daily dietary intake of mixed 
flavonoids in the human population ranges from 65 to 250 mg a day (22). 
The most predominant flavonoid in the human diet is the flavonol quercetin (Figure 1B), 
which is mainly found in onions, apples, tea and red wine (19, 20). The average daily 
dietary intake of quercetin is estimated to be in the range of 10-100 mg (23). This 
polyphenolic compound is a potent free radical scavenger and iron chelator (24, 25).  
Another important flavonoid is the isoflavone genistein (Figure 1C), which is mainly found 
in soybeans. Genistein is also known to be a phytoestrogen due to its structural similarities 
to 17ɴ-estradiol and can therefore mimic or antagonize estrogen (26, 27).  Due to the low 
soy-containing food consumption in Western countries the daily intake of isoflavones is in 
the range of several milligrams a day. However, isoflavone intake can increase 
dramatically when consuming soymilk, for instance by people allergic to cow milk, as soy 
milk contains between 30 and 175 mg/ L isoflavones. In Asian countries the daily intake of 
isoflavones is much higher due to the high consumption of soy and reaches levels of 25-40 
mg a day (28). Moreover, the level of isoflavones, mainly genistein, found in soy-based 
infant formula lies even above the levels found in Asian adults (29). 
 
 
 
 
 
 
 
 
Figure 1. A. Basic flavonoid structure, B. Structure of quercetin, C. Structure of genistein. 
 
In addition, as quercetin and genistein both are flavonoids, they possess besides the above 
mentioned properties very potent antioxidant capacities. Up till now, this is the best 
studied property of flavonoids to which several health benefits, like anti-inflammatory (30, 
31), protection against cardiovascular diseases (32, 33), protection against 
neurodegenerative diseases (34, 35), protection against COPD (progression) (36, 37), and 
protection against ocular disease (38, 39) are attributed. This is also the main reason why 
flavonoids are gaining interest as treatment and prevention of adult diseases (19, 40-42). 
Flavonoids are therefore freely available as high dose supplements, with a daily 
recommended dose that can be as high as 1-2 gram per day (43, 44).  
Moreover, studies concerning the use of dietary supplements during pregnancy are 
limited, it has been reported for the US that 78 % of the pregnant woman take 
supplements during pregnancy (45). Although it is know that flavonoids transfer across the 
placenta to accumulate in the fetus (46, 47), there is yet little known about their actions in 
pregnancy and the effects on the offspring. 
Flavonoids during pregnancy: Infant leukemia 
Besides the assumed health benefits, it is suggested that flavonoids can be detrimental 
when exposed to in utero, as they are thought to be involved in the onset of infant 
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leukemia  (48,  49).  Infant  leukemia  is  characterized  by  an  increased  white  blood  cell  count  
within the first twelve months after birth. It is the second most common malignancy within the 
first year of life (50, 51). Infant leukemia is thought to be the result of chromosomal 
translocations, creating fusion genes; deletions of chromosomal segments or of individual 
genes;  duplication  of  segments  or  whole  chromosomes  (50,  52).  The  chromosomal  
translocations seen in infant leukemia are thought to be the result of the inhibition of 
topoisomersase II (topoII), for which fetal cells are more sensitive to as they are rapidly 
proliferating cells and have high topoII activity (53). This nuclear enzyme is normally involved in 
the relaxation of supercoiled DNA during replication and transcription. It binds to double-
stranded DNA, cuts one of both helical chains, creating a transient double-strand break (DSB) 
through which the other helical chain passes after which the DNA strand is religated. This 
decreases the winding of the DNA, making it more available for replication or transcription. 
However, topoII-inhibitors can inhibit the religation, increasing the risk on translocations 
(Figure 2) (52, 54). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. DNA helix relaxation by topoisomerase II.  
TopoII relaxes the DNA helix by binding to topoII binding sites on both DNA chains. Next, it generates a transient 
DSB in one of the helical chains through which the other chain passes, followed by the resealing of the break. 
TopoII-inhibitors, like genistein, quercetin and etoposide inhibit the resealing of the DNA, increasing the risk on 
translocations. (The figure was adapted from Nitiss (55)) 
 
The most common genetic aberration associated with infant leukemia is a rearrangement in 
the mixed-lineage leukemia gene (MLL)  found  in  up  to  80  %  of  the  children  suffering  from  
acute lymphoblastic leukemia (ALL; concerning abnormal expansion of T- or B-cells) and up to 
50 % of children with myeloid leukemia (AML; concerning all other white blood cell types). This 
gene is involved in normal hematopoiesis and is located at chromosome 11q23. Largely all MLL 
translocations are located at a 8.3 kb breakpoint cluster region (BCR) which covers exon 5 to 11 
of the gene. However, no specific translocation partners are identified. In addition, MLL 
rearrangements are also found in 25 % of patients suffering from secondary leukemia resulting 
from chemotherapy with DNA topoII-inhibitors (e.g. etoposide) (52). Strikingly, it has been 
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suggested that several dietary compounds, for instance flavonoids (48, 49, 56) but also caffeine 
(57)  can  inhibit  the  action  of  topoII.  Still,  the  complex  nature  of  human  diets  makes  it  
impossible to elucidate the exact contribution of these dietary compounds to the onset of 
infant leukemia. It is generally accepted that childhood leukemia originates in utero as 
leukemia is present in newborns. Moreover, monozygotic twins suffering from leukemia have 
identical rearrangements of the MLL gene (49, 58). 
Normally DSB are recognized by the ataxia-telangiectasia mutated (ATM) protein. This protein 
will activate checkpoints to slow down the cell cycling of cells carrying DNA damage and recruit 
proteins to repair the damage or if the DNA damage is too severe lead to apoptosis. Mutations 
in this gene result in the disease ataxia-telangiectasia (A-T). Patients suffering from this 
autosomal recessive disorder have an increased risk on developing cancer. One third of the A-T 
patients develop cancer of which the majority being lympoid malignancies (e.g. leukemia) (59). 
About 0.5-1 % of the human population carries at least one mutated ATM gene (59, 60).  
Different studies suggest that mutations in ATM could  play  a  role  in  the  development  of  
leukemia (61-63). Lavin et al. (64, 65) developed a murine model of A-T carrying a common 
mutation seen in humans with A-T, namely the 7636del9 deletion. These AtmͲȴSRI mice have 
an in-frame deletion of 9 nucleotides, resulting in a non functional Atm protein, lacking its 
kinase activity. Heterozygous AtmͲȴSRI mice have a mean age of tumor onset of 18.6 months, 
while only 30 % of homozygous AtmͲȴSRI  mutant  mice  are  still  alive  at  16  months  of  age.  
Heterozygous and homozygous AtmͲȴSRI mice suffer from different tumors of which one third 
is represented by leukemias and lymphomas.  
Flavonoids during pregnancy: Fetal programming 
Since the late 1980s the idea that maternal nutrition during pregnancy associates with an 
increased risk on degenerative diseases later in life gained interest (66, 67). A large number of 
studies on fetal over- or under-nutrition have been performed to investigate the adverse 
effects at adult age (66, 68-70). A clear example is given by the Dutch famine, which occurred 
during the winter of 1944-1945. Here, reduced nutrient supply during the first trimester of 
pregnancy resulted in a higher prevalence of obesity and cardiac heart diseases in the adult 
male progeny (71, 72). This study produced evidence for the ‘thrifty genotype’ also known as 
the `Barker Hypothesis`, defining the concept of fetal programming, namely an attempt of the 
fetus to adapt to adverse conditions encountered in utero resulting in adaptations that will be 
detrimental when these conditions will not prevail later in life (73). A general overview of the 
concept of fetal programming is given in Figure 3. 
Over the years, it turned out that also other diseases at adulthood are linked to in utero 
malnutrition. For instance, maternal low caloric diets are also thought to increase the risk on 
diabetes type 2 in offspring at adult age (74-77). These studies on the concept of fetal 
programming showed that fetal nutritional deprivation (maternal caloric or macronutrient 
deficiency during pregnancy) is a strong programming stimulus (66, 68, 70). However, in many 
Western societies, maternal nutrition is sufficient or even excessive. For instance, maternal 
high saturated fat diet resulted in insulin resistance, obesity and hypertension in offspring at 
adult age (78), which indicates that developmental problems may not only be a consequence 
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of under-nutrition, but can also be achieved by an unbalanced diet during pregnancy. Thus, 
maternal over-nutrition can be deleterious to the health of the offspring and results in a 
phenotype of the offspring that is linked to increased health risks in adulthood. 
The use of dietary supplements has tremendously increased over the past decades, and 
sometimes the manufacturer advices the intake of excessive amounts. Also for flavonoid 
supplements  the  recommended intake  is  high,  because  up  till  now no human data  on  long-
term effects  of  high-dose  flavonoid  supplementation  are  available  (21).  As  much as  78  % of  
woman use natural health products during pregnancy as these micronutrients are essential for 
a good pregnancy outcome (45), which includes the intake of folate. However, the ideal diet 
composition for pregnant woman has still to be found, especially in relation to dietary 
supplements. Although the intake may not be directly toxic to the developing child, the fetal 
programming hypothesis predicts that physiological alterations may occur that persist into 
adulthood. To fully understand the safety of supplements during pregnancy, such effects 
should be taken into account, and more research is needed in understanding the phenomenon 
of ‘fetal programming’. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Overview of the concept of fetal programming.  
During pregnancy the fetus will adapt according to its nutritional demand and its mother’s nutritional supply, 
making  the  fetus  programmed  to  the  in utero nutritional status as it is thought to reflect the nutritional 
situation it will encounter once born. Indeed, when the postnatal nutritional demand corresponds to the 
nutritional supply, the adaptations made by the fetus in utero will result in a normal development and disease 
susceptibility. However, if the postnatal nutritional demand does not correspond to the nutritional supply, the 
risk on adult diseases increases. 
Epigenetics: a tool for fetal programming 
The first theory comprising the responsiveness of the genome to the environment and its 
modifying capacity was proposed by Jean-Baptiste Lamarck, in the early 19th century (79). 
However, his ideas were neglected due to lack of evidence and aberrant conceptualization (79, 
80). Conrad Waddington was the first to follow in Lamarck’s steps, in the first half of the 20th 
century. He introduced the word ‘epigenetics’, which stands for ‘epi’ meaning ‘upon’ or ‘over’ 
and ‘genetics’ implying the involvement of genes, to define the study of events over or beyond 
genes. The term ‘epigenetics’ was derived from the Aristotelian word ‘epigenesis’ implying that 
developmental changes are gradual and qualitative, but that there is a link to heredity (81).  
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As the phenomena of epigenetic manifestations are gaining increasing appreciation, 
researchers grow eager, focusing their studies on understanding the control of gene expression 
and its connection with the underlying processes of human development of diseases. 
Moreover, they seek the origin of disease in the epigenetic regulation within the placenta (82, 
83). Evidently studies regarding the epigenetic alterations within the placenta have provided 
crucial insights into the fetal origins of the susceptibility to specific diseases later in life. Such 
epigenetic mechanisms include changes in promoter DNA methylation resulting in hypo- or 
hyper-methylation of DNA CpG regions; modifications of histone proteins; chromatin 
conformation  as  well  as  micro-  and  non-coding  RNA-mediated  control  of  gene  expression  
within the placenta (82-85). However, considering this thesis, only the epigenetic regulation via 
DNA methylation will be further elaborated. 
DNA methylation can be described as the incorporation of a methyl (CH3) group, obtained from 
the S-adenylmethionine that serves the purpose of a methyl donor, on a cytosine ring located 
in CG dinucelotides forming methyl-cytosine, which is catalyzed by DNA methyltransferases 
(DNMTs)  (86).  The  maintenance  and incorporation  of  these  methyl  groups  is  carried  out  by  
specific  DNMTs,  namely  DNMT3A,  DNMT3B and DNMT1 (82,  86).  The  finding  that  this  DNA 
modification occurs predominantly on cytosines that come before guanosine in the sequence 
and  that  this  occurs  mostly  in  non-coding  DNA  indicates  its  importance  in  global  genomic  
maintenance. Methylation of so-called CpG islands in DNA generally leads to silencing of 
transcription. CpG islands are mainly located in gene promoter regions, which are mostly 
unmethylated in order to allow normal gene expression. Therefore, aberrant methylation 
patterns may be detrimental for the well being and can lead to the development or 
progression of human diseases. 
During fetal development, epigenetic alterations are crucially involved in the orchestration of 
gene expression; the epigenome cycles through several precisely timed methylation changes 
to ensure proper development (87). Shortly after fertilization the paternal genome is actively 
demethylated, while the maternal genome is passively demethylated. Some epigenetic marks 
are maintained to allow proper expression of imprinted genes (parent-of-origin methylation 
marks) (87) (about 100 identified in mammals) (88). Subsequently, a new pattern of DNA 
methylation, which is also referred to as de novo methylation, is established predominantly at 
the  blastocyst  stage  (82,  83,  89).  This  de novo methylation can be considered as a 
reprogramming of the DNA methylation patterns in the zygote, which are normally retained 
throughout  the  organism’s  life,  and  are  crucial  for  somatic  cell  viability  (82,  83,  89).  The  
appropriate succession of the resetting and reprogramming phase of methylation is 
fundamental to post-gestational health and survival. This signifies an important sensitive 
window within the development of an embryo, where the environment can have profound 
effects on the expression pattern of certain genes throughout life (83, 90). A clear example of 
fetal programming by diet induced changes in methylation is given by Dolinoy et al. (91). They 
showed that heterozygous agouti mice exposed to the flavonoid genistein via the maternal 
diet, at levels comparable with humans consuming a high-soy diet, resulted in an altered coat 
color, namely towards pseudo-agouti. These mice were also protected against obesity later in 
life, which is associated with the agouti phenotype. These changes were caused by 
hypermethylation of transposable repetitive elements, namely intracisternal A particles (IAP), 
upstream of the transcription start site of the Agouti gene which remained unaltered 
throughout life. 
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Aims and outlines of this thesis 
Many studies on human diseases, including many types of cancers, suggest that the in 
utero period plays a role in the occurrence of adult diseases (92-94). Therefore, in this 
thesis we aimed to provide more insight in how dietary flavonoids could alter cancer 
susceptibility of the individual through direct effects on genomic stability (Chapter 2) and 
via fetal programming (Chapter 3-6). 
Effects on genetic stability and formation of translocations 
In Chapter 2 the effect of in utero exposure to the flavonoids genistein and quercetin on 
the onset of Mll translocations, is assessed using a mouse model with an impaired DNA 
repair for double-strand breaks. As translocations in MLL may not directly result in the 
onset of infant leukemia, they do increase the risk on developing leukemia later in life 
(Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Assumed outcome of increased maternal intake of topoII-inhibitors during pregnancy on infant leukemia.   
Via the maternal diet the fetus will be exposed to increased levels of the topoII-inhibitors genistein or 
quercetin. This could result in Mll translocation (‘first hit’) as fetal cells are rapidly dividing cells and therefore 
more sensitive towards topoII inhibitors. Throughout life, the offspring has an increased risk on developing 
leukemia. Whether or not the offspring will develop leukemia depends on following events (‘second hit’ or 
more) it will encounter throughout life. 
 
Health effects later in life by persistent changes; examples studied in this thesis 
Persistent changes in gene expression 
It has been shown that prenatal exposure to genistein results in long-lasting alterations in 
gene expression of agouti mice. Therefore the long-lasting effects of prenatal exposure to 
genistein on bone marrow cell gene expression, concerning genes involved in 
hematopoiesis and estrogen responsive genes (as genistein is a know phytoestrogen) are 
investigated as described in Chapter 3.  
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Oxidative stress related processes 
Flavonoids are mostly known for their protective antioxidant effects in adults. However, 
there is no unambiguous hypothesis as some studies show that flavonoids act as 
antioxidants, while other studies attribute a pro-oxidant function to these compounds at 
high concentrations (95-97). Breinholt et al. (98) showed that female rats exposed to 
genistein or quercetin via the diet had reduced enzymatic antioxidant capacity of red 
blood cells. They hypothesized that the antioxidant enzymes in red blood cells were down- 
regulated by the flavonoids in response to an improved antioxidant status of the red blood 
cells due to the presence of flavonoids. Furthermore, it has been demonstrated that 
quercetin up-regulates the gene expression of NQO1 and GSTP1,  as  well  as  the  gene  
expression of Nrf2 in Caco-2 cells (99). This can be considered as a pro-oxidant effect, 
because when oxidative stress occurs, nuclear factor erythroid 2-related factor (Nrf2) 
pathway is activated to overcome this stress. Nrf2, a cytosolic protein, is associated with 
its chaperon Kelch-like ECH-associated protein (Keap1) via protein-protein interactions 
resulting in its proteasomal degradation. However, in the presence of oxidative stress, 
Keap1-Nrf2 interactions are disrupted and Nrf2 translocates into the nucleus were it binds 
to antioxidant response elements (ARE), resulting in the transcription of phase II enzymes, 
including NQO, GST and UGT (100). Other important antioxidant enzymes are superoxide 
dismutase (SOD) which scavenges O2
-• and catalase and glutathione peroxidase (GPX) 
which scavenges hydrogen peroxide (H2O2). The body’s innate antioxidant capacity can be 
augmented by antioxidants delivered through the diet, for instance vitamin C and E, ɴ-
carotene, but also for these dietary antioxidants it is known that they may promote 
oxidative stress under certain conditions (101), leading to damage to proteins and 
membranes (18, 102). Damage to membranes caused by free radicals (lipid peroxidation) 
results in the generation of malondialdehyde that can react with DNA resulting in the 
formation  of  M1dG-adducts. However, M1dG-adducts can also be generated by hydroxyl 
radicals, independently from lipid peroxidation by the removal of deoxyribose 4’-hydrogen 
in  DNA,  generating  a  base  propenal.  M1dG-adducts are normally repaired via the 
nucleotide excision repair pathway, but malfunctioning of this pathway can result in 
mutations and eventually cancer (103). Oxidized proteins can be repaired by ascorbate or 
glutathione (GSH). If not, for instance if the levels of ascorbate and GSH are depleted, then 
these proteins are recycled by proteases. When irreversibly modified proteins cannot be 
processed by proteases and accumulate in the cell, making it impossible for the cell to 
properly function resulting in its death (102). ROS can also directly oxidize DNA resulting in 
the formation of 8-oxo-7,8-dihydro-2’deoxyguanosine (8-oxo-dG) (103). 
As  CYP450  activity  also  results  in  the  formation  of  ROS  (18,  103),  a  link  between  the  aryl  
hydrocarbon receptor (AhR) and Nrf2-pathway is suggested (104, 105). This has been 
confirmed by the finding of a xenobiotic binding site of AhR in the regulatory region of the 
Nrf2 gene (106). For this interaction, see section ‘Quercetin as AhR agonist modifies 
xenobiotic metabolism’ below. 
Therefore, the effect of prenatal exposure to quercetin, but also to genistein on the 
antioxidant capacity at adult age is investigated to elucidate whether a pre-emptive 
trigger of the antioxidant system during fetal development will result in adaptations at 
adulthood (Chapter 4). 
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Iron chelating properties of quercetin as programming trigger 
In addition, as quercetin is a powerful iron chelator, the effects of prenatal exposure to 
quercetin on iron homeostasis and eryhtropoiesis was determined at adulthood but also 
during the fetal development, as iron is an essential micronutrient for a normal 
development (Chapter 5). Iron plays an essential role in the generation of ROS. Its redox 
cycling promotes the formation of the potent oxidating hydroxyl radical (Fenton reaction: 
Fe2+ +  H2O2 Æ Fe3+ +  OH• +  OH-) (107). However, iron is also an essential micronutrient 
that besides the oxidative metabolism is also required for erythropoiesis and optimal 
functioning of immune responses. About 1-2 mg of iron is daily absorbed from the diet 
and this absorption is tightly regulated due to the fact that the body has no effective 
means of excreting iron. Once iron is released into the circulation it binds to transferrin 
and is transported to sites of use or to be stored. About 65 % of the body’s iron is used for 
the production of hemoglobin (108, 109). Hemoglobin consists out of a porphyrin ring 
containing an iron ion (heme part of hemoglobin) and 4 globin chains (2 ɲ-globin and 2 ɴ-
globin chains). The production of the globin chains is dependent on the availability of 
heme and because heme production is limited by iron supply it is the amount of available 
iron that limits the hemoglobin production (110).  
Depending on the phase of life, different forms of hemoglobin are produced, namely 
embryonic hemoglobin and adult hemoglobin. In case of mice the first form of hemoglobin, 
that is the embryonic hemoglobin, consists out of embryonic globins, namely ɺ -globin, which 
is the embryonic form of ɲ-globin and ɴH1- and ɸy-globins the embryonic forms of the ɴ-
globin (111, 112). This form of hemoglobin is produced solely by primitive erythrocytes, 
which are generated by the yolk sac and consist of large erythroblasts which are present in 
the bloodstream from embryonic day (E) 7.5 (111-113). Adult hemoglobin consists out of the 
adult ɲ- and ɴ-globins (111, 112) and is produced by erythrocytes from the definitive adult 
lineage, but also by the primitive erythrocytes, though the amount of adult globins 
expressed in the primitive erythrocytes is negligible (111, 112). At E11.5 erythrocytes from 
the definitive adult lineage appear in the bloodstream. These cells are first formed by the 
fetal liver and from birth onwards, primarily by the bone marrow (111-113). After E16.5 the 
definitive erythrocytes are the predominant cell type in the fetal circulation and ultimately 
become the exclusive erythrocyte lineage in the adult (111-113). One main difference 
between both lineages is the place they undergo terminal maturation. Primitive 
erythroblasts enucleate in the bloodstream, resulting in the formation of a reticulocyte and a 
pyrenocyte (this is the extruded nucleus). Definitive adult erythrocytes on the other hand 
mature and enucleate in the fetal liver and later on in life in the bone marrow after which 
the reticulocyte is released into the bloodstream (111, 112, 114). During erythroid ontogeny 
in humans, a third form of hemoglobin is produced, namely the fetal hemoglobin, which 
appears between the embryonic and the adult hemoglobin (112).  
For both humans and mice, the switch from embryonic to adult globins is thought to be 
triggered by difference in oxygen environment at the different stages of pregnancy. During 
early development, in the uterus, the embryo resides in a low oxygen environment. This 
hypoxic state is necessary for the early embryogenesis and organogenesis, because at this 
time point the embryo is the most vulnerable for oxidative stress, which could lead to 
damage or disruption of the embryo (115, 116). In mice, the utero-placental circulation is 
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well established between E9.5 and E11. This leads to a higher concentration of oxygen and 
therefore to an increase in ROS, but it also leads to an enhancement of the antioxidant 
defense system (116).  Because of the low oxygen supply during early development, cells 
from the primitive erythroid lineage are expressed. Since they consist of embryonic 
globins which have a high affinity to oxygen they can permanently remove oxygen from 
the adult globins expressed in the maternal erythrocytes through the placenta (117, 118). 
Later, when the oxygen supplies increases between E9.5 and E11 (116), the switch from 
primitive to definitive erythroid lineage takes place (111-113). 
During pregnancy the maternal iron absorption raises to fulfill the increasing iron 
requirement of the fetus However, the increase in iron absorption by the mother during 
pregnancy is normally not sufficient and therefore maternal iron stores are implemented 
what could result in iron deficiency anemia (119, 120). Iron deficiency represents the most 
common nutritional deficit worldwide (121) and has serious consequences for both the 
mother and the unborn child as it increases the risk of maternal mortality and the risk on 
cardiovascular disease for the child later in life (119, 120).  
Iron homeostasis is highly regulated in adults to prevent the generation of ROS. Therefore, iron 
that is not used is mainly stored in the liver, where it is bound to ferittin. For an optimal 
erythropoiesis, internal turnover of iron is needed. Senescent erythrocytes are cleared by 
macrophages in the liver but primarily in the spleen. The heme part of hemoglobin is 
metabolized by hemoxygenase-1 (HO1) and the released iron is then recycled for the 
subsequent hemoglobin production (108, 109). In iron overload diseases the liver is the main 
organ suffering from injury. In mice, dietary quercetin supplementation decreased the hepatic 
iron storage and increased the excretion of iron through the feces, thereby lowering the risk on 
ROS induced damage (122). Previous studies have shown that quercetin can penetrate the 
cytoplasm of erythrocytes to interact with the heme iron in hemoglobin. This results in the 
oxidation of heme iron from the ferrous (Fe2+) to the ferric (Fe3+) state and consequentially to 
the formation of methemoglobin, which is inactive and incapable of transporting oxygen. 
However, it also decreases the risk on ROS induced hemolysis (24, 25, 107).  
Quercetin as AhR agonist modifies xenobiotic metabolism 
Quercetin is also a know aryl hydrocarbon receptor (AhR) ligand an could therefore protect 
against DNA damage induced by compounds that need metabolism via the  expression  of  
phase I and II enzymes, including polycyclic aromatic hydrocarbons (PAH). Therefore, the effect 
of prenatal exposure to quercetin on detoxifying enzymes is described in Chapter 6. 
Throughout their life, humans are exposed to drugs, environmental contaminants and other 
foreign compounds. To prevent that these substances cause any damage, they are usually 
neutralized by xenobiotic metabolism and excreted. Environmental genotoxicants and 
mutagens cause about 80 % of human malignancies (4). PAHs are widespread environmental 
contaminants to which we are exposed to through inhalation of smoke from coal, wood, diesel 
fuel and tobacco; but also through ingestion of roasted, smoked or charbroiled foods. 
Benzo[a]pyrene  (B[a]P)  is  the  best  studied  PAH  and  is  found  to  be  a  mutagenic  and  
carcinogenic environmental pollutant. B[a]P needs to be metabolically activated to become 
genotoxic. This is mainly performed by the heme-containing phase I enzymes, cytochrome 
P450 (CYP) 1A1 and CYP1B1 (4, 123, 124). The initial step in B[a]P metabolism is performed by 
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these phase I enzymes and results in the formation of epoxides, which are in turn the substrate 
for epoxide hydrolase, resulting in the formation of diols. Next the phase I enzymes will convert 
the diols into diol epoxides (125). The formed diol epoxide of B[a]P, namely B[a]P-7,8-
dihydrodiol-9,10-epoxide (BPDE), is a reactive intermediate that can bind covalently to nucleic 
acids and proteins. In addition, B[a]P can also be converted into phenols and subsequently to 
quinones  by  phase  I  enzymes  (125).  However  B[a]P  can  also  be  detoxified  by  phase  I  and  
especially by phase II enzymes (glutathione-S-transferases (GST), UDP-glucurosyltransferases 
(UGT) and sulfotransferases (SULT)), converting it into a water-soluble derivate facilitating its 
excretion  (see  Figure  5).  Activation  of  these  enzymes  is  regulated  through  the  activation  of  
AhR. This cytosolic protein is activated by B[a]P, whereupon it transfers into the nucleus. Here 
it dimerizes with AhR nuclear translocator (ARNT) after which it can bind to xenobiotic 
responsive elements to induce phase I and phase II enzymes (124). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Simplified overview of B[a]P metabolism. 
Simplified scheme of B[a]P metabolization, activation and detoxification performed by phase I (CYP450s) and 
phase II enzymes (EH: epoxide dehydrolase, GST: glutathione-S-transferases, UGT: UDP-glucurosyltransferases, 
SULT: sulfotransferase, and NQO1: NAD(P)H:quinine oxidereductase 1) (from Ambrosone et al. (126)). 
 
Inter-individual variation in drug metabolism and associated cancer susceptibility can partly be 
explained by different expression and/ or activity of phase I and II enzymes induced by genetic 
polymorphisms in these genes (127-129), and therefore reduce or increase the exposure to 
harmful compounds. Other studies also suggest that there is a gender-dependent expression 
of  phase  I  and  II  enzymes  (130-133).  This  is  thought  to  be  the  result  of  endocrine  factors,  
namely estrogen, which is the female hormone and is also metabolized by CYPs. Metabolism of 
estrogen  by  CYPs  can  also  result  in  reactive  metabolites  that  can  damage  the  DNA  (134).  
Moreover, males and females have a differential susceptibility for B[a]P induced 
carcinogenicity as males seem to have more protection due to higher levels of GST isoenzymes 
compared to females (135). In addition, PAHs or their metabolites could have estrogenic 
effects, which could contribute to their carcinogenicity (136). Though, up till now 
epidemiological studies are inconsistent regarding the differences in carcinogen metabolism 
between genders (137, 138). 
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Another important factor explaining inter-individual differences in xenobiotic metabolism 
are environmental factors, especially the diet (139, 140). It is estimated that the diet can 
reduce cancer death rates by 35 % (139). For instance, flavonoids can bind and therefore 
activate AhR, resulting in an altered expression of phase I enzymes (100, 141, 142). 
Different studies have also shown that flavonoids can induce phase II gene expression 
preventing DNA damage (100, 143). Moreover, maternal quercetin intake leads to long-
term alterations of CYP activity in female rat offspring (144). Besides altering phase I and 
phase II gene expression, quercetin also enhances the excretion of B[a]P metabolites from 
the body (145). When quercetin was co-incubated with B[a]P, it influenced the B[a]P 
induced effects by increasing the B[a]P induced expression of CYP1A1 and 1A2. It also 
resulted in a diminishing B[a]P induced up-regulation of Nrf2 and some of its target genes 
and in an up-regulation of the AhR repressor, which was suppressed by B[a]P (99). 
Summary: overall aim of the thesis 
Taken together, Chapter 2 describes the possibility of in utero exposure to genistein and 
quercetin to affect genetic stability, namely by assessing the onset of Mll translocations in 
a mouse model with an impaired DNA repair for double-strand breaks. Chapter 3 
describes the long-lasting effects of prenatal exposure to genistein on hematopoiesis and 
on the expression of genes involved in hematopoiesis and estrogen responsive genes (as 
genistein is a know phytoestrogen). As genistein and quercetin both are potent antioxidants, 
the  effect  of  prenatal  exposure  to  both  flavonoids  on  the  antioxidant  capacity  at  adult  age  is  
investigated in Chapter 4 by  pre-emptive  triggering  of  the  antioxidant  system  during  fetal  
development. Quercetin is, besides a potent antioxidant, also a powerful iron chelator. 
Therefore, the effect of prenatal exposure to quercetin on iron homeostasis and 
eryhtropoiesis was determined during fetal development and at adulthood as described in 
Chapter 5.  Chapter 6 describes the effect of prenatal exposure to quercetin on detoxifying 
enzymes,  as  quercetin  is  also  a  know  aryl  hydrocarbon  receptor  (AhR)  ligand  and  could  
therefore protect against B[a]P induced DNA damage, as B[a]P needs to be metabolized by 
AhR induced phase I and II enzymes. As in Chapter 3, 5 and 6 long-lasting changes in gene 
expression due to in utero exposure to genistein or quercetin are investigated, epigenetic 
mechanisms, namely the induction of changes in methylation status of repetitive 
elements, are also investigated in these chapters. Overall Chaptor 4-6 describes the effect 
of prenatal exposure to flavonoids on the overall risk of an individual to develop cancer. 
Finally, a summary and general discussion on the most important findings of all studies 
presented in this thesis and the future perspectives are given in Chapter 7. 
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Abstract 
Flavonoids are potent antioxidants, freely available as high-dose dietary supplements. 
However, they can induce DNA double-strand breaks (DSB) and rearrangements in the 
mixed-lineage leukemia (MLL) gene, which are frequently observed in childhood leukemia. 
We hypothesize that a deficient DSB-repair, as a result of an Atm mutation, may reinforce 
the clastogenic effect of dietary flavonoids and increase the frequency of Mll 
rearrangements. Therefore we examined the effects of in vitro and transplacental 
exposure to high, but biological amounts of flavonoids in mice with different genetic 
capacities for DSB-repair (homozygous/ heterozygous knock-in for human Atm mutation 
(AtmͲȴSRI) versus wild-type). In vitro exposure to genistein/ quercetin induced higher 
numbers of MLL rearrangements in bone marrow cells of AtmͲѐSRI mutant mice 
compared to wild-type mice. Subsequently, heterozygous AtmͲѐSRI mice were placed on 
either a flavonoid-poor or a genistein-enriched (270 mg/ kg) or quercetin-enriched (302 
mg/ kg) feed throughout pregnancy. Prenatal exposure to flavonoids associated with 
higher frequencies of Mll rearrangements and a slight increase in the incidence of 
malignancies in DNA repair-deficient mice. These data suggest that prenatal exposure to 
both genistein and quercetin supplements could increase the risk on Mll rearrangements 
especially in the presence of compromised DNA repair.  
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Introduction 
Bioflavonoids are a diverse group of polyphenolic compounds found in fruits, vegetables, soy, 
tea, coffee and wine. They are most commonly known for their protective effect against 
cardiovascular diseases, cancer and inflammation, as a result of their antioxidant capacity (1, 
2). Because of the presumed health benefits flavonoid supplements are worldwide over-the-
counter available in pharmacies and drugstores. Unfortunately, there is a general belief that 
these herbal supplements are safe because they are labeled as “natural”. Reasons for concern 
are that besides their antioxidant properties, flavonoids are also potent topoisomerase II 
(topoII)-inhibitors. TopoII is a nuclear enzyme that plays an essential role in controlling the 
topology of DNA during replication and recombination. TopoII binds to specific sites on both 
DNA strands  and generates  a  transient  double  strand break  (DSB).  These  DSBs  are  normally  
relegated. However, certain topoII-inhibiting drugs, such as etoposide or flavonoids can 
stabilize DSBs and increase the risk of chromosomal abnormalities (3-5). 
One of the most common loci involved in chromosomal translocations due to double-
stranded DNA lesions caused by topoII-inhibitors, is the breakpoint cluster region (BCR) of 
the mixed-lineage leukemia (MLL) gene. This gene is involved in normal hematopoiesis 
and  is  located  at  chromosome  11q23  (6-8).  Approximately  80  %  of  infants  which  suffer  
from acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) have 
chromosomal translocations involving the MLL gene (3-5). These translocations are also 
identified in patients with secondary leukemia caused by chemotherapy with topoII-
inhibitors (e.g. etoposide) (3, 9-11). It has previously been suggested that dietary 
flavonoids are also capable of introducing these translocations and cause leukemia (12). 
Although there are some indications that flavonoids might be involved in leukemogenesis 
(4), the complex nature of human diet made it impossible to elucidate the contribution of 
flavonoids. Our previous data (13) demonstrates that exposure of human CD34+ 
hematopoietic progenitor cells to biologically relevant levels of the flavonoids quercetin, 
genistein and kaempferol can induce MLL translocations in vitro. Since the concentrations 
used in this in vitro study can also be obtained in vivo, and knowing that flavonoids can 
penetrate the placenta and accumulate in the fetus (2, 14, 15), it is crucial to further 
examine the safety of flavonoids, especially during pregnancy. Fetal cells are rapidly 
proliferating cells and thus have high topoII activity (16), which can theoretically make 
them more sensitive to the topoII inhibiting effect of flavonoids.  
As flavonoids execute their clastogenicity through inhibiting the religation of DSBs, one might 
expect that any defect in DSB-repair may predispose cells to clastogenic effects of these 
compounds. DSBs are normally detected by ataxia-telangiectasia-mutated (ATM) protein 
kinase (17-19). Ye et al. (20) demonstrated that exposure of human lymphoblastoid cell lines to 
quercetin or genistein leads to autophosphorylation of ATM on serine 1981 leading to the 
active form of ATM (21). Hence, ATM phophorylates its downstream targets (e.g. p53, Chk2 
and histone H2AX), which based on the severity of the damage will either execute DNA repair 
or cell-cycle arrest and apoptosis (20, 22-24). Patients with mutations in the ATM gene are 
prone to developing chromosomal abnormalities (17, 19). Heterozygous germ-line mutations 
in the ATM gene are frequent and occur in 0.5-1 % of the general population (25, 26). These 
mutations  are  associated  with  an  increased  risk  for  developing  different  types  of  cancer,  
including  leukemia  (19,  23,  27,  28).  Accordingly,  missence  mutations  in  the  ATM gene  have  
been detected in 25 % of cases with childhood ALL (23). 
Chapter 2 30 
This study examines the effect of both in vitro and transplacental exposure to high, but 
biological amounts of flavonoids in mice with different genetic capacities for DSB-repair 
(homozygous/heterozygous knock-in for human Atm mutation (AtmͲȴSRI) versus wild-
type). We examined whether a decreased capacity in DNA DSB-repair in AtmͲȴSRI mutant 
mice enhances flavonoid-induced clastogenicity.  
Material and methods  
Exposure of bone marrow cells to genistein, quercetin or etoposide 
Bone marrow cells collected from one femur of adult wild-type (wt) and homozygote 
mutant (mut) AtmͲȴSRI mice were isolated by flushing the marrow with Iscove’s 
Modified Dulbecco’s Media (IMDM, Invitrogen, Breda, the Netherlands) supplemented 
with 10 % FCS. Next, cells were washed, incubated in IMDM and treated for one day 
with 50 ʅM of etoposide (Sigma-Aldrich, St. Louis, MO, USA), genistein (LC 
Laboratories, Woburn, MA, USA), quercetin (Sigma) or the vehicle dimethylsulphoxide 
(0.05  %  DMSO).  After  exposure  cells  were  washed  twice,  and  left  to  recover  for  
another  day  before  DNA  isolation.  Cell  counts  and  viability  were  determined  by  a  
hemocytometer and trypan blue exclusion. 
Mice and sample collection 
Female AtmͲȴSRI heterozygous mice (129/SvJ:C57BL/6J background) approximately 8 
weeks of age, received either normal chow (low phytoestrogen content complete feed 
for mice breeding, in which neither soybean nor alfalfa products were used, resulting in 
minimized concentrations of the phytoestrogens genistein, daidzein and coumestrol, 
ssniff®, Soest, Germany, n=8) or the same chow (ssniff®)  supplemented with genistein 
(270  mg/  kg  feed,  n=9)  (LC  Laboratories)  or  quercetin  (302  mg/  kg  feed,  n=8)  (Sigma)  
from 3 days before conception until the end of pregnancy. Male Atm-ȴSRI heterozygous 
mice were placed in the cage only for the duration of copulation. Heterozygote female 
and male mice were mated because this gives the opportunity to study the in utero 
effects of the three expected genotypes in offspring (homozygous/heterozygous Atm-
ȴSRI and wild-type). After delivery all mothers and pups received the normal chow. At 
day 5 after birth, pups were weighted and genotype and gender was determined. At 12 
weeks of age, offspring were sacrificed by cardiac puncture, checked for tumor 
development and blood was collected in EDTA-tubes (Terumo, Leuven, Belgium) to 
determine the blood composition. Bone marrow was isolated by removing the femurs 
and flushing the marrow with PBS. Offspring that died before sacrificing day were also 
checked for tumor development. 
To study the direct effects of diet on fetal hematopoiesis, wild-type mice 
(129/SvJ:C57BL/6J background, control n=5, genistein n=4, quercetin n=3) were mated 
overnight. The presence of a vaginal plug the next morning was defined as 0.5 day post 
conception. On day 14.5 of pregnancy (E14.5), mice were sacrificed to isolate the fetuses 
and fetal liver (please note that the liver is the organ for hematopoiesis at this time point).  
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Blood composition 
Blood composition was determined in duplicate, using the ADVIA 120 Hematology System 
(Siemens AG, Erlangen, Germany) following the manufacturer’s protocol. The following 
blood cell parameters were measured: total number of red blood cells (1012/ L), 
hemoglobin level (mmol/ L),  hematocrit  level (L/ L),  mean corpuscular volume (fL),  mean 
corpuscular hemoglobin (fmol), mean corpuscular hemoglobin concentration (mmol/ L), 
red blood cell distribution width (%), hemoglobin distribution width (mmol/ L), total 
amount of platelets (109/ L), mean platelet volume (fl), total amount (109/  L)  and  
percentage of reticulocytes, mean corpuscular hemoglobin concentration of reticulocytes 
(fmol), total number of white blood cells (109/ L), total amount (109/ L) and percentage of 
neutrophils, lymphocytes, monocytes, eosinophils and basophils. In case of suspected 
leukemia by abnormal blood composition, the diagnosis was further confirmed by 
performing a May-Grünwald staining on blood smear preparations.  Briefly, 10 ʅl of blood 
was fixed by methanol. Next, smears were stained in May-Grünwald solution (Sigma) for 5 
minutes and washed in tap water. Subsequently, the smears were stained with Giemsa 
solution (Merck, Darmstadt, Germany) for 20 minutes and washed again in tap water. All 
preparations were judged by an experienced animal pathologist. 
Inverse-PCR assay and sequencing 
Genomic DNA was isolated from bone marrow cells (in vitro culture or in vivo from 12 week 
old mice) and from the fetal liver of E14.5 fetuses, using DNeasy Blood & Tissue Kit (Qiagen, 
Venlo, the Netherlands). Fetal livers were first homogenized using an Ultra-Turrax 
homogenizer (IKA, Staufen, Germany). Next, 1 ʅg of each DNA sample was subjected to SAP 
digestion (1 unit of shrimp alkaline phosphatase) (Promega, Madison, WI, USA) for 1 hour at 
37 °C followed by an inactivation at 65 °C for 20 minutes. Then, the DNA was digested with 3 
units of PciI (Biolabs, Leusden, the Netherlands) for 1 hour at 37 °C followed by 20 minutes 
inactivation at 80 °C. The DNA was circularized overnight at 6 °C followed by 2 hours at 22 °C 
and 20 minutes of inactivation at 75 °C using 3 units of T4 DNA ligase (Promega) in a final 
volume of 50 ʅl. Approximately, 80 ng of the circularized DNA was used for the first PCR, in 
which  the  circularized  DNA  was  amplified.  Both  the  first  PCR  and  nested  PCR  were  
performed using 0.7 ʅl expand long template polymerase mix (Roche, Mannheim, 
Germany), system 2 reaction buffer, 20 pmol of each primer (Eurogentec, Liege, Belgium, 
Table  1)  and  dNTPs  (500  ʅM)  in  a  volume  of  50  ʅl.  The  reaction  was  performed  using  a  
Biometra Tprofessional thermocycler (Biometra, Leusden, the Netherlands) under the 
following cycling conditions: 94 °C for 2 minutes, 10 cycles: 94 °C for 30 seconds, 56 °C for 45 
seconds, 68 °C for 4 minutes; 25 cycles: 94 °C for 30 seconds, 56 °C for 45 seconds, 68 °C for 
4 minutes (+ 20 s/cycle); followed by 7 minutes at 68 °C. The amplified fragments from the 
first PCR were diluted (1/50) and 2 ʅl was taken for the nested PCR.  
The nested PCR products were separated by electrophoresis on a 1 % agarose gel, 
aberrant sized bands were excised and DNA was isolated using the QIAquick Gel Extraction 
Kit (Qiagen). The purified PCR products were subsequently sequenced using big dye v3.1 
(Applied Biosystems, Foster city, CA, USA) and 5 pmol primer (Table 1) under the following 
cycling conditions: 1 minute at 96 °C, 25 cycles: 96 °C for 30 seconds, 50 °C for 15 seconds, 
60 °C for 4 minutes followed by 10 minutes at 72 °C. After purification by sephadex 
columns, the products were sequenced by ABI 3730 Automatic DNA Sequencer (Applied 
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Biosystems). Nucleotide sequences were analyzed using ‘Nucleotide blast’ tool of the 
National Center for Biotechnology Information (BLAST NCBI, Bethesda, MD, USA). 
 
Table 1. Overview of used primers 
Primer Forward primer (5’-3’) Reverse primer (5’-3’) 
First PCR primer CCA GAG TAG TGT GCT TTC TC AGG TGG CTT CTC CTG AGA CAG 
Nested PCR primer AGT GGG CAT GTA GAG GTA AG AAC AAT GAC TTG CCC TCA TAT TG 
Sequence PCR primers: 
1 
2  
3  
 
AAA CAG TGT GCA CAG GTA CG 
AAC CGC TGA ACC ATC TCT CC 
TGG TGG GA GGT CAT TAG CC 
 
Statistical analysis 
Statistical analysis was performed with Statistical Package for Social Sciences (SPSS version 
15 for Windows, SPSS Inc., Chicago, IL, USA). The non-parametric Mann-Whitney test was 
used to compare the distribution of gender, genotype, pup survival, litter sizes, average 
weight of pups at postnatal day 5 and tumor development between litters of the different 
diet groups. 2x2x2 multifactorial univariate ANOVA was performed to identify predictors 
(diet, genotype, gender) of persistent hematological changes in mice.  
Results 
Bone marrow cells with Atm-ѐSRI mutation are more sensitive to genistein- and quercetin-
induced chromosomal aberrations 
In order to examine whether dietary exposure to topoII-inhibitors can induce 
chromosomal aberrations and whether AtmͲѐSRI mutations actually increase this risk, an 
inverse-PCR method was set-up to detect murine Mll translocations. The assay was 
validated by detecting Mll translocations in murine bone marrow cells after exposure to 
the known topoII-inhibitor etoposide (50 ʅM). In addition, bone marrow cells from 
homozygous wild-type and mutant AtmͲȴSRI mice were isolated and cultured for 
approximately 24 hours with either genistein (50 ʅM) or quercetin (50 ʅM). Cell viability 
was evaluated by trypan blue exclusion. We observed no significant decrease in cell 
viability due to exposure to either flavonoids or etoposide or due to genotype of bone 
marrow cells in comparison with DMSO treated cells (Figure 1).  
Cells were allowed to repair the DSBs for 24 hours in a drug-free medium. Subsequently, 
DNA  was  extracted  and  screened  for  Mll aberrations by inverse-PCR. The DNA isolated 
from DMSO treated samples resulted in amplification of the wild-type (wt) Mll (5.6kb) as 
visualized by agarose gel electrophoresis (Figure 2) and the identity was confirmed by 
sequence analysis. In contrast, exposure of bone marrow cells to quercetin, genistein or 
etoposide generated multiple bands of different sizes. The variety in the size of PCR 
products was determined by both the location of the breakpoint junction in Mll and the 
position of the PciI site in the fusion partner. Smaller sized bands were more likely to be 
detected by inverse-PCR than the wt Mll, because wt Mll is more difficult to amplify due to 
its length. Sequencing of the breakpoint junction of several distinct Mll translocations  
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Figure 1. Viability of wt and AtmͲѐSRI mutant bone marrow cells was determined after 1 day of exposure to 
50 ʅM of the flavonoids genistein and quercetin, 50 ʅM etoposide and the vehicle DMSO (0.05 %) by trypan 
blue exclusion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Inverse-PCR products representing Mll rearrangements found in bone marrow of wild-type and AtmͲѐSRI 
mutant cells after 24 hours in vitro exposure to quercetin (50 ʅM), genistein (50 ʅM) or etoposide (50 ʅM).  
Equal  aliquots  of  DNA  were  used  for  each  inverse-PCR  reaction.  The  samples  were  visualized  by  gel  
electrophoresis. Each band with a size different from the wt 5.6 kb band represents a translocation that results 
in an abberant size of the PCR product. Wild-type Mll is indicated with *. 
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induced by flavonoids or etoposide confirmed that the bands of abberant size were indeed 
translocations (Table 4). Although etoposide and both flavonoids induced Ml 
rearrangements in bone marrow cells regardless of the genotype of the mice, the AtmͲѐSRI 
mutant  cells  (0,  2.1,  5,  1.2  translocations/  80  ng  genomic  DNA for  the  control,  quercetin,  
genistein or etoposide exposed cells, respectively, Figure 2) showed more chromosomal 
translocations than the wt cells (0.7, 0.2, 0.2, 3 translocations/ 80 ng genomic DNA for the 
control, quercetin, genistein or etoposide exposed cells, respectively). This indicates that the 
Atm mutation predisposes cells to the clastogenic effects of flavonoids. 
 Effect of prenatal diet on litter characteristics 
Heterozygous AtmͲȴSRI  mice  were  exposed  to  genistein  (270  mg/  kg  feed,  n=9)  or  
quercetin (302 mg/ kg feed, n=8) or control diet (n=8) throughout their pregnancy. There 
were no differences in gender ratio, average weight of the offspring measured at day 5 
after birth or average liter size between control, genistein or quercetin exposed groups (Table 2). 
Interestingly, the incidence of different genotypes was to some extent affected by 
prenatal diet. Theoretically, the homozygous wild-type (wt) and mutant (mut) offspring 
should each count for approximately 25 % of the offspring. Accordingly, wt and mut 
offspring showed equal prevalence (respectively 28 % and 29 %) in the control group 
(Table 2).  The genistein and quercetin diet groups however, had different prevalences of 
the genotypes. The number of mut mice born in the quercetin group was lower than in the 
control or genistein group (P=0.06 and P=0.01, respectively). In the genistein group, the 
percentage of heterozygote animals seemed to be low, however the distribution of 
distinct genotypes was not significantly different from the control group. 
Changes in blood composition and incidence of malignancies in mice prenatally exposed to 
flavonoids 
A total number of 45 control, 45 genistein- and 40 quercetin-exposed mice reached the 
age of 12 weeks. The percentage of animals that died before this time point was not 
significantly different for all three diet groups (Table 2). We were unable to determine the 
cause of death, but at autopsy no tumors were noted. The mice that reached 12 weeks of 
age  were  sacrificed  and  their  internal  organs  were  examined  for  visual  signs  of  
abnormalities  and  presence  of  gross  tumors  (Table  2).  In  a  previous  study  (29),  
malignancies were detected in heterozygous AtmͲȴSRI  mice  on  average  after  18.6  
months. In our study, several mice had already developed malignancies at 12 weeks of 
age. One mouse in the control group (1/45) demonstrated splenomegaly with 
concomitant erythroleukemia and thymoma. On the other hand, thymoma were detected 
in three mice (3/45, 7 %) of the genistein exposed group and in one of the 40 mice (2.5 %) 
that were prenatally exposed to quercetin.  Blood count and blood smear examination 
showed concomitant acute lymphoblastic leukemia in two mice that were exposed to 
genistein. In general, leukemia and thymoma were only detected in mice that were 
homozygous for the Atm mutation. The only heterozygous mouse that was diagnosed with 
malignancy (fallopian tube tumor) belonged to the genistein group. Altogether, mutant 
mice prenatally exposed to genistein showed a slightly higher risk for developing tumors 
and leukemia compared with wt control mice. 
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Table 2 Characteristics of the litters and malignancies detected in offspring within different diet groups 
 Control Genistein Quercetin 
Average litter size 6.38 ± 2.07 5.22 ± 2.28 5.13 ± 2.30 
Genotype (%) 
        Total numbers of litters 
        wt 
        hetero 
        mut  
 
8 
 28  
43  
29  
 
9 
31 
41 
28**c 
 
8 
38 
53 
8#, **c 
Average pup weighta 3.18 ± 0.71 3.32 ± 0.58 3.13 ± 0.26 
Percentage of males 47 57 51 
% of deceased pupsb 10 7 2.5 
 Malignancies detected in offspring at 12 weeks of age 
Number of animals with 
malignancies/ total analyzed (%) 
1/45 (2 %) 4/45 (9 %) 1/40 (2 %) 
Tumor type erythroleukemia acute lymphoblastic 
leukemia, thymoma, 
fallopian tube cancer 
thymoma 
Tissue involved bone marrow,  thymus, 
spleen 
bone marrow, 
thymus, ovarian 
ducts 
thymus 
Genotype Mut mut, hetero mut 
General characteristics of the litters prenatally exposed to genistein-, quercetin-supplemented or normal 
diet. Results represent the mean ± the standard deviation.  # P=0.06, ** Pч0.01. a Average pup weight (grams) 
at day 5. b Average number of deceased pups after birth and before sacrifice day (week 12). c Significant 
difference between quercetin and genistein group. 
 
The complete blood count at 12 weeks of age was successfully carried out in duplicate 
for 41 control, 41 genistein and 39 quercetin exposed mice. The three mice that 
suffered  from  leukemia  (as  assessed  by  ADVIA  1200  Hematology  System  and  
subsequent May-Grünwald staining of blood smears) were excluded from the analysis 
due to the extreme outlying measurements. As shown in Table 3, 2x2x2 multifactorial 
univariate analysis was used to adjust for confounding variables (gender and genotype). 
Analysis of the red blood cell fraction demonstrated an increase in the mean 
corpuscular volume (MCV) for both genistein and quercetin group in comparison to the 
control (mean ± SE respectively 46.31 ± 0.34 fL, P=0.01; 46.33 ± 0.50 fL, P=0.4 and 44.96 
± 0.45 fL for control,). The red blood cell distribution width (RDW) was only significantly 
increased in the genistein group (13.92 ± 0.19 % versus 13.35  ±  0.12  %  for  control,  
P=0.03). A combined high MCV and RDW could be an indication of a higher reticulocyte 
count. Indeed, the total amount of reticulocytes was elevated in the genistein group 
(157.57 ± 17.51 x 109/ L versus 106.79 ± 15.88 x 109/ L in control, P=0.4). Although 
prenatal quercetin exposure was not associated with an increased reticulocyte count, 
the mean hemoglobin content of reticulocytes (MCHR) was higher (1.03 ± 0.01 fmol) 
compared  to  the  control  group  (0.96  ±  0.01  fmol,  P=0.07).  Prenatal  exposure  to  
genistein on the contrary significantly decreased MCHR (0.94 ± 0.03 fmol, P=0.02). 
In the genistein group, the total number of red blood cells (7.44 ± 0.12 x 1012/ L versus 
7.03 ± 0.13 x 1012/ L for control, P=0.07) and consequently the hemoglobin (7.25 ± 0.09 
mmol versus 6.78 ± 0.11 mmol for control,  P=0.009) and hematocrit  levels (0.35 ± 0.01 
L/ L versus 0.32 ± 0.01 L/ L for control, P=0.02) levels were significantly elevated. 
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Detection of Mll translocations in mice prenatally exposed to flavonoids 
In order to investigate the clastogenic effects of prenatal genistein and quercetin exposure 
we studied the occurrence of Mll translocations  in  the  fetal  liver  of  E14.5  wt  fetuses  by  
inverse-PCR.  Genomic  DNA obtained from the  fetal  liver  was  screened for  chromosomal  
aberrations (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Inverse-PCR products representing Mll rearrangements found in fetal liver cells of fetuses exposed 
to genistein or quercetin.  
Equal  aliquots  of  DNA  were  used  for  each  inverse-PCR  reaction.  The  samples  were  visualized  by  gel  
electrophoresis. Each band with a size different from the wt 5.6 kb band represents a translocation that results 
in an abberant size of the PCR product. Wild-type Mll is indicated with *. 
 
Interestingly, regardless of the maternal diet Mll rearrangements  could  be  detected  in  all  the  
fetuses. The rate of translocations between the control group and both exposure groups showed 
no differences (control: 4.3 translocations/ 80 ng genomic DNA versus 2.5 translocations/ 80 ng 
genomic DNA and 6.5 translocations/ 80 ng genomic DNA for the genistein and quercetin 
exposed fetuses, respectively). The average number of translocations is calculated as average 
number of alternative sized band seen in one inverse-PCR reaction/ DNA input in an inverse-PCR 
reaction. However, when both flavonoid exposed groups were compared, the quercetin exposed 
fetuses showed more chromosomal translocations compared to the genistein exposed fetuses. In 
order  to  confirm the  mutant  sized  bands  as  genuine  translocations  instead of  PCR-artifacts,  a  
selection of aberrant Mll products were sequenced (Table 4) and all appeared to be real Mll 
translocations with various chromosomes as fusion partners. 
Next, bone marrow of 12 week old wt or AtmͲȴSRI mut mice prenatally exposed to genistein or 
quercetin was screened for Mll translocations. As shown in Figure 4, prenatal exposure to both 
genistein and quercetin increased the frequency of Mll rearrangements. In wt control mice we 
identified 0.9 translocations/ 80 ng genomic DNA by inverse-PCR. Prenatal exposure to 
genistein increased the mutation rate in wt mice to 2.5 translocations/ 80 ng genomic DNA, 
whereas wt mice prenatally exposed to quercetin showed no change in the frequency of Mll 
rearrangements (1 translocations/ 80 ng genomic DNA).  
All three diet groups increased the incidence on Mll translocations in mice carrying the Atm 
mutation. In the control group the mutation rate increased up to 2.7 translocations/ 80 ng 
genomic DNA. This is comparable with the rate seen in wt mice prenatally exposed to 
genistein. AtmͲȴSRI mut mice prenatally exposed to genistein had a 2 fold higher translocation 
rate (5.6 translocations/ 80 ng genomic DNA) compared with their wt siblings. Although 
prenatal exposure to quercetin had no effect on the occurrence of Mll translocations  in  wt  
mice, it increased the mutation rate in AtmͲȴSRI mut mice considerably (up to 16 
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translocations/ 80 ng genomic DNA). This suggests that prenatal exposure to genistein leads to 
a modest increase in the number of Mll rearrangements, while prenatal quercetin exposure 
considerably elevates the rearrangement rate in AtmͲȴSRI  mut  mice.  Again,  a  selection  of  
aberrant Mll products was sequenced to confirm that the alternative PCR products were 
comprised of genuine translocations (Table 4). No genuine translocations were detected in the 
wt mice on control diet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Inverse-PCR products representing Mll rearrangements found in bone marrow cells of wild-type and 
AtmͲѐSRI mutant offspring mice at 12 weeks of age, prenatally exposed to genistein or quercetin.  
Equal  aliquots  of  DNA  were  used  for  each  inverse-PCR  reaction.  The  samples  were  visualized  by  gel  
electrophoresis. Each band with a size different from the wt 5.6 kb band represents a translocation that results 
in an abberant size of the PCR product. Wild-type Mll is indicated with *. 
Discussion 
It has been suggested that high intake of dietary flavonoids contributes to infant leukemia (4, 
30). However, no direct experimental evidence has yet been presented. Our previous study 
(13), together with the study of Strick (5), showed that flavonoids could induce MLL 
translocations  in  CD34+ cells.  However,  we are  the  first  to  report  that  prenatal  exposure  to  
flavonoids  can  increase  the  risk  for  leukemia  onset,  as  assessed  by  the  frequency  of  Mll 
translocations in a mouse model prone to develop cancer. To detect potential translocations, 
an inverse-PCR method was developed. In order to validate this method, murine bone marrow 
cells  of  wt  and AtmͲȴSRI mut mice were exposed to 50 ʅM of genistein, quercetin and the 
known topoII-inhibitor etoposide. DNA isolated from these cells was then subjected to inverse-
PCR amplification to detect murine Mll translocations. Although all exposures induced Mll 
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translocations, AtmͲȴSRI mut bone marrow cells that lack adequate DSB-repair were more 
susceptible for flavonoid and etoposide induced Mll rearrangements. 
To investigate the effect of prenatal exposure to flavonoids and the predisposing role of deficient 
DSB-repair, AtmͲȴSRI hetero mice were mated to obtain pups with different genetic capacity for 
DNA repair from a single mother. Bone marrow of 12 week old wt and AtmͲȴSRI mut offspring 
mice  that  were  prenatally  exposed  to  genistein  or  quercetin,  were  screened  for  Mll 
translocations, by using the inverse-PCR method. Both flavonoids were capable of inducing Mll 
translocations in wt and AtmͲȴSRI mut mice, but AtmͲȴSRI  mut  mice  showed  a  higher  
susceptibility to develop these chromosomal aberrations, which was expected from the in vitro 
results. This suggests that exposure to flavonoid supplements can have more severe 
consequences in individuals with a malfunctioning DNA repair system. Alike flavonoids, radiation 
induces DNA DSBs. Accordingly, radiation exposure has been shown to induce significantly more 
cell death and chromosomal aberrations in Atm-ȴSRI mut thymocytes than in wt cells (31). 
In order to study the direct effects of flavonoid exposure on the growing fetus, fetal livers were 
isolated at day 14.5 of pregnancy and screened for Mll translocations. These translocations 
were  detectable  in  all  fetuses,  regardless  of  the  maternal  diet.  This  indicates  that  such  
translocations might be common events during fetal development, which are probably 
generated due to high topoII activity of the proliferating cells (16). However, the fact that less 
Mll translocations  were  detected  at  12  weeks  of  age,  suggests  that  the  cells  carrying  these  
translocations are either eliminated or have restricted expansion capacity.   
Prenatal quercetin exposure in this study, led to a minor decrease in average litter size. It 
seems that quercetin exposure is more lethal to fetuses with homozygous AtmͲȴSRI 
mutations. In fact studying the direct effect of the flavonoids on the fetuses shows that 
transplacental quercetin exposure induces more chromosomal translocations than genistein. 
Both prenatal genistein and quercetin exposure had no effect on gender ratio and average 
birth weight, which suggest that in utero dietary supplementation did not affect normal 
development. Also the number of pups that died spontaneously after birth was not influenced 
by the diet. Three mice, all AtmͲȴSRI mut, developed leukemia (acute lymphoblastic leukemia 
or  erythroleukemia),  at  12  weeks  of  age,  confirming  our  hypothesis  that  a  decrease  in  DNA 
DSB-repair (ATM dysfunction) could enhance the leukemia risk. One mouse that developed 
erythroleukemia was not prenatally exposed to flavonoid supplements, suggesting that in this 
case the AtmͲȴSRI predisposition was responsible for the development of leukemia. Indeed, 
AtmͲȴSRI mut mice are known to have a 50 % chance on developing malignancies (31).  The 
ratio of malignancies between control and genistein exposed mice suggests that prenatal 
genistein exposure may increase the risk on developing malignancies. All malignancies, except 
acute lymphoblastic leukemia detected in our mice, were previously described in AtmͲȴSRI 
mice (29, 31). AtmͲȴSRI hetero mice develop different categories of tumors at an average age 
of 18.6 months. However, 44 % of the AtmͲȴSRI mut mice die of thymic lymphomas up to 10 
months  of  age.  In  our  study,  1  out  of  13  AtmͲȴSRI mut mice in the control group had 
developed malignancy at the age of 3 months. The percentage of malignancies in the genistein 
and quercetin group was respectively 23 % (3 out of 13 AtmͲȴSRI mut mice) and 25 % (1 out of 
4 AtmͲȴSRI  mut  mice).  The  decrease  in  the  number  of  AtmͲȴSRI  mut  mice  born  in  the  
quercetin group further suggests the hazards of such exposure in a vulnerable population that 
lacks an effective DNA DSB-repair.  
A complete blood count analysis showed that prenatal exposure to genistein not only influenced 
the lymphoblastic cell development, but also the myeloblastic cell development and overall 
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erythropoiesis. Prenatal exposure to genistein associates with an up-regulation of erythropoiesis 
in adult mice, as seen in the increase in the number of red blood cells, which results in an increase 
in hemoglobin and hematocrit levels (ratio cells/plasma). The increase in red blood cell 
distribution width could be the result of an increase in the number of reticulocytes, which could 
also  explain  the  increase  in  mean  cell  volume.  However,  it  could  also  indicate  that  there  is  a  
coexistence of young and old red blood cells, suggesting a longer survival of these cells. Prenatal 
exposure to quercetin on the other hand only increased the size of the red blood cells and the 
amount of hemoglobin in reticulocytes. The increase in red blood cell size could be the result of 
an increase in the amount of hemoglobin per cell. An increase in the amount of hemoglobin in 
reticulocytes, would automatically lead to an increase in the amount of hemoglobin in 
erythrocytes. Knowing that quercetin has iron ion chelating capacities (32) and the fact that the 
heme part of hemoglobin contains iron, it can be suggested that the effects seen is due to a 
disturbed iron metabolism in these mice. Further investigation is needed to unravel these aspects 
of prenatal genistein/ quercetin exposure and the mechanisms behind the long term effects of 
diet during pregnancy on blood composition.  
Due to the fact that flavonoids are present in a variety of food sources, the incidental daily intake 
can be as high as 1 g, but can increase up to several grams in those supplementing their diet with 
flavonoids.  The  average  daily  dietary  intake  of  quercetin  is  in  the  range  of  4–68  mg.   Daily  
isoflavone intake in Western countries is approximately 1 to 9 mg. In Asian countries however, 
the  daily  intake  of  isoflavones  is  much  higher,  reaching  levels  of  20-240  mg,  due  to  the  high  
consumption of soy (3).  In our study pregnant mice were exposed to approximately 26.7-36.7 
mg/ kg bodyweight genistein and 33.3-46.7 mg/ kg bodyweight quercetin per day. Record et al. 
(33) determined that mice fed 20 mg/ kg genistein had an average plasma concentration of 10 
ʅM. In this study, pregnant mice were exposed to a higher dose of genistein and quercetin, 
probably resulting in even higher plasma concentrations. These concentrations are also higher 
compared with  plasma concentrations  seen in  humans  on  both  a  Western  or  Asian  diet  (34).   
However, both flavonoids are freely available as supplements and the daily dose recommended 
by  manufacturers  can  be  as  high  as  1-2  g  per  day.  When  supplements  are  taken,  plasma  
concentrations can be 10 to 20 times higher (35) than the levels we tested in mice, indicating that 
the doses used in this study are biologically relevant. It is also noteworthy that the metabolism of 
phytoestrogens  is  different  in  the  fetus  and  adults.  In  human,  fetal  cord  blood  has  a  higher  
genistein level than maternal serum (14, 15, 36). Taken together it is important to establish clear 
guidelines for the use of flavonoid supplements during pregnancy. 
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Abstract 
Recent studies demonstrate that maternal diet during pregnancy results in long-lasting 
effects on the progeny. Supplementation of maternal diet with genistein, a phytoestrogen 
ubiquitous in the daily diet, altered coat color of Agouti mice due to epigenetic changes. 
We studied hematopoiesis of mice prenatally exposed to genistein (270 mg/ kg feed) 
compared with mice prenatally exposed to phytoestrogen-poor feed and observed a 
significant increase in granulopoiesis, erythropoiesis and mild macrocytosis at the adult 
age of 12 weeks. Genistein exposure was associated with hypermethylation of certain 
repetitive elements, which coincided with a significant down-regulation of estrogen 
responsive genes and genes involved in hematopoiesis in bone marrow cells of genistein-
exposed mice, as assessed by microarray technology. Although, genistein exposure did not 
affect global methylation in fetal liver of fetuses at embryonic day 14.5, it accelerated the 
switch from primitive to definitive erythroid lineage. Altogether, our data demonstrate 
that prenatal exposure to genistein affects fetal erythropoiesis and exerts life-long 
alterations in gene expression and DNA methylation of hematopoietic cells.   
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Introduction 
Genistein is a naturally occurring phytoestrogen found in soy products. There is an 
increasing interest in this flavonoid due to its antioxidant properties, but also because 
there is a general believe that phytoestrogen intake has beneficial effects (1, 2) . 
However, recent studies have revealed that genistein exposure through maternal diet 
during pregnancy can result in long-lasting effects on the progeny. Prenatal exposure of 
heterozygous yellow agouti mice to genistein, through maternal diet, altered both coat 
color and body weight. These changes were caused by hypermethylation of transposable 
repetitive elements (IAP) upstream of the transcription start site of the Agouti gene (3). 
Other studies have shown that transplacental exposure of rats to genistein exerts long-
lasting effects on the endocrine and immune system and altered stress response and post-
weaning  growth (4,  5).  Recently,  Möller  et al. (6) demonstrated that genistein exposure 
during development induces long-term effects on the uterine gene expression profile. 
Nutritional deficiencies (including vitamin B12 and folate) and drug exposure can affect 
blood composition; for instance macrocytosis can have different causes, ranging from 
primary bone marrow disorders to nutritional deficiencies (7). Prolonged use of estrogenic 
compounds such as oral contraceptives is also reported to induce macrocytosis, presumably 
by interfering with folate cofactor interactions and affecting DNA synthesis (8).  
In the present study we observed significant changes in blood composition of mice that 
were prenatally exposed to genistein. Prenatal genistein exposure was associated with 
increased granulopoiesis and erythropoiesis together with moderate macrocytosis at adult 
age. The macrocytosis observed in the genistein exposed animals may be attributed to 
estrogenic properties of this compound, due to its structural similarity to 17ɴ-estradiol (9). 
However, it is remarkable that such effects are observed at adult age, while genistein 
exposure has taken place only during the prenatal period. We therefore assume that the 
past exposure to genistein has left a permanent signature on the hematopoietic lineage of 
these mice. As genistein exposure is known to alter both global DNA methylation (3) and 
gene expression (6), we hypothesize that prenatal exposure to genistein leads to 
adaptation of hematopoiesis by altering both DNA methylation as well as gene expression. 
In order to find out whether genistein leaves permanent transcriptomic/epigenetic 
signatures in hematopoietic cells, we compared both DNA methylation of repetitive 
elements and gene expression profiles in hematopoietic cells of mice prenatally exposed 
to genistein with the control group at adult age. The methylation status and fetal blood 
development was also assessed during the fetal period, to study the direct effects of the 
genistein supplementation.  
Material and methods  
Mice and sample collection 
Mice  (129/SvJ:C57BL/6J  background)  approximately  8  weeks  of  age,  received  either  
normal chow (n=8, low phytoestrogen content complete feed for mice breeding, in 
which neither soybean nor alfalfa products are used, resulting in minimized 
concentrations of the phytoestrogens genistein, daidzein and coumestrol, ssniff®, 
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Soest, Germany) or the same chow (ssniff®)  supplemented with genistein (270 mg/ kg 
feed, n=9)  (LC Laboratories, Woburn, MA, USA) from 3 days before conception until 
the end of pregnancy. Male mice were placed in the cage only for the duration of 
copulation. After delivery litters were not equalized and all mothers and pups 
received normal (low phytoestrogen) diet, making the prenatal period the only 
window of exposure. Offspring were sacrificed at 12 weeks of age by cardiac puncture 
(Figure  1).  Blood  was  collected  in  EDTA-tubes  (Terumo,  Leuven,  Belgium).  Bone  
marrow was isolated by removing the femurs and flushing the marrow with PBS.  
To study the direct effects of diet on fetal hematopoiesis, mice were mated overnight. 
The presence of a vaginal plug the next morning was defined as 0.5 day post 
conception.  On  day  14.5  of  pregnancy  (E14.5),  mice  were  sacrificed  to  isolate  the  
fetuses, fetal blood and fetal liver.  
The mouse experiments were conducted in accordance with Dutch animal protection 
laws by the guidelines of the local veterinary authorities. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Study design 
Blood composition of adult mice 
Blood composition was determined in duplicate, using ADVIA 120 Hematology System 
(Siemens AG, Erlangen, Germany) following user’s manual. The following parameters 
were measured: total number of red blood cells (1012/L), hemoglobin level (mmol/ L), 
hematocrit level (L/ L), mean corpuscular volume (fL), mean corpuscular hemoglobin 
(fmol), mean corpuscular hemoglobin concentration (mmol/ L), red blood cell 
distribution width (%), hemoglobin distribution width (mmol/ L), total amount of 
platelets (109/ L),  mean platelet volume (fl),  total  amount (109/ L) and percentage of 
reticulocytes, mean corpuscular hemoglobin concentration of reticulocytes (fmol), 
total number of white blood cells (109/ L), total amount (109/ L) and percentage of 
neutrophils, lymphocytes, monocytes, eosinophils and basophils.   
Blood (fetuses) and bone marrow (adult mice) cytology  
After  initial  fixation  of  blood  (10  ʅl)  or  bone  marrow  smears  (isolated  from  one  of  
both femurs) by methanol, smears were stained in May-Grünwald solution (Sigma-
Aldrich, Steinham, Germany) for 5 minutes and washed in tap water. Subsequently, 
the smears were stained with Giemsa solution (Merck, Darmstadt, Germany) for 20 
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minutes and washed again in tap water. The blood and bone marrow smears were 
examined by two independent, experienced examiners, counting approximately 500 
cells per slide, using a Leica DMRB microscope (Leica Microsystems B.V., Rijswijk, the 
Netherlands).  
Genome-wide gene expression analysis of adult mice 
RNA  from  bone  marrow  cells  isolated  from  one  femur  was  isolated  with  TRIzol  Reagent  
(Invitrogen, Breda, the Netherlands) according to the manufacturer’s instructions. Genome-
wide gene expression was determined using whole mouse genome (4X44K) oligonucleotide 
microarrays (Agilent, Santa Clara, CA, USA) according to the manufacturer's instructions. Using 
the Low RNA Input Linear Amplification Kit (Agilent), cyanine-5-labeled cRNA was generated 
from  RNA  of  each  sample  (a  total  of  6  bone  marrow  samples:  3  controls  and  3  genistein-
exposed male mice). Next, samples were hybridized together with cyanine-3-labeled reference 
cRNA produced from the RNA pool of the 3 control mice (reference sample).  Image analysis 
and initial quality control were performed using the Agilent Feature Extraction (FE) Software 
v10.5 and Spotfire DesicionSite v9.1 (TIBCO Spotfire, Somerville, MA, USA). Thereafter, 
microarray data analysis was performed by importing the text-files generated by the Agilent FE 
Software into R2.8.1 using the Bioconductor ‘limma’ package 2.8.1 (10). The values for control 
spots and spots that did not meet the quality control criteria were flagged. The flagged spots 
were not used in the statistical analysis. In addition, the background-corrected intensities of all 
microarrays were normalized using the locally weighted scatterplot smoothing (LOESS) 
algorithm. Finally, a linear model was fitted to the intensities for each reporter, and the 
genistein-treated mice were compared to controls using an unpaired moderated t-test using 
the ‘limma’ functions lmfit and eBayes (10). Benjamini-Hochberg adjusted P-values were used 
to correct for multiple testing. All Agilent reporters were re-annotated to ensure reporter 
specificity and to optimize recognition by the pathway analysis procedures  (11).  
Methylation-sensitive McrBC-real-time polymerase chain reaction (PCR) assay of fetuses 
and adult mice 
Analysis of methylation pattern of the repetitive elements, i.e. long interspersed 
nucleotide elements (LINEs), short interspersed nucleotide elements (SINEs), 
intracisternal A particle (IAP), major and minor satellites, was performed using the 
methylation-sensitive McrBC-real-time PCR assay (12). 1 ʅg of genomic DNA was 
digested  overnight  at  37  °C  using  10  U of  McrBC (New England Biolabs,  Beverly,  MA,  
USA), an endonuclease which cleaves DNA containing 5-methylcytosine, but will not 
cleave unmethylated DNA. The DNA strand breaks prevent amplification of 
methylated DNA in the quantitative real-time PCR assay. Two-step quantitative real-
time PCR was performed using IQ SYBR Green Supermix (Bio-Rad Laboratories, 
Veenendaal, the Netherlands) with 4 ng of McrBC-digested DNA and 25 pmol of each 
primer (Eurogentec, Maastricht, the Netherlands) in a reaction volume of 25 ʅl. The 
forward and reverse primers sequence for the different repetitive elements and 
endogenous reference were: LINE: 5`-TTTGGGACACAATGAAAGCA-3` and 5`-
CTGCCGTCTACTCCTCTTGG-3`; SINEB1: 5`-GTGGCGCACGCCTTTAATC-3` and 5`-
GACAGGGTTTCTCTGTGTAG-3`; SINEB2: 5`- GAGATGGCTCAGTGGTTAAG-3` and 5`-
CTGTCTTCAGACACTCCAG-3`; IAP-GAG: 5`-AGCAGGTGAAGCCACTG-3` and 5`-
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CTTGCCACACTTAGAGC-3; Major satellite: 5`-GACGACTTGAAAAATGACGAAATC-3` and 5`-
CATATTCCAGGTCCTTCAGTGTGC-3`; and Minor satellite: 5`-CATGGAAAATGATAAAAACC-
3` and 5`-CATCTAATATGTTCTACAGTGTGG-3`. The cycling conditions consisted of an initial 
denaturation at 95 °C for 10 minutes, followed by 40 cycles of 95 °C for 45 seconds, 58 °C 
for 90 seconds, with an exception for the major and minor satellites for which this step 
was performed at 60 °C, using the iCycler (Bio-Rad). Data were analyzed by MyiQ Software 
system (Bio-rad), Ct values were normalized for endogenous reference (HPRT), compared 
with the calibrator (i.e. average Ct value of 4 control samples for the adult mice and of 3 
control samples for the fetuses) and expressed as relative expression (2ͲȴȴCt). An increase 
in PCR amplification products is indicative of hypomethylation, whereas a decrease in PCR 
amplification products indicates hypermethylation. 
Results 
Prenatal exposure to genistein influences hematopoiesis in adulthood 
A comparison of the complete blood count of 41 male and female adult mice (12 
weeks  of  age)  from  9  different  litters  (with  an  average  size  of  6.4  ±  2.1)  that  were  
prenatally exposed to genistein through maternal diet (supplemented with 270 mg 
genistein/ kg diet from 3 days before conception throughout pregnancy), with the 
same number of age matched male and female control mice from 8 different litters 
(with an average litter size of 5.2 ± 2.3), demonstrated significant differences in blood 
composition (Table 1). Prenatal exposure to genistein was associated with higher 
number of red blood cells (mean ± SD, 7.44 ± 0.71 x 1012 cells versus 7.03 ± 0.80 x 1012 
cells, P=0.03) and reticulocytes (157.57 ± 52.54 x 109 cells versus 106.79 ± 42.00 x 109 
cells,  P=0.06).   In  accordance,  the  mean  corpuscular  volume  (46.31  ±  2.10  fL  versus 
44.96 ± 2.80 fL, P=0.02), red blood cell distribution width (13.92 ± 1.12 versus 13.35 ± 
0.75, P=0.01), hemoglobin (7.25 ± 0.53 mmol/ L versus 6.78 ± 0.67 mmol/ L, P=0.001) 
and hematocrit levels (0.35 ± 0.04 L/ L versus 0.32 ± 0.05 L/ L, P=0.004) were elevated 
in the genistein group. Examination of the bone marrow cellularity of adult mice 
(n=3), which were prenatally exposed to genistein, showed no significant difference in 
the number of early and late erythroid progenitors with the control group.  
 
Table 1. Persistent effects of prenatal genistein exposure on blood composition in 12 week old mice 
 Control (n=41) Genistein (n=41)  
 Mean ± SE Mean ± SE P-value 
Red blood cells  (1012/  L) 7.03 ± 0.13 7.44 ± 0.12 0.026 
Hemoglobin (mmol / L) 6.78 ± 0.11 7.25 ± 0.09 0.001 
Mean corpuscular volume (fL) 44.96 ± 0.45 46.31 ± 0.34 0.018 
Hematocrit (L/ L) 0.32 ± 0.008 0.35 ± 0.007 0.004 
Absolute amount of reticulocytes (109/ L) 106.79 ± 15.88 157.57 ± 17.51 0.056 
Red blood cell distribution width (%) 13.35 ± 0.12 13.92 ± 0.19 0.013 
White blood cells (109/ L) 1.45 ± 0.9 1.79 ± 0.16 0.064 
Absolute amount of neutrophils (109/ L) 0.23 ± 0.14 0.32 ± 0.03 0.021 
Absolute amount of eosinophils (109/ L) 0.06 ± 0.005 0.09 ± 0.02 0.041 
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However, the number of pyrenocytes was significantly elevated in the genistein 
exposed animals, indicating an increased enucleation of the erythroid cells (10.47 ± 
5.39 % versus 1.28 ± 1.49 %, P=0.047) (Figure 2).  Furthermore, we observed a higher 
number of granulocytic cells in the genistein exposed animals (39.57 ± 4.93 % versus 
24.91 ± 9.58 %, P=0.08), which is in accordance with the significantly higher number of 
neutrophils (0.32 ± 0.20 x 109 cells versus 0.23 ± 0.09 x 109 cells, P=0.02) and 
eosinophils (0.09 ± 0.09 x 109 cells versus 0.06 ± 0.03 x 109 cells,  P=0.04)  in  the  
peripheral blood. 
 
 
 
Figure 2. Long-term effect of prenatal exposure to genistein on bone marrow cellularity.  
Bone marrow smears of 12 week old mice from the control (n=3; white bars) and genistein exposed (n=3; black 
bars) group were analyzed to determine the number of pyrenocytes, early and late (proerythroblast, basophilic 
erythroblast and ortochromic erythroblast) erythroid progenitors and granulocytic cells. Bars represent the 
percentage of cells. Error bars represent the standard error. Statistically significant differences were analyzed 
using One-way ANOVA: *: P<0.05. 
Prenatal genistein exposure modifies gene expression in adulthood 
As prenatal exposure to genistein had induced long-term effects on the blood and 
bone marrow composition, we hypothesized that the effects of this past exposure to 
genistein would still be detectable in the gene expression profile of the hematopoietic 
cells.  Therefore,  we  compared  the  gene  expression  profile  of  bone  marrow  cells  of  
animals which were prenatally exposed to genistein (n=3) with that of the control 
group (n=3), using whole mouse genome (4X44K) oligonucleotide microarrays 
(Agilent).  The  animals  selected  for  the  microarray  analysis  were  all  male  mice  and  
belonged to different litters to minimize possible litter effects. Approximately 20 % of 
the 21,742 annotated gene products was differentially expressed between the 
genistein and the control group (n=4352, 1.2<fold change or fold change <-1.2, 
P<0.05). 83 % and 36 % of the gene products belonging respectively to the estrogen 
receptor signaling and hematopoiesis pathway (according to GO terms and literature) 
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were differentially expressed. Unsupervised hierarchical clustering of differentially 
expressed genes with a high degree of statistical significance (P<0.001) demonstrates 
overall differences in gene expression between groups. It is noteworthy that the gene 
products that were significantly up-regulated in the genistein group (fold change>1.2, 
P<0.001) represent only 10 % of the total number of differentially expressed genes.  
Previously, it has been demonstrated that in vitro exposure of XG-1 myeloma cell line 
to genistein results in down-regulation of NF-ʃB and NF-ʃB-regulated gene products, 
including Bcl2l1, Cyclin D1 and intercellular adhesion molecule-1 (Icam-1) (13). In our 
study, genistein exposure resulted in a down-regulation of NF-ʃB and NF-ʃB-regulated 
gene products, including Bcl2l1, Cyclin D1 and intercellular adhesion molecule-1 
(Icam-1) in the hematopoietic cells of mice prenatally exposed to genistein. In 
addition to Icam-1, prenatal genistein exposure attenuated the expression of several 
other  adhesion  molecules,  such  as  neural  cell  adhesion  molecule  1  (Ncam1), E-
cadherin (Cdh1), integrin beta 1 (Intgb1), integrin alpha 1 (Itga1) and chemoattractant 
protein  1  (MCP-1), P-selectin and  selectin  P  ligand  (Selplg). Also Nocht1, Mdm2 and 
Pdkcd showed a significantly lower mRNA expression, 12 weeks after withdrawal from 
genistein exposure. Likewise, the expression levels of certain genes, such as Cdkn1b 
(p27kip1) and retinoblastoma binding protein 8 (Rbbp8) were elevated in the 
genistein exposed animals. Interestingly, some other genes that were previously 
reported to be up-regulated in reaction to direct genistein exposure at adulthood 
(Stat3, Pten and component C3) (14, 15) were significantly suppressed in mice that 
were exposed to genistein during in utero development.  
Although some of the differences in gene expression can partly be attributed to 
differences in bone marrow cellularity, persistent effects of genistein exposure on 
gene expression were still observed 12 weeks after withdrawal of the genistein 
exposure. 
Significant down-regulation of estrogen responsive genes 
Because it is known that genistein is a phytoestrogen, and thus has estrogenic 
properties (16), we studied the expression of different estrogen responsive genes. 
Notably, several estrogen responsive genes (Grin2d, ApoE, Cdkn1a, Macrod, Vegfa, 
Hdac6, Tacc1, Abcc5, Ctsd, Ccnd1, Pcna, Igf2) were suppressed in the hematopoietic 
cells of adult mice prenatally exposed to genistein (Table 2). It is known that 
activation of the aryl hydrocarbon receptor (AhR) by its ligands, e.g. benzo[a]pyrene 
and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), promotes the expression of the 
estrogen-responsive genes (17). It is remarkable that the AhR expression level was 
indeed significantly elevated (fold change=1.49, P-value=0.006) in the bone marrow of 
mice that were prenatally exposed to genistein. 
Changes in expression of genes involved in hematopoiesis 
AhR is known to regulate mRNA expression of several genes with important roles in 
hematopoiesis, including Cdkn1b (p27Kip1), Cdkn1a (p21 waf1/cip1), Cdk2, Myc and 
genes encoding for CCAAT/enhancer-binding protein (18). Strikingly, the expression of 
Cdkn1b, Cebpa, Cebpb was  up-regulated,  while  the  expression  of  Myc was down-
regulated, indicating that granulocyte differentiation was stimulated. Cdk2, up-
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regulated during primitive erythropoiesis, was significantly repressed in the genistein 
group, suggesting an increase in adult erythropoiesis (Table 3). AhR normally binds its 
chaperon Arnt to associate with the estrogen receptors and to activate transcription 
of estrogen-responsive genes (19). However, Arnt mRNA expression was significantly 
down-regulated (fold change=-3.06, P-value=6.4 x 10-6) in the genistein group. In 
addition to the genes regulated by AhR, we encountered several other hematopoiesis-
related genes that were differentially expressed in bone marrow of the genistein 
group. A deficiency in Cdkn1a, Egln1, Stat3, Dok1 and Pten gene expression is known 
to increase proliferation of hematopoietic stem cells. All these genes were 
significantly repressed in the genistein group; while Bmi1 and Angpt1,  which  are  
required respectively for the self-renewal and protection of hematopoietic stem cells, 
were up-regulated. A down-regulation of Myc in the genistein group was also associated 
with lower expression of Thbs1 and Vegf, resulting in a lower expression of the cell-
surface receptor of Vegf (Kdr). In general, the expression of several genes that regulate 
erythroid cell function and development (Bcl2l1, Stat5a, Gata1, Mapk14, Epb4.2, Maea, 
Slc12a4, Dhfr, Flvcr1, Thpo, Epb4.1 and Ptprc) were significantly altered in the genistein 
group, resulting in an up-regulation of erythrocyte proliferation. Moreover, genistein 
exposed mice showed an altered expression of genes contributing to an enhanced 
granulocytic differentiation/proliferation (Lrg1, Cebpa, Icam1, JunB, Thbs1, Cdk2 and 
Cdkn1b).  
 
Table 2. Down-regulation of estrogen responsive genes in the bone marrow of adult mice prenatally exposed 
to genistein 
 
Gene 
Genebank 
accession  
number 
Description 
Fold 
change 
P-value 
Cdkn1a  (p21 
waf1/cip1)  
NM_007669 Cyclin-dependent kinase inhibitor 1A -1.78 0.006 
Ctsd NM_009983 Cathepsin D -2.05 0.0002 
Ccnd1 NM_008796 Cyclin D1 -2.04 0.0002 
Pcna NM_011045 Proliferating cell nuclear antigen -1.99 0.0007 
ApoE NM_009696 Apolipoprotein E -2.14 0.002 
C3 NM_009778 Complement component 3 -1.50 0.009 
Igf2 NM_010514 Insulin-like growth factor 2 -2.69 0.02 
Grin2d NM_008172 Glutamate receptor, ionotropic, N-methyl-
D-aspartate subunit 2d 
-1.50 0.02 
Macrod1 NM_134147 Macro domain-containing 1 -1.73 0.003 
Vegfa NM_001025250 Vascular endothelial growth factor -1.93 0.004 
Hdac6 NM_010413 Histone deacetylase 6 -1.89 0.006 
Abcc5 NM_013790 ATP-binding cassette subfamily C member 5 -2.50 0.00008 
Tacc1  NM_177089 Transforming, acidic, coiled-coil-  
containing protein 
-2.52 0.0003 
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Prenatal genistein exposure leads to long-term epigenetic changes  
As genistein exposure, early in development, exerts long-term changes in gene expression, 
we assumed that these effects might be mediated through epigenetic modification.  
To examine whether prenatal genistein exposure could lead to long-term epigenetic 
modifications, we employed an assay in which the methylation-sensitive endonuclease 
McrBC cleaves methylated DNA but leaves unmethylated CpGs intact. By subsequent PCR 
ampliĮcation, one could quantify the unmethylated repetitive elements (12).  
Using this assay, we determined the methylation status of major and minor satellites, 
intracisternal A particle (IAP-GAG), long interspersed nucleotide elements (LINE1) and 
short interspersed nucleotide elements (SINEB1 and SINEB2) in hematopoietic cells of 
both the control and the genistein group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The effect of genistein on DNA methylation of repetitive elements.  
A Long-term effects of prenatal exposure to genistein on DNA methylation of repetitive elements in bone 
marrow  cells  of  mice  prenatally  exposed  to  genistein  (n=3)  compared  with  control  mice  (n=3).  B  Short-term  
effects of prenatal exposure to genistein on DNA methylation of repetitive elements in fetal liver at E14.5 
(genistein exposed fetuses n=4 versus control fetuses n=4). The degree of methylation of repetitive elements: 
long interspersed nucleotide elements (LINE1), short interspersed nucleotide elements (SINEB1 and SINEB2), 
intracisternal A particle (IAP-GAG), and Major and Minor satellites were determined by methylation-sensitive 
McrBC-real-time PCR assay. Bars represent the normalized average expression level of the unmethylated 
repetitive elements between the genistein-exposed (black bars) and the control group (white bars). Error bars 
represent standard error. Statistical significance was determined by One-way ANOVA: *: P<0.05. 
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These elements constitute almost 37.5 % of the mouse genome (20). Overall, bone 
marrow cells of the genistein group (n=3) showed moderate hypermethylation of the 
repetitive elements observed as lower level of PCR products after McrBC digestion 
compared with the control group (n=3, Figure 3A). Especially, the SINEB1 and SINEB2 
elements were significantly hypermethylated (P=0.045 and P=0.042, respectively). In order 
to investigate whether these epigenetic modifications had already occurred in utero, we 
studied the methylation status of the repetitive DNA elements in the fetal liver (E14.5) of 
the control group (n=4) and compared with genistein exposed fetuses (n=4). We did not, 
however, observed any difference in the methylation status of repetitive elements 
between the diet groups at that particular time point (Figure 3B).  
Genistein exposure affects fetal blood cell development  
Although methylation status of the repetitive elements in fetuses which were exposed to 
genistein through maternal diet was not significantly different from that of the control 
group, their blood composition already showed substantial differences. Normally the 
switch from primitive to definitive erythroid lineage starts at embryonic day 11.5 (21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effect of genistein exposure on the primitive and definitive erythroid lineage. 
Blood smears of fetuses (E14.5) from the control (n=15; white bars) and genistein exposed (n=9; black bars) 
group were analyzed.  Bars represent the percentage of cells from the primary and different definitive erythroid 
(i.e. proerythroblast, basophilic erythroblast and ortochromic erythroblast) lineage.  Error bars represent 
standard error. Statistical significance was determined by One-way ANOVA: *: P<0.05; ***: P<0.001. 
 
A comparison of fetal blood composition (Figure 4) between the genistein (9 mice from 2 
litters, n=9) and the control animals (15 mice from 2 litters, n=15) at E14.5, demonstrated 
an accelerated switch from primitive erythroid lineage to definitive lineage in the fetuses 
that were exposed to genistein. The percentage of primary erythrocytes was significantly 
decreased due to genistein exposure (22.23 ± 26.02 % versus 92.05 ± 8.31 %, P<0.001) 
while the percentage of definitive erythrocytes was increased (77.77 ± 26.01 % versus 7.96 
± 8.31 %, P<0.001). This increase reflected an overall expansion of definitive progenitors at 
various  stages.  The  percentage  of  proerythroblasts  (4.92  ±  3.86  % versus 1.92  ±  1.75  %,  
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P=0.02), and especially of basophilic (26.89 ± 17.88 % versus 3.17 ± 3.27 %, P<0.001) and 
orthochromic  erythroblasts  (45.97  ±  37.57  %  versus 2.86  ±  3.82  %,  P<0.001)  were  
significantly different between the diet groups. 
Discussion 
In this study, we demonstrate that prenatal exposure of mice to genistein affects fetal red 
blood cell development and leaves a permanent signature on the hematopoietic lineage. 
Microarray  analysis  of  hematopoietic  cells  of  mice  at  12  weeks  of  age  revealed  that  
prenatal genistein exposure had induced a distinct gene expression profile. Strikingly, 
some persistent effects of genistein exposure on gene expression could be observed (e.g. 
down-regulation of NF-ʃB, NF-ʃB-regulated gene products and several adhesion 
molecules), while genistein was no longer provided through diet. In general, prenatal 
genistein exposure was associated with pronounced down-regulation of gene expression. This 
down-regulation might be partly due to hypermethylation of CpG motifs in the regulatory 
regions of certain genes. In fact, we demonstrate that prenatal genistein exposure induced 
hypermethylation of some CpG-rich repetitive elements. However there is no straightforward 
relation between the hypermethylation seen in the repetitive elements and the change in gene 
expression. Pogribny et al. (22) previously reported that DNA hypermethylation and 
macrocytosis coincided, as observed in our study. This is presumably by interfering with folate 
cofactor interactions what affects DNA synthesis and points to the involvement of one-carbon 
metabolism pathway. It is noteworthy that several genes involved in this pathway, e.g. 
dihydrofolate reductase (Dhfr; fold change=-1.59; P-value=0.004), serine 
hydroxymethyltransferase 2 (Shmt2; fold change=-1.76; P-value=0.005), 
methylenetetrahydrofolate dehydrogenase 2 (Mthfd2; fold change=-2.98; P-value=8.93 x 
10-5), 5,10-methenyl-tetrahydrofolate synthetase (Mthfs; fold change=-1.58; P-value=0.05) 
and S-adenosylhomocysteine hydrolase-like 2 (Ahcyl2; fold change=-3.31; P-
value=0.0008), were significantly down-regulated in the genistein exposed animals.  
Prenatal genistein exposure in mice resulted in significant alterations in blood and bone 
marrow composition later in life, manifested as increased granulopoiesis and 
erythropoiesis. It is noteworthy that genistein exposed mice exhibited macrocytosis (3 % 
increase in mean corpuscular volume). The increase in mean corpuscular volume is partly 
due to the higher number of reticulocytes. On the other hand, the increased 
erythropoiesis may demand recruitment of more primitive erythroid cells and the 
progenitor cells may differentiate without prior division. All these phenomena can lead to 
macrocytosis (23). Remarkably, both Dhfr (24) and Flvcr1 (25), whose deficiencies 
associate with macrocytosis were down-regulated in the genistein exposed mice. 
Furthermore, these mice showed down-regulation of Vegf. Inhibition of Vegf is reported 
to increase the hematocrit level (26). Hence the hematocrit level was significantly 
increased (P=0.004) in mice prenatally exposed to genistein.  
Mice in the genistein group had significantly higher numbers of neutrophils (P=0.02) and 
eosinophils (P=0.04) in the peripheral blood, which was probably a result of the increased 
granulopoiesis in their bone marrow as seen in Figure 2. Microarray analysis showed that 
several genes, whose lack of expression associates with defects in granulocytic lineage, 
were down-regulated in the genistein group (e.g. Cebpa (27), JunB (28) and Icam1 (29)). 
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Furthermore, Cdk2 expression was down-regulated in the bone marrow, while Cdkn1b 
mRNA was increased. This gene expression pattern relates to end-stage differentiation of 
neutrophil granulocytes (30).  Thus indicating that prenatal exposure to genistein results in 
an up-regulation of the granlulocytic differentiation, what also could be seen in the 
increased level of granulocytes detected in both blood and bone marrow of these mice.  
As it is know that genistein can stimulate bone marrow formation (31), we assume that most 
alterations in gene expression are related to genistein-induced changes in bone marrow 
cellularity. However there are certain changes that do not seem to be directly related to 
differences in marrow cellularity, for instance changes in the expression of genes that are 
directly related to genistein exposure or changes in estrogen responsive genes.  
Genistein is a well known endocrine-disrupting compound that, due to its structural 
similarity to 17ɴ-estradiol, exerts its effect through estrogen receptors (9). Several 
estrogen responsive genes were suppressed in the bone marrow of adult mice that were 
prenatally exposed to genistein. Down-regulation of estrogen responsive genes has also 
been reported after exposure to certain other endocrine-disrupting chemicals, known as 
AhR agonists (e.g. benzo[a]pyrene and TCDD) (17). It is therefore possible that AhR is 
involved in the genistein-induced gene expression pattern. In fact Zhang et al. (32) 
demonstrated that genistein is a ligand of AhR. It has previously been shown that 
exposure to AhR ligands can affect hematopoietic blood composition. Exposure of mice to 
TCDD, skewed differentiation of bone marrow cells in favor of granulocytic and myeloid 
lineage and altered transcription of several genes (e.g. Myc, Hes1, Cdkn1a, Cdkn1b, Cebp, 
Per1 and Per2). Likewise, culturing CD34+ progenitors with the polyaromatic hydrocarbon 
benzo[a]pyrene, another AhR ligand, skews differentiation toward myeloid cells (30). 
Therefore, not only the distinct gene expression profile, but also cellular composition of 
the blood and bone marrow of the genistein exposed mice show signs of AhR 
involvement. Future studies need to explore the effects of prenatal exposure to other 
AhR-ligands on hematopoiesis.  
In our study, direct exposure of mice fetus to genistein accelerated the switch from primitive 
erythroid lineage to definitive erythroid lineage. Normally, this switch starts at embryonic day 
11.5 when blood circulation has been fully established (21). Examination of fetal blood 
composition at E14.5 revealed that the percentage of definitive erythrocytes were significantly 
higher in the genistein group (P<0.001). It is therefore evident that genistein exposure during 
development has both direct- and long-term effects on hematopoiesis. 
Prenatal genistein exposure leads to long-term epigenetic changes. Exposure of 
heterozygous yellow agouti mice to genistein via maternal diet shifted the coat color by 
hypermethylation of transposable repetitive elements upstream of the transcription start 
site of the Agouti gene. Although genistein exposure terminated after weaning, the 
altered coat color remained unchanged throughout life (3). Our results show that prenatal 
genistein exposure associates with hypermethylation of the SINEB1 (P=0.045) and SINEB2 
(P=0.042) repetitive elements in bone marrow, at adult age. SINE transcripts are normally 
up-regulated in response to cell stress. Both the SINEB1 and SINEB2 classes are strongly 
up-regulated in mice after prolonged exposure to gamma radiation or DNA-damaging 
compounds, e.g. cisplatin, etoposide (33). Genistein is also a potent DNA-damaging agent, 
due to its topoisomerase-II inhibiting property (34). It is also interesting to study the direct 
effects of genistein exposure on SINE repetitive elements. The results presented here 
demonstrate that despite of the long-term effects of genistein on SINEB1 and SINEB2, the 
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methylation status of these repeats is not affected directly by genistein exposure during 
fetal development, but occurs at later time points.   
In our study pregnant mice were exposed to approximately 0.8 mg genistein per day. In 
human, adults consuming modest amounts of soy-containing foods have a total dialy 
isoflavone intake of approximately 1 to 9 mg. In Asian countries however, the daily intake 
of isoflavones is much higher, reaching levels of 20-240 mg, due to the high consumption 
of soy (35). Also vegetarians, who consume large amounts of soy products, have a high 
intake of genistein.  Due to potential health benefits associated with genistein intake, 
observed as decreased risk for developing breast and prostate cancer in Asian countries 
(36), genistein supplements are becoming increasingly popular. The manufacturers 
recommend a daily dose of up to 6 tablets of 25-100 mg of these supplements. It is 
noteworthy that the metabolism of phytoestrogens is different in the fetus. In human, 
fetal cord blood has a higher genistein level than maternal serum (16). As genistein 
accumulates in the fetus and affects hematopoiesis, it is important to establish clear 
guidelines for fetal exposure to soy derivatives. 
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Abstract 
The in utero environment is predominantly determined by the maternal diet and may alter 
the risk for several diseases at adult age. Flavonoids are polyphenolic compounds in our 
diet that are known for their antioxidant properties and their ability to up-regulate the 
enzymatic antioxidant capacity of cells. Therefore, we investigated whether maternal 
intake  of  genistein  (1  mmol/  kg  feed)  or  quercetin  (1  mmol/  kg  feed)  could  modulate  
antioxidant capacity and subsequent oxidative stress induced DNA damage in liver and 
lung tissue of 12 week old offspring mice. At day 14.5 of gestation, intake of these 
flavonoids increased gene expression of several antioxidant genes in the liver of fetuses. 
This effect persisted till adult age, because 12 week old mice prenatally exposed to 
flavonoids still had enhanced expression of some of these antioxidant genes in liver and 
lung. In liver, relative expression of hemeoxygenase-1 (Ho1) was >6-fold enhanced by 
maternal quercetin intake, which indicates Nrf2-pathway activation. This is in line with the 
observation that prenatal exposure to genistein, but especially to quercetin resulted in 
lower levels of oxidative stress induced DNA lesions in liver, while no effects were found in 
lung. Prenatal diet had mild effect on the non-enzymatic antioxidant capacity of the liver 
at adult age, which was vitamin C independent. Prenatal exposure to genistein increased 
the non-enzymatic antioxidant capacity of the lung, though no changes in the amount of 
oxidative stress induced DNA lesions were found. These results suggest that prenatal 
exposure to flavonoids protects against oxidative stress induced DNA damage in the liver 
by a persistent pre-emptive trigger of the enzymatic antioxidant system. 
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Introduction 
Studies in humans and animals have shown that the in utero environment is determinant for 
the risk of several diseases at older age, including cancer (1, 2) as well as metabolic (3-5) and 
cardiovascular  disorders  (3,  6).  Since  reactive  oxygen  species  (ROS)  are  thought  to  play  an  
important  role  in  the  development  and  progression  of  all  these  chronic  diseases  (7)  and  
because the in utero environment is predominantly determined by the maternal diet, one 
could speculate that intake of dietary antioxidants during pregnancy may provide an in utero 
environment that may prevent the development of chronic diseases later in life. One major 
source of antioxidants in our diet are the polyphenolic flavonoids (8). The daily dietary intake of 
mixed flavonoids in the human population ranges from 65 to 250 mg/ day (9). The most 
predominant flavonoid in the human diet is quercetin, which is mainly found in onions, apples, 
tea and red wine (8, 10). Another widely consumed flavonoid is the phytoestrogen genistein, 
which is mainly found in soy products (11, 12). Flavonoids are thought to be health beneficial 
since in epidemiological studies they were associated with protection against cardiovascular 
diseases (13, 14) and neurodegenerative diseases (15, 16) and they acted anti-inflammatory 
(17, 18). These effects are mainly thought to be the result of their antioxidant property (8, 19) 
as  ROS  play  a  major  role  in  disease  development  and  progression  (20-26).  However,  pro-
oxidant effects have also been reported (27-30). 
Besides antioxidant nutrients, cells also possess enzymatic antioxidants to protect them against 
endogenous and exogenous sources of oxidative stress, like superoxide dismutase (Sod) which 
scavenges superoxide (O2
-•) and catalase (Cat) and glutathione peroxidase (Gpx) which 
scavenge hydrogen peroxide (H2O2) (31, 32). An important transcription factor that regulates 
gene expression to counteract oxidative stress is the nuclear erythroid 2-related factor 2 (Nrf2). 
This transcription factor is normally targeted for proteasomal degradation by binding to its 
chaperon Kelch-like ECH-associated protein (Keap1). However, ROS and electrophiles can alter 
the conformation of the Nrf2-Keap1 complex resulting in the nuclear translocation of Nrf2. 
Here, it can bind to antioxidant response elements (ARE) in the promoter region of target 
genes (for instance hemeoxygenase-1, Ho1) resulting in up-regulation of their gene expression 
(33, 34). The flavonoid quercetin was found to regulate the Nrf2-pathway and as such enhance 
the antioxidant potential of cells (35, 36). Hur et al. (34) stated that a pre-emptive activation of 
the Nrf2 pathway potentiates the level of a wide range of protective enzymes that counteract 
oxidative and environmental stresses, and confers resistance to subsequent challenges of 
cellular stress. On the other hand, Breinholt et al. (37) showed that female mice exposed for 2 
weeks to high doses of several flavonoids, including genistein and quercetin, had reduced 
activity of glutathione reductase, Cat and Gpx in red blood cells. Still, these rats were protected 
from 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP)-induced oxidative stress as 
seen in the decreased levels of plasma malondialdehyde.  
Overall, these data indicate that there is a close relation between dietary and enzymatic 
antioxidants and this relation can potentially be affected by the presence of antioxidants in the 
in utero environment. Therefore, we investigated whether prenatal exposure to genistein and 
quercetin could affect the antioxidant capacity at adult age. To this end, we exposed female 
mice from 3 days before and throughout the gestation to genistein (1 mmol/ kg feed) or 
quercetin (1 mmol/ kg feed).  The gene expression of genes involved in the Nrf2-pathway and 
of several other antioxidant genes (Cat, Sod2 and Gpx3) was determined in liver and lung of 
adult  offspring  mice,  and  also  in  the  liver  of  fetuses  (at  day  14.5  of  gestation)  exposed  to  
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genistein or quercetin. To study the non-enzymatic antioxidant capacity of liver and lung the 
trolox equivalent antioxidant capacity (TEAC), vitamin C levels and the presence of vitamin C 
radicals in 12 week old mice prenatally exposed to genistein or quercetin was determined. ROS 
induced DNA damage was determined in adult mice by measuring 8-oxo-7,8-dihydro-2ƍ-
deoxyguanosine (8-oxo-dG) and malondialdehyde-deoxyguanosine (M1dG) levels in DNA from 
liver and lung.  
Material and methods  
Mice and sample collection 
Female mice (129/SvJ:C57BL/6J background) approximately 8 weeks of age, received 
either normal chow (low phytoestrogen content complete feed for mice breeding, ssniff®, 
Soest, Germany) or the same chow supplemented with genistein (1 mmol (270 mg)/ kg 
feed, LC Laboratories,  Woburn, MA, USA) or with  quercetin (1 mmol (302 mg)/ kg feed, 
Sigma, Zwijndrecht, the Netherlands) from 3 days before conception until the end of 
gestation. After delivery all mothers and pups, regardless of their prenatal diet, received 
normal chow and the offspring were sacrificed by cardiac puncture after anesthesia at 12 
weeks of age. Liver and lung tissue of 5 male mice per diet were isolated.  
To determine the direct effects of genistein and quercetin exposure on antioxidant gene 
expression, female mice (129/SvJ:C57BL/6J background) were mated overnight and 
conception day was determined by recognition of a vaginal plug the next morning 
(considered  as  day  0.5  of  gestation).   Female  mice  were  placed  on  the  same  control  or  
genistein- or quercetin-enriched chow as described above, starting three days before 
conception. On day 14.5 of gestation (E14.5), mice were sacrificed to isolate fetal livers. 
Quantitative real-time PCR 
RNA was isolated from liver of E14.5 fetuses and from the lung and liver of 12 week old mice 
by homogenizing the tissue using TRIzol Reagent (Invitrogen, Breda, the Netherlands) 
according to manufacturer’s instructions and using the Ultra-Turrax homogenizer (IKA, 
Staufen, Germany). Quantity and purity control of the RNA was spectrophotometrically 
assessed by using the Nanodrop 1000 (Thermo Scientific, Wilmington, USA). Next, 1 ʅg of 
RNA was used to synthesize cDNA using the iScript cDNA synthesis kit (Biorad, Hercules, 
USA) following manufacturer’s instructions. The reaction was performed using a Biometra 
Tprofessional thermocycler (Biometra, Leusden, the Netherlands).  
An aliquot of one 10th of the resulting cDNA was applied for quantitative PCR ampliĮcation 
together  with  12.5  µl  SYBR  Green  (Qiagen)  and  7.5  pmol  of  each  primer  (see  Table  1,  
Eurogentec, Maastricht, the Netherlands) in a volume of 25 ʅl. The reactions were carried 
out using a MyiQ Single Color RT-PCR detection system (Bio-rad), under the following 
conditions: 1 cycle at 95 °C for 3 minutes and then 40 cycles at 95 °C for 15 seconds and 60 
°C for 1 minute followed by 1 cycle at 95 °C for 1 minute and 1 cycle at 65 °C. Data were 
analyzed  by  MyiQ  Software  system  (Bio-rad),  Ct  values  were  normalized  for  an  
endogenous reference gene (ɴ-actin) and compared with the calibrator (i.e. average Ct 
value of control samples) and expressed as fold change (2ͲȴȴCt). 
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Table 1: Forward and reverse primers used for quantitative real-time PCR 
  Forward primer (5’-3’) Reverse primer (5’-3’) 
Cat AGCGACCAGATGAAGCAGTG TCCGCTCTCTGTCAAAGTGTG 
Sod2 CAGACCTGCCTTACGACTATGG CTCGGTGGCGTTGAGATTGTT 
Gpx3 CCTTTTAAGCAGTATGCAGGCA CAAGCCAAATGGCCCAAGTT 
Keap1 CGGGGACGCAGTGATGTATG TGTGTAGCTGAAGGTTCGGTTA 
Nrf2 CTTTAGTCAGCGACAGAAGGAC AGGCATCTTGTTTGGGAATGTG 
Ho1 TCCAGAGTTTCCGCATAC CGGACTGGGCTAGTTCA 
ɴ-actin CAAGAAGGAAGGCTGGAAAAGA ACGGCCAGGTCATCACTATTG 
Liver and lung tissue homogenates  
To determine TEAC, vitamin C level and vitamin C radical formation in liver and lung tissue, 
liver and lung extracts were obtained by homogenizing the tissue in cold 10 mM Tris 150 
mM KCl buffer (pH 7.4), using the Ultra-Turrax homogenizer (IKA), followed by 
centrifugation at 4 °C for 15 minutes. Protein concentration of the homogenates was 
determined by the Lowry assay (Bio-Rad) with bovine serum albumin as a standard. 
Trolox equivalent antioxidant capacity 
The antioxidant capacity (TEAC) was quantified as TEAC according to Fischer et al. (38). 
The samples were deproteinized with a final concentration of 5% trichloroacetic acid 
(TCA). The samples were than incubated with ABTS radical solution prepared according 
the procedure described previously (38). After five minute incubation, the absorbance at 
734 nm was determined. The assay was calibrated using solutions of the synthetic vitamin 
E analog trolox. The TEAC is expressed in trolox equivalents.  
Vitamin C concentration in liver and lung tissue 
To determine the vitamin C level, 250 ʅl of liver or lung homogenate was deproteinized 
using 10 % trichloroacetic acid (TCA) (1:4). Ascorbate was oxidized to dehydroascorbate 
using ascorbate oxidase. Subsequently, o-phenylene diamine was added, to convert 
dehydroascorbate into a fluorescent product that was quantified using HPLC. HPLC 
analysis of the samples was performed using a reverse phase C18 column with methanol 
potassium phosphate buffer (20/80) as eluens, using a fluorescence detector with 355 nm 
as excitation and 425 nm as emission wavelengths. 
Electron spin resonance spectroscopy 
To determine the presence of vitamin C radicals, liver and lung homogenates were placed 
on ice for direct measurements using electron spin resonance (ESR) spectroscopy. ESR 
spectra were recorded using the settings as previously described by Linschooten et al. (39) 
on a Bruker EMX 1273 spectrometer equipped with an ER 4119HS high sensitivity 
resonator. Vitamin C radical signals, characterized by a doublet with a splitting constant 
(AH) of 1.8 G were quantified (in arbitrary units) through peak surface measurements 
using the WIN-EPR spectrum manipulation program. 
 
 
Chapter 4 72 
8-oxo-dG measurements 
Genomic DNA isolation and 8-oxo-dG measurements were performed as described 
previously (40). Briefly, HPLC with electrochemical detection (ECD) was performed using 
genomic DNA obtained by grinding frozen liver and lung, followed by standard phenol 
extraction (41). The DNA-extraction procedure was optimized to minimize artificial 
induction of 8-oxo-dG, by using radical-free phenol, minimizing exposure to oxygen and by 
addition  of  1  mM  deferoxamine  mesylate  and  20  mM  TEMPO  (2,2,6,6-
tetramethylpiperidine-N-oxyl). DNA concentrations were spectrophotometrically 
quantified at 260 nm. HPLC-ECD of 8-oxo-dG was performed by digesting 30 ʅg DNA to 
deoxyribonucleosides by adding of 6 ʅl 0.5 M NaAc, 9 ʅl 10 mM ZnCl2 and 1.5 ʅl nuclease 
P1 (stock: 1 U/ ʅl) and incubation for 90 minutes at 37 °C. Subsequently, 30 ʅl 0.5 M Tris–
HCl  (pH  7.4)  and  1.5  ʅl  alkaline  phosphatase  (0.014  U/  ʅl)  were  added  followed  by  
incubation at 37 °C for 45 minutes. The digest was then analyzed by HPLC-ECD on a 
Supelcosil™ LC-18S column (250 mm × 4.6 mm) (Supelco Park, Bellefonte, PA, USA) in 
combination with a DECADE electrochemical detector (Antec, Leiden, the Netherlands). 
The ECD-signal was first stabilized with mobile phase (94 mM KH2PO4, 13 mM K2HPO4, 
26 mM KCl and 0.5 mM EDTA, 10 % methanol) for approximately 3 hours at a flow rate of 
1 ml/ minute. After stabilization, 8-oxo-dG was detected at a potential of 400 mV and dG 
was simultaneously monitored by UV absorption at 260 nm. 
M1dG level measurements 
Genomic DNA was isolated from liver and lung tissue of adult mice using DNAzol Reagent 
(Invitrogen, Bleiswijk, the Netherlands) following the manufacturer’s protocol and by 
homogenizing the tissue using an Ultra-Turrax homogenizer (IKA, Staufen, Germany). 32P-
DNA post-labeling of M1dG was performed as described previously (42).  Reference adduct 
standards were used for the optimization of the 32P-DNA post-labeling procedure. DNA (2 
ʅg)  was  digested  by  micrococcal  nuclease  and  spleen  phosphodiesterase.  Hydrolyzed  
samples were subsequently treated with 2.5 ʅg of nuclease P1 for 30 minutes at 37 °C. The 
nuclease P1-treated samples were incubated with 15–25 ʅCi of [ɶ-32P]-ATP (3000 Ci/ mmol) 
and T4-polynucleotide kinase (0.75 U/ ʅl) to generate 32P-labeled  M1dG. Samples were 
applied to the origin of polyethyleneimine-cellulose (PEI) sheets (10 x 20 cm) and developed 
with  0.35  MgCl2 for  2.0  cm on a  filter  paper  wick.  Plates  were  developed in  the  opposite  
direction with 2.1 M lithium formate, 3.75 M urea (pH 3.75), and then run at the right angle 
to the previous development with 0.24 M sodium phosphate, 2.4 M urea (pH 6.4). Detection 
and quantification of M1dG and total nucleotides was obtained by storage phosphor imaging 
technique employing intensifying screens (Molecular Dynamics, Sunnyvale, CA, USA) for 
0.20–48 hour. The screens were scanned using a Typhoon 9210 (Amersham, 
Buckinghamshire,  UK).  To  process  the  data  ImageQuant  (Molecular  Dynamics)  was  used.  
After background subtraction, the levels of M1dG-adducts were expressed as relative adduct 
labeling (RAL=screen pixel in adducted nucleotides/ screen pixel in total normal nucleotides). 
To calculate the levels of total normal nucleotides, aliquots of hydrolyzed DNA were 
appropriately diluted and reacted in the same mixtures used for M1dG labeling. The 
obtained 32P-labeled total nucleotides were separated on PEI-cellulose-sheets using 280 mM 
ammonium sulfate and 50 mM sodium phosphate. The values measured for M1dG-adducts 
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were corrected across experiments based on the recovery of internal standard after the 32P-
DNA postlabeling assay. 
Statistical analysis 
Statistical analysis was performed with Statistical Package for Social Sciences (SPSS version 
17 for Windows, SPSS Inc., Chicago, IL, USA). Nested ANOVA was performed to investigate 
the effect of genistein or quercetin exposure on genes involved in antioxidant defense 
system of the fetal liver (day 14.5 of gestation). ANOVA was applied to test differences in 
antioxidant gene expression, non-enzymatic antioxidant capacity, vitamin C level and radical 
formation; and oxidative stress induced DNA damage in liver and lung of 12 week old control 
mice compared to 12 week old mice prenatally exposed to genistein or quercetin. To avoid 
litter effects no more than two adult mice per litter were used for statistical analysis. 
Results 
Exposure to quercetin induced Nrf2 and Sod2 expression in the liver of fetuses at day 14.5 
of the pregnancy  
To investigate whether exposure to antioxidants/ pro-oxidants could directly affect the 
gene expression of several antioxidant genes including the key regulators of the oxidative 
stress response pathway, namely Nrf2, its negative regulator Keap1 and down-stream 
target gene Ho1, of the unborn child, female mice were exposed via their diet to genistein 
(1 mmol/ kg feed) or quercetin (1 mmol/ kg feed) starting from three days before 
conception and female mice were sacrificed at day 14.5 of gestation. The liver of the 
fetuses were isolated to determine gene expression. Results showed that only exposure to 
quercetin could induce the gene expression significantly at day 14.5 of the gestation, 
namely of Sod2 (P=0.001) and Nrf2 (P=0.04, Figure 1). 
Prenatal exposure to flavonoids induced Nrf2-pathway in liver and antioxidant genes in 
liver and lung of 12 week old mice 
To investigate whether the prenatal diet still had a measurable effect on gene expression 
of enzymatic antioxidants in offspring at adulthood, expression of genes involved in the 
antioxidant defense system (Cat, Sod2, Gpx3, Nrf2, Keap1 and Ho1)  was assessed in liver 
and lung of adult offspring mice. In the liver of 12 week old mice prenatally exposed to 
quercetin we found that Nrf2 (P=0.002), Ho1 (P=0.02), Cat (P=0.04) and Gpx3 (P=0.05) 
gene expression was increased compared to offspring mice of non-supplemented mothers 
(Figure 2A). Interestingly, of these genes only Nrf2 gene  expression  was  already  up-
regulated in liver of fetuses at day 14.5 of gestation. Adult mice prenatally exposed to 
genistein also showed a significant increase in gene expression of Nrf2 (P=0.01), while 
induction of Cat in the liver did just not reach statistical significance (P=0.06).  
In the lung of the genistein exposed mice only Gpx3 gene expression showed a significant 
increase (P=0.03) compared to control animals (Figure 2B). In addition, prenatal exposure 
to genistein also resulted in a modest increase in gene expression of Sod2 gene expression 
(P=0.07) in the lung of 12 week old mice whereas prenatal exposure to quercetin induced 
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Sod2 gene expression significantly (P=0.01). Keap1 gene expression was also significantly 
increased (P=0.04) in mice prenatally exposed to quercetin, as was for Nrf2, though not 
statistically significant (P=0.09). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Direct effect of genistein and quercetin exposure on antioxidant, Keap1, Nrf2 and Ho1 gene 
expression in the liver of E14.5 fetuses.  
mRNA expression level of antioxidant genes (Cat, Sod2 and Gpx3), Keap1, Nrf2 and Ho1 were measured in the 
liver of E14.5 fetuses. Grey bars represent the genistein exposed group (n=5), black bars the quercetin exposed 
group (n=5) and white bars the control group (n=5). Bars represent the normalized average fold change 
(calculated as 2ͲȴȴCT) and error bars represent the standard errors. *: P<0.05, ***: Pч0.001. 
Prenatal exposure to genistein increases the non-enzymatic antioxidant capacity of the lung 
Although a relation between maternal flavonoid intake during gestation and enzymatic 
antioxidant expression was observed, one cannot exclude that there might also be a long-
lasting effect on the non-enzymatic antioxidant capacity directly induced by the prenatal 
diet or in response to alterations in the enzymatic antioxidant defense system. Therefore, 
the non-enzymatic antioxidant capacity of both liver and long tissue of 12 week old mice 
prenatally exposed to genistein or quercetin was determined. Hence, the trolox equivalent 
antioxidant capacity (TEAC) was assessed, in combination with vitamin C levels and the 
presence of vitamin C radicals in tissue extracts. In liver tissue of adult mice prenatally 
exposed to genistein or quercetin no significant differences in TEAC were noticeable, 
though it seemed that the liver TEAC levels were slightly decreased, while for the lung 
prenatal exposure to genistein significantly increased TEAC levels (P<0.05, Table 2). This 
suggests that only prenatal exposure to genistein could affect the non-enzymatic 
antioxidant capacity of liver and lung at adult age.  
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Figure 2. Long-term effect of genistein and quercetin exposure on antioxidant, Keap1, Nrf2 and Ho1 gene 
expression in the liver and lung of 12 week old mice.  
mRNA expression level of antioxidant genes (Cat, Sod2 and Gpx3), Keap1, Nrf2 and Ho1 were measured in the 
liver (A) and lung (B) of 12 week old mice prenatally exposed to either genistein (grey bars, n=5) or quercetin 
(black bars, n=5) compared to the control group (white bars, n=5). Bars represent the normalized average fold 
change (calculated as 2ͲȴȴCT) and error bars represent the standard errors. #: Pч0.09, *: P<0.05, **: Pч0.01. 
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Next, vitamin C levels were measured in liver and lung tissues of mice prenatally exposed 
to either genistein or quercetin. Although it appeared that more vitamin C was present in 
the lung of adult mice prenatally exposed to genistein compared to quercetin exposed and 
control mice, no significant differences were found, due to the high variation within the 
genistein exposed group (Table 2). In addition, when comparing the contribution of 
vitamin C to the trolox capacity of these organs, there was no difference between control 
and exposed animals (Table 2).  
 
Table 2: TEAC, vitamin C concentration and vitamin C radical level measured in the liver and lung of 12 week 
old mice prenatally exposed to genistein or quercetin 
  Control Genistein Quercetin 
Liver TEAC (ʅmol/ g) 54. 2 ± 8.9 41.8 ± 4.1 40.9 ± 8.7 
 Vitamin C (ʅmol/ g) 21.5 ± 4.4 20.2 ± 1.7 21.2 ± 1.8 
 Vitamin C/ TEAC ratio 0.4  0.5  0.5 
 Vitamin C radical (1 x 105 AUC/ g) 0.3 ± 0.2 0.4 ± 0.2 0.3 ± 0.1 
Lung TEAC (ʅmol/ g) 50.3 ± 4.7 64.6 ± 4.0* 49.3 ± 4.6 
 Vitamin C (ʅmol/ g) 7.5 ± 1.7 19.2 ± 7.2 8.2 ± 4.2 
 Vitamin C/ TEAC ratio 0.1 0.3 0.2 
 Vitamin C radical (1 x 105 AUC/ g) 8.5 ± 0.6 7.2 ± 0.3#a 7.2 ± 0.2#a 
For each measurement n=5 for all three the diets. AUC: area under the curve. Data represent mean ± SE.  
*: P<0.05; #: P<0.08; a: P=0.05 for both flavonoids compared to control. 
Prenatal exposure to flavonoids decreased the in vivo scavenging of ROS by vitamin C in 
the lung tissue of adult mice 
Next, we investigated how these organs coped with oxidative stress in vivo by measuring 
the vitamin C radical level in tissue homogenates using ESR spectroscopy. In the liver of 
mice prenatally exposed to genistein or quercetin there were no differences seen in the 
amount of vitamin C radicals compared to control mice (Table 2). In the lung on the 
contrary, prenatal exposure to flavonoids resulted in a decrease in the amount of vitamin 
C radicals formed in vivo (P=0.05 taken both flavonoids together; P=0.06 for genistein; P= 
0.08 for quercetin) compared to control mice.  
Prenatal exposure to flavonoids protected the liver against oxidative stress induced DNA 
damage 
In both liver and lung of adult offspring mice, Nrf2 expression was upreglated by maternal 
flavonoid intake. However, its downstream regulated gene Ho1 was only increased in liver, 
which indicates that an antioxidant response may have been triggered in the liver. In lung, 
increased Nrf2 expression coincided with enhanced Keap1 expression, which may inhibit 
further Nrf2 signaling. Therefore, it was expected that a persistent antioxidant effect can 
only be seen in the liver. Indeed, oxidative stress induced DNA damage in liver was 
decreased in mice prenatally exposed to genistein (P=0.04) or quercetin (P=0.003) as they 
displayed lower levels of 8-oxo-dG compared to control mice (Figure 3A). In the lung, 
prenatal exposure to genistein or quercetin had no effect on the amount of 8-oxo-dG 
levels compared to control mice (Figure 3C).  
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Another type of DNA damage induced by oxidative stress and lipid peroxidation is M1dG. 
Interestingly, these data confirmed the findings observed for 8-oxo-dG, since prenatal 
exposure to both genistein and quercetin resulted in decreased levels of M1dG in liver 
(P=0.008  for  genistein  and  P=0.001  for  quercetin;  Figure  3B),  while  no  differences  in  the  
amount of M1dG was detected in the lung of 12 week old mice (Figure 3D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. ROS induced DNA damage in liver and lung tissue of 12 week old mice prenatally exposed to 
genistein or quercetin.  
8-oxo-dG (A, C) and M1dG (B, D) levels were assessed as measure for ROS induced DNA damage in the liver (A, 
B)  and lung  (C,  D)  of  12  week  old  mice  prenatally  exposed to  either  genistein  (grey  bars)  or  quercetin  (black  
bars) compared to the control group (white bars). Data represents the mean ± SE. RAL=relative adduct labeling. 
*: P<0.05, **: Pч0.01, ***: Pч0.001 
Discussion 
In this study we showed that prenatal exposure to both genistein and quercetin protected 
against oxidative stress induced DNA damage in the liver,  as shown by lower levels of 8-
oxo-dG and M1dG in 12 week old mice. We assume that this is the result of long-lasting 
adaptations made in the antioxidant network as seen in the up-regulation of the 
enzymatic antioxidants. 
During development, direct exposure to quercetin resulted in an up-regulation of Nrf2 gene 
expression in the fetal liver at day 14.5 of gestation. Nrf2 is the key transcription factor 
regulating the antioxidant response. It is normally targeted for proteasomal degradation by 
Keap1. However it translocates into the nucleus when oxidative stress occurs, since this 
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results  in  a  conformational  change  of  Keap1  and  therefore  the  release  of  Nrf2  (43).  The  
increase in Nrf2 gene expression suggests that quercetin acted as a pro-oxidant in utero, 
which has also been shown in vitro (35, 44). Fetuses exposed to genistein also had an 
increase in Nrf2 gene expression, though not statistically significant. This suggests that 
genistein also had a pro-oxidant action in utero, but milder compared to quercetin. 
However, the lower induction of Nrf2 gene expression seen in fetuses exposed to genistein 
could also be due to the fact that genistein impedes the nuclear export and degradation of 
Nrf2 after it has activated antioxidant response genes (45). This suggests that an up-
regulation of Nrf2 gene expression is not essential for genistein induced activation of the 
Nrf2-pathway, which may in our model also result in a different effect in the adult offspring. 
Although Nrf2 gene expression was elevated in exposed fetuses compared to control 
fetuses, expression of a major target gene of Nrf2, namely Ho1 was only modestly elevated. 
This indicates that gene expression levels of Nrf2 does not necessarily result in more 
functional Nrf2 proteins; or upon an oxidative stress induced trigger, Nrf2 could not 
translocate into the nucleus to perform its function. Moreover, due to the fact that Nrf2 has 
to reach a threshold before it can enter the nucleus and induce downstream effects (43), it 
could be that in our model at gestationa day 14.5 this threshold has not been reached yet. 
Fetuses exposed to quercetin were also found to have increased gene expression of Sod2. 
Sod2 normally converts O2
-•, a byproduct of the mitochondrial electron transport chain into 
H2O2 and O2. De Marchi et al. (46) showed that rat liver mitochondria exposed to quercetin 
had an increased production of O2
-•,  explaining the up-regulation of Sod2 gene expression 
seen in fetuses exposed to quercetin.  
At adult age, mice prenatally exposed to genistein, but especially to quercetin still had 
increased expression of Nrf2 in their liver. Moreover, they also showed an increased 
expression of the Nrf2 target gene Ho1 in their liver, suggesting that the increased 
expression of Nrf2 also resulted in an increased down-stream effect, modulating oxidative 
stress responses.  
Moreover, prenatal exposure to genistein and quercetin resulted in the increased 
expression of the antioxidant genes Cat and Gpx3 in the liver of adult mice. Both 
antioxidants are responsible for scavenging H2O2 and their mRNAs are shown to 
accumulate in utero to be translated in advance of birth (47),  as  these  enzymes  are  
needed from then onwards for protection against oxidative stress by aerobic respiration. 
Therefore, it is possible that the effect of genistein and quercetin exposure on the 
induction of gene expression of these genes could not be observed during mid-gestation, 
but long-lasting effects are seen in adult offspring.  
The lung of mice prenatally exposed to genistein and quercetin showed a totally different 
enzymatic antioxidant network compared to the liver. Here, Nrf2 gene expression was also 
up-regulated in case of both flavonoids. However, Keap1 gene expression was increased to a 
comparable extent. Therefore, we assume that the oxidative stress response pathway was 
activated to a lesser degree, which was also confirmed by the modest increase in Ho1 gene 
expression and no effect on DNA damage parameters. In the lung, prenatal exposure to 
genistein and quercetin also resulted in the up-regulation of Sod2 and Gpx3 gene expression, 
while Cat gene expression remained unaffected. Differences in antioxidant gene expression 
profiles between liver and lung tissue of adult mice prenatally exposed to genistein or 
quercetin could be explained by the fact that the liver is largely differentiated before birth 
(48), while the lung develops mainly in the final stages of pregnancy and even continues to 
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develop after birth (49). Therefore, the different responses of both tissues to the flavonoids 
could be the result of a difference in maturation state of the organ during exposure.  
Although prenatal exposure to genistein and quercetin resulted in the up-regulation of the 
gene expression of enzymatic antioxidants, it had only minor effects on the non-enzymatic 
antioxidant capacity. TEAC levels in liver were slightly decreased while in lung they were 
only increased in case of prenatal exposure to genistein. The contribution of vitamin C to 
the TEAC did not differ between diet groups, suggesting that prenatal exposure to 
genistein or quercetin affected other components of the non-enzymatic antioxidant 
network. Still, lungs of mice prenatally exposed to genistein had increased levels of 
vitamin C, although not significantly due to the large variation within the genistein 
exposed group, compared to the control group. Unlike humans, mice synthesize vitamin C 
from glucose in the liver (50). As genistein exposure can result in an increased uptake of 
glucose by cells (51) and improves glucose tolerance (52), we assume that mice prenatally 
exposed to genistein produce more vitamin C and transport it throughout the body, for 
instance to the lung, as they may be programmed to take up more glucose.  
Vitamin C radicals were measured in liver and lung homogenates as they seem to provide 
a stable and reliable signal for oxidative stress (39). In the liver of mice prenatally exposed 
to genistein and quercetin, there was no difference in the amount of vitamin C radicals 
formed in vivo. In the lung however, the amount of vitamin C radicals was slightly 
decreased in mice prenatally exposed to flavonoids, probably as a result of modest 
increase in both the enzymatic as non-enzymatic antioxidant activity.   
In our study pregnant mice were exposed to approximately 26.7-36.7 mg/ kg bodyweight 
genistein and 33.3-46.7 mg/ kg bodyweight quercetin per day. This is a high, but biological 
relevant dose, because the average human daily dietary intake of quercetin is in the range 
of 10–100 mg (53) and the average human daily dietary isoflavone intake lies between 1-
40 mg (54). Both flavonoids are freely available as dietary supplements with a daily 
recommended dose that can be as high as 1-2 gram per day (55, 56), which could 
correspond to 14-28 mg for a person weighing 70 kg. Moreover, it is noteworthy that the 
metabolism of flavonoids differs between fetuses and adults. In humans, fetal cord blood 
has a higher genistein level than maternal serum (57), suggesting that the fetus could be 
exposed to even higher concentrations. 
These data show that prenatal exposure to genistein but especially quercetin results in a 
pro-oxidant trigger in utero, with long-lasting effects on the antioxidant capacity of the 
liver and lung. These long-lasting effects may be mediated through epigenetic mechanisms 
and need further study. Mild effects were seen for the non-enzymatic antioxidants, 
suggesting that prenatal exposure to genistein and quercetin results in an adapted 
antioxidant defense system in both organs and activated the Nrf2-antioxidant pathway in 
the liver. This resulted in the protection from oxidative stress induced DNA damage in the 
liver of adult mice prenatally exposed to genistein and quercetin. 
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Abstract 
The flavonoid quercetin is a powerful iron chelator, capable of oxidizing heme iron in 
hemoglobin from Fe2+ to Fe3+. Moreover, quercetin crosses the placenta and accumulates 
in the fetus. Since adaptations made by the fetus to cope with inappropriate nutrition may 
lead to permanent changes, a relative high intake of quercetin may have detrimental 
affects later in life. Therefore, we investigated the effects of maternal exposure to 
quercetin (302 mg/ kg feed), starting from 3 days before conception until the end of 
gestation, on erythropoiesis and iron homeostasis at embryonic day 14.5 and in 12 week 
old mice. During fetal development, quercetin exposure had no effect on the erythroid 
lineage switch and concomitant globin switch. However, adult mice prenatally exposed to 
quercetin had significant increased iron storage in the liver, by up-regulating iron-
associated cytokine expression (hepcidin, IL-1ɴ, IL-6 and IL-10). These long-term changes 
in gene expression could be mediated through epigenetic modifications, as prenatal 
quercetin exposure resulted in a modest hypermethylation of repetitive elements. Despite 
the increased iron levels, oxidative stress was significantly decreased in the liver of these 
animals as assessed by 8-oxo-dG levels. These data suggest that prenatal quercetin 
exposure results in increased iron storage, while decreasing oxidative stress induced DNA 
damage together with a shift towards increased expression of inflammation associated 
cytokines in the liver at adult age. 
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Introduction 
Flavonoids are polyphenolic compounds found in diverse foods and beverages of plant origin, 
such as fruits, vegetables, soy products, tea and wine. They are most commonly known for the 
health benefits they provide against cancer and heart diseases, which is attributed to their 
antioxidant capacity (1). Quercetin (3,3',4',5,7-pentahydroxyflavone) is the most widely 
consumed flavonoid in the diet. This polyphenolic compound is a potent free radical scavenger 
and iron chelator. Previous studies have shown that quercetin can penetrate the cytoplasm of 
erythrocytes (2, 3). Here, it interacts with the heme iron in hemoglobin and oxidizes it from the 
ferrous (Fe2+) to the ferric (Fe3+) state. This latter form of hemoglobin, namely methemoglobin, is 
inactive and is incapable of transporting oxygen (3). About 65 % of the body’s iron is used for the 
production of hemoglobin. Iron is an essential micronutrient that besides erythropoiesis is also 
required for oxidative metabolism and immune responses. Iron absorption is tightly regulated 
due to the fact that the body has no effective means of excreting iron and iron overload leads to 
toxicity due to increased free radical formation (4). Quercetin can also have pro-oxidant 
capacities (5), especially in the presence of transition metal iron (6). As it has been shown that 
several  flavonoids  can  cross  the  placenta  to  accumulate  in  fetal  tissue  (7),  and  because  we  
previously  showed  that  prenatal  exposure  to  quercetin  resulted  in  a  higher  incidence  of  Mll 
translocations in mice with an impaired DNA repair (8), we assume that quercetin can also cross 
the placenta. Therefore it is interesting to study the iron chelating effect of quercetin in 
developing fetuses. Godfrey et al. (9) stated that adaptations made by the fetus to cope with 
inappropriate nutrition may lead to morphological and physiological changes that persist into 
postnatal life. These changes, although ensuring fetal survival, may have detrimental affects later 
in life. We therefore investigated whether prenatal exposure to the iron chelator quercetin could 
result in a permanent change in iron homeostasis and erythropoiesis later in life. 
To this end, mice were prenatally exposed to quercetin (302 mg/ kg feed) and erythropoiesis (red 
blood cell (RBC) progenitor composition, RBC turnover and globin status) was assessed at adult 
age. Microarray analysis of the bone marrow cells was performed to investigate the expression of 
genes involved in erythropoiesis and iron homeostasis. Liver and spleen iron levels and gene 
expression of hepcidin and interleukins (IL) involved in iron storage in the liver were investigated. 
In addition, 8-oxo-dG levels were measured in the liver of 12 week old mice as a measure for iron 
induced oxidative stress. To investigate whether long-term effects already occurred in utero, the 
effect of quercetin exposure on fetal erythropoiesis was studied in female mice that were 
exposed to quercetin and sacrificed at gestational day 14.5 as the switch in erythroid lineage 
occurs at that developmental time point. Subsequently, erythropoiesis in the liver of fetuses was 
investigated. Also the total amount of iron, bilirubin and erythropoietin (EPO) levels were 
measured in the amniotic fluid of these fetuses to characterize iron status and homeostasis. 
Material and methods  
Mice and sample collection 
Female mice (129/SvJ:C57BL/6J background) approximately 8 weeks of age, received either 
normal chow (low phytoestrogen content complete feed for mice breeding, ssniff®, Soest, 
Germany, n=8) or the same chow supplemented with quercetin (302 mg/ kg feed, n=8, 
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Sigma, Zwijndrecht, the Netherlands) from 3 days before conception until the end of 
gestation. After delivery all mothers and pups, regardless of their prenatal diet, received 
normal chow and the offspring were anesthetized and sacrificed by cardiac puncture at 12 
weeks of age. Bone marrow was isolated by removing the femurs and flushing the marrow 
with PBS; liver and spleen were isolated and stored at -80 °C until further analysis.  
To determine the direct effects of quercetin on erythropoiesis in fetuses, female mice 
(129/SvJ:C57BL/6J background, n=5 for control group and n=3 for quercetin exposed group) 
were mated overnight and conception day was determined by recognition of a vaginal plug 
the  next  morning  (E0.5).   Female  mice  were  placed  on  the  same  control  or  quercetin  
enriched chow, as described above, from three days before conception. On day 14.5 of 
gestation, mice were sacrificed and the amniotic fluid, placentas, fetuses and their blood and 
liver were isolated. Also the liver of the mothers was isolated for further analysis. 
Fetal blood and adult bone marrow cytology 
After initial fixation of the fetal blood or adult bone marrow smears by methanol, smears 
were stained for 5 minutes with May-Grünwald solution (Sigma). After removing the 
excess May-Grünwald solution by washing the smears in tap water, they were stained 
with Giemsa solution (Merck, Darmstadt, Germany) for 20 minutes. Afterwards, smears 
were again washed in tap water. Blood and bone marrow smears were examined using a 
Leica DMRB microscope (Leica Microsystems B.V., Rijswijk, the Netherlands) under a 620 × 
oil-immersion magnification and analyzed using the Leica IM50 image manager (Leica). 
Two independent examiners assessed the blood and bone marrow smears and judged 
approximately 500 cells on each slide. 
Microarray analysis of bone marrow cells  
RNA from bone marrow cells isolated from one femur (n=3 for both diet groups) was 
isolated with TRIzol Reagent (Invitrogen, Breda, the Netherlands) according to the 
manufacturer’s instructions. Genome-wide gene expression was determined using whole 
mouse genome (4X44K) oligonucleotide microarrays (Agilent, Santa Clara, CA, USA) as 
described previously  (10). More detailed information regarding the analysis of microarray 
data can be found in the supplementary data†. 
 Quantitative real-time PCR analysis  
RNA was isolated from the liver of E14.5 fetuses, from the spleen and liver of 12 week old mice 
and from the liver of maternal mice at gestational day 14.5 by homogenizing the tissue using 
the Ultra-Turrax homogenizer (IKA, Staufen, Germany), after which TRIzol Reagent (Invitrogen) 
was added according to the manufacturer’s instructions. RNA isolation of the bone marrow 
samples of 12 week old mice was performed using TRIzol LS Reagent (Invitrogen) according to 
the manufacturer’s instructions. Quantity and purity control of the RNA was 
spectrophotometrically assessed by using the Nanodrop 1000 (Thermo Scientific, Wilmington, 
USA).  Next,  1  ʅg  of  RNA  was  used  to  synthesize  cDNA  using  the  iScript  cDNA  synthesis  kit  
(Biorad, Hercules, USA) following manufacturer’s instructions. The reaction was performed 
using a Biometra Tprofessional thermocycler (Biometra, Leusden, the Netherlands).  
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For determination of globin mRNA levels a quantitative real time-PCR was carried out 
using 12.5 µl iQ Supermix (Biorad), 7.5 pmol of each forward/reverse primer (see Table 1, 
Eurogentec, Maastricht, the Netherlands), 5 pmol FAM-probe (Eurogentec) in a volume of 
25 ʅl. cDNA concentration used depended on the analyzed gene (ɺ-, ɴH1-, ɸɶ-globin: 667 
ng; ɲ-, ɴ-globin:  67  ng  for  adults  and  667  ng  for  fetuses).  For  determination  of  
hemeoxygenase-1 (Ho1), hepcidin and interleukin (IL)-1ɴ, IL-6, IL-10, a quantitative real-
time PCR mixture comprising of 12.5 µl IQ SYBR Green (Qiagen), 7.5 pmol of each 
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forward/reverse  primer  (see  Table  1,  Eurogentec)  in  a  volume  of  25  ʅl  was  used.  cDNA  
concentration used depended on the analyzed gene (hepcidin, IL-1ɴ, IL-6, IL-10: 667 ng; 
Ho1:  200  ng).  All  of  the  reactions  were  performed  using  a  MyiQ  Single  Color  RT-PCR  
detection system (Biorad) under the following cycling conditions: 1 cycle at 95 °C for 3 
minutes and then 40 cycles at 95 °C for 15 seconds and 60 °C for 1 minute followed by 1 
cycle  at  95  °C  for  1  minute  and 1  cycle  at  65  °C.  Data  were  analyzed  by  MyiQ Software  
system (Biorad), Ct values were normalized for endogenous reference (GPA for ɺ-, ɴH1-, 
ɸɶ-, ɲ-,ɴ-globin; and ɴ-actin for Ho1, hepcidin, IL-1ɴ, IL-6 and IL-10), compared with the 
calibrator (i.e. average Ct value of control samples) and expressed as fold change using the 
2ͲȴCt method for the globin genes and the 2ͲȴȴCt for  Ho1, hepcidin and IL genes. 
Biochemical component determination in amniotic fluid 
For the determination of the total amount of iron, bilirubin and EPO levels, the amniotic fluid 
of  all  pups  from  one  litter  were  pooled.  The  total  iron  amount  and  bilirubin  levels  were  
determined in the amniotic fluid using the Synchron LX20 system (Beckman Coulter, Fullerton, 
USA). Briefly, the Synchron LX20 system determined the iron concentration using a fixed-time 
endpoint method. First, iron was dissociated from the transport protein transferrin and Fe3+ 
was reduced to Fe2+. Hereafter, the total amount of Fe2+ was complexed with the Ferrozine iron 
reagens. The difference in absorption was measured and was proportional to the amount of 
total iron in the sample.  
Bilirubin was determined using a timed-endpoint diazo method to measure the concentration 
of total bilirubin. In the reaction, bilirubin reacted with diazo reagent in the presence of 
caffeine, benzoate, and acetate as accelerators to form azobilirubin. The system monitored the 
change  in  absorbance  at  520  nm  at  a  fixed  time  interval.  This  change  in  absorbance  was  
directly proportional to the concentration of total bilirubin in the sample.  
The amount of EPO was detected in the amniotic fluid by IMMULITE 1000 (Siemens), an 
automated quantitative immunoassay analyzer that uses the immulite chemiluminescent 
immunoassay system. Sample and ligand-labeled anti-EPO antibody were incubated with 
the solid phase. EPO in the sample bound to the monoclonal antibody was immobilized 
onto the solid phase. Alkaline phosphatase labeled polyclonal anti-EPO antibody was then 
introduced, which bound to the EPO attached to the solid phase, and unbound enzyme 
conjugate was removed by a wash step. A chemiluminescent substrate was added, and 
the photon output, which was proportional to the EPO concentration in the sample, was 
measured by a luminometer. 
Total iron levels measured by atomic absorption spectrometry 
Total amount of iron was measured in the liver of the mothers during gestation, and liver 
and spleen of 12 week old offspring by atomic absorption spectrometry. Ground tissues 
were hydrolyzed overnight in 1 ml of 7 M HNO3 at 60 °C. After centrifugation, 20 ʅl of the 
supernatant was directly injected into a graphite-furnace atomic absorption spectrometer 
with Zeeman background correction (Varian, Bergen op Zoom, the Netherlands). Fe 
concentrations were determined at 372 nm. Solutions with known concentrations of Fe 
were  used  for  calibration.  All  the  glassware  was  rinsed  with  1  %  HNO3 to avoid 
contamination. Total Fe-concentration in ng Fe per mg tissue was calculated from the 
calibration curves and the weight of the tissue. 
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8-oxo-dG measurements  
Genomic DNA isolation and 8-oxo-7,8-dihydro-2ƍ-deoxyguanosine (8-oxo-dG) measurements 
were performed as described earlier (11). Briefly, to detect the base-oxidation product 8-oxo-
dG, HPLC with electrochemical detection (ECD) was performed. Genomic DNA was obtained by 
grinding frozen liver tissues followed by standard phenol extraction. The DNA-extraction 
procedure was optimized to minimize artificial induction of 8-oxo-dG, by using radical-free 
phenol, minimizing exposure to oxygen and by addition of 1 mM deferoxamine mesylate and 
20 mM TEMPO (2,2,6,6-tetramethylpiperidine-N-oxyl). DNA concentrations were 
spectrophotometrically quantified. HPLC-ECD of 8-oxo-dG was performed by digesting 30 ʅg 
DNA  to  deoxyribonucleosides  by  addition  of  6  ʅl  0.5  M  NaAc,  9  ʅl  10  mM  ZnCl2 and 1.5 ʅl 
nuclease P1 (stock: 1 U/ ʅl) and incubation for 90 minutes at 37 °C. Subsequently, 30 ʅl 0.5 M 
Tris–HCl  (pH  7.4)  and  1.5  ʅl  alkaline  phosphatase  (0.014  U/  ʅl)  were  added  followed  by  
incubation at 37 °C for 45 minutes. The digest was then analyzed by HPLC-ECD on a Supelcosil™ 
LC-18S column (250 mm × 4.6 mm) (Supelco Park, Bellefonte, PA, USA) in combination with a 
DECADE electrochemical detector (Antec, Leiden, the Netherlands). The ECD-signal was first 
stabilized with mobile phase (94 mM KH2PO4, 13 mM K2HPO4, 26 mM KCl and 0.5 mM EDTA, 
10 % methanol) for approximately 3 hours at a flow rate of 1 ml/ minute. After stabilization, 8-
oxo-dG was detected at a potential  of 400 mV and dG was simultaneously monitored by UV 
absorption at 260 nm. 
Methylation-sensitive McrBC-real-time PCR assay  
Genomic DNA isolation was performed by lysating livers of E14.5 fetuses and bone 
marrow  cells  of  12  week  old  mice  using  0.5  ml  lysis  buffer  (25  mM  EDTA,  10  mM  
TRIS-HCl,  pH 8.0,  100  mM NaCl,  1% SDS)  and 20  ʅl  of  proteinase  K  (Qiagen).  Tissue  
was homogenized, incubated at 56 °C for 1 hour and homogenized again. Samples 
were then allowed to completely lyse by incubating at 56 °C overnight. DNA was 
extracted with phenol/chloroform extraction (phenol/chloroform/isoamyl alcohol 
(25:24:1)) and DNA concentration and purity determined by measuring the OD 
260/280. Analysis of methylation pattern of the repetitive elements, i.e. long 
interspersed nucleotide elements (LINEs), short interspersed nucleotide elements 
(SINEs), intracisternal A particle (IAP), Major and Minor satellites, was performed as 
described earlier (10). Briefly, 1 ʅg of genomic DNA was digested overnight at 37 °C 
using  10  U  of  McrBC  (New  England  Biolabs,  Beverly,  MA,  USA).  The  DNA  strand  
breaks prevent amplification of methylated DNA in the subsequent two-step 
quantitative real-time PCR, which consisted of IQ SYBR Green Supermix (Biorad) 
with  4  ng  of  McrBC-digested  DNA  and  25  pmol  of  each  primer  (See  Table  1,  
Eurogentec) in a reaction volume of 25 ʅl. The cycling conditions consisted of an 
initial  denaturation  at  95  °C  for  10  minutes,  followed  by  40  cycles  of  95  °C  for  45  
seconds, 58 °C for 90 seconds, with an exception for the Major and Minor satellites 
for which this step was performed at 60 °C, using the iCycler (Biorad). Data were 
analyzed by MyiQ Software system (Biorad), Ct values were normalized for 
endogenous reference (HPRT),  compared  with  the  calibrator  (i.e.  average  Ct)  and  
expressed as relative expression (2ͲȴȴCt). An increase in PCR amplification products is 
indicative of hypomethylation, whereas a decrease in PCR amplification products 
indicates hypermethylation. 
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Statistical analysis 
Statistical analysis was performed with Statistical Package for Social Sciences (SPSS version 
17  for  Windows,  SPSS  Inc.,  Chicago,  IL,  USA).  Nested  ANOVA  was  performed  to  analyze  
erythropoietic changes in fetuses prenatally exposed to quercetin to account for litter 
effects. One-way ANOVA was used to assess the impact of quercetin on: 1. litter sizes at 
birth and at day 14.5 of gestation, 2. average pup weight at postnatal day 5 or at day 14.5 
of gestation, 3. placental weight at day 14.5 of gestation, 4. dietary effects between 
control and prenatally exposed 12 week old mice and maternal iron homeostasis. To avoid 
litter effects in the analyses of 12 week old animals, not more than two mice per litter 
were used for analysis and nests with less than 5 litters were excluded from the analysis. 
Log transformed data were used for analysis by an independent sample t-test for the 
biochemical determination of amniotic fluid and the gene expression levels of IL-1ɴ, Il-6, 
IL-10 and hepcidin as these results were not normally distributed.  
Results 
Quercetin exposure during fetal development  
To investigate the effect of quercetin exposure on fetal development and fetal 
erythropoiesis, female mice were exposed to quercetin (302 mg/ kg feed) from 3 days 
before conception until day 14.5 of gestation, at which the mice were sacrificed and 
fetuses were isolated. As shown in Table 2, no differences in litter size, fetal weight or 
placental weight could be observed between control and quercetin exposed fetuses.   
Furthermore, as quercetin is known to chelate iron in vitro (2, 3), the total amount of 
free iron was measured in the amniotic fluid. Again, no differences between fetuses 
exposed to quercetin and control fetuses could be detected (4.1 ± 0.6 ʅmol/ L for 
quercetin exposed fetuses versus 5.9  ±  0.3  ʅmol/  L  for  control  fetuses,  P=0.54,  
amniotic fluid was pooled per litter, n=3 in case of both diets).  
Although we could not directly measure the iron level of fetal livers, levels measured 
in the liver of their mothers were assessed to gain insight in the fetal situation. Iron 
levels measured in the liver of maternal mice were similar for both diet groups (84.5 ± 
17.0 ng/ mg versus 85.2 ± 5.5 ng/ mg, P= 0.97, n=3 for quercetin exposed mothers and 
n=5 for control mothers). In addition we also measured the gene expression of 
hepcidin, the main iron regulatory hormone (4), in the liver of the mothers and found 
no differences between both diet groups (0.5 ± 0.2-fold versus 1.0 ± 0.2-fold for 
control animals (n=5), n=3 for quercetin exposed, P=0.11). Interestingly, Ho1 levels in 
the maternal spleen were significantly increased in expression in case of the mothers 
that were exposed to quercetin (3.6 ± 0.9-fold versus 1.0 ± 0.3-fold for control animals 
(n=5), P=0.03, n=3 for quercetin exposed).  
As 65 % of the body’s iron is used for the production of hemoglobin (4),  the globin 
status was analyzed in the liver of E14.5 fetuses (Supplementary data, Table 1†) using 
a quantitative real-time PCR method  Results showed that fetuses exposed to 
quercetin (n=8: 8 fetuses from 3 different litters) had no changes in the level of 
embryonic  (ɺ-, ɴH1-, and ɸɶ-globins) and adult (ɲ- and ɴ-globins) globins compared 
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with control fetuses (n=9: 9 fetuses from 3 different litters), suggesting that quercetin 
exposure also had no effect on hemoglobin profile in utero. 
Since the globin status is expected to change simultaneously with the change in 
erythroid lineage, the distribution of primitive and adult RBCs in E14.5 fetuses was 
determined (Supplementary data, Table 2†) by blood smear analysis. Here, quercetin 
exposure had no statistically significant effect on the amount of primitive erythrocytes 
or definitive erythrocytes (proerythrocytes, basophilic erythrocytes and ortochromic 
erythrocytes, n=9: 9 fetuses from 2 different quercetin exposed litters and n=15: 15 
fetuses from 3 different control litters), suggesting that prenatal exposure to 
quercetin did not influence the switch in erythroid lineage during fetal development. 
The level of bilirubin, a breakdown product of the heme part of hemoglobin (12), was 
measured in the amniotic fluid (amniotic fluid was pooled per litter, n=3 in case of 
both diets). This showed a slight elevation in bilirubin levels in the amniotic fluid of 
fetuses exposed to quercetin (2.7 ± 0.5 ʅmol/ L for quercetin exposed fetuses versus 
1.2 ±  0.1 ʅmol/ L for control fetuses, P=0.05). Therefore, Ho1 gene expression level 
was measured in the liver of E14.5 fetuses using quantitative real-time PCR to further 
investigate the possibility of higher heme degradation. The results showed no effect 
of quercetin exposure on the expression of Ho1 (1.4-fold, P=0.43, n=4 for both diets).  
Finally, EPO, the principal regulator of erythropoiesis which stimulates erythrocyte 
production in response to a decrease in oxygen delivery (13), was not significantly 
modulated in the amniotic fluid of fetuses exposed to quercetin as compared with 
control fetuses (3.1 ± 0.5 U/ mL for quercetin exposed fetuses versus  2.6 ± 0.8 U/ mL 
for  control  fetuses;  P=0.19;  amniotic  fluid  was  pooled  per  litter,  n=3  in  case  of  both  
diets). 
 
Table 2. Characteristics of the control and quercetin exposed litters during fetal period and after birth  
 Control Quercetin P-value 
Litter size during gestation 4.6 ± 1.6 7.3 ± 1.2 0.28 
Fetal  weight (mg) 192.4 ± 22.8 212.6 ± 32.8 0.62 
Placental weight (mg) 91.9 ± 11.0 84.5 ± 4.6 0.64 
Litter size at birth 6.4 ± 0.7 5.1 ± 0.8 0.27 
Pup weight (g) at day 5 3.2 ± 0.3 3.1  ± 0.1 0.87 
General characteristics of the litters prenatally exposed to quercetin-supplemented or normal diet. Results 
represent the mean ± SE.  At day 14.5 of gestation: n=5 for control litters and n=3 for quercetin exposed 
litters. N=8 for litters that were born in case of both diets. No significant differences were found by nested 
ANOVA accounting for litter effects. 
Prenatal exposure to quercetin and erythropoiesis in adulthood 
Since there were no statistically significant differences in litter characteristics at day 
14.5 of gestation, we did not expect any differences in litter characteristics at birth 
(average litter size and pup weight (g) at day 5 after birth), as was confirmed and 
shown in Table 2. Additionally, we investigated whether prenatal exposure to 
quercetin resulted in changes in globin gene expression at adult age by determining 
the globin mRNA expression levels in the bone marrow of 12 week old mice using 
quantitative real-time PCR (Figure 1A-B).  At adult age there were also no differences 
in globin gene expression noticeable.   
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Next, RBC maturation in the bone marrow of three 12 week old mice from 2 different 
litters per diet group was analyzed using May-Grünwald staining. Bone marrow 
smears showed that prenatal quercetin exposure had no effect on maturation of RBCs 
as there were also no observed differences in the number of RBC progenitors 
(proerythroblast, basophilic erythroblast, ortochromic eryhtroblast, reticulocyte) and 
pyrenocytes (measure for enucleation of immature RBCs, Figure 1C).  
Hemoglobin degradation was examined by determining Ho1 mRNA expression level (Figure 
1D), which catalyzes the rate-limiting step in heme degradation during RBC degradation (12). 
Ho1 gene expression was determined by quantitative real-time PCR in the spleen which is 
the  main  site  for  RBC degradation  and in  the  bone marrow,  where  RBC production  takes  
place. Results did not indicate an increase in heme degradation and therefore in RBC 
turnover in the bone marrow (n=4 for both diets) in 12 week old mice prenatally exposed to 
quercetin. In spleen, however, a significant increase in Ho1 expression (P=0.04, n=4 from 
different litters for both diets) was detected, suggesting that there is an increase in heme 
degradation in the spleen of 12 week old mice prenatally exposed to quercetin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Prenatal exposure to quercetin has no effect on erythropoiesis at adulthood.  
mRNA expression level of embryonic globins (ɺ, ɴH1, ɸɶ; A) and adult globins (ɲ, ɴ;  B) were measured in 
the  bone  marrow  of  12  week  old  control  (n=6)  or  quercetin  exposed  (n=6)  mice.  Bars  represent  the  
average fold change (calculated as 2ͲȴCT) of each globin gene quantified by quantitative real-time PCR. C. 
Bone  marrow  smears  of  12  week  old  mice  from  the  control  (n=3)  and  quercetin  exposed  (n=3)  group  
were analyzed to determine the different RBC progenitors cells in the bone marrow. Bars represent the 
percentage of cells of each cell type. D. mRNA expression level of  Ho1 measured in the spleen and bone 
marrow of  12  week  old  mice  from the  control  group (n=4)  and the  quercetin  exposed group (n=4).  Bars  
represent the normalized average fold change (calculated as 2 ͲȴȴCT) of Ho1 gene quantified by 
quantitative real-time PCR. White bars represent the control group, black bars the quercetin exposed 
group. Error bars represent the standard error. *: Pч0.05 
Maternal quercetin intake during pregnancy and iron homeostasis at adulthood   95 
Finally,  gene  expression  analysis  of  the  bone marrow cells  of  12  week  old  mice  (n=3  
for both groups) were performed using microarrays and showed that of the 88 genes 
involved in erythropoiesis or iron homeostasis according to their Gene-Ontology 
terms, there was only one gene differentially expressed, namely Steap4 (-1.7-fold, 
P=0.009, Supplementary data, Table 3†), indicating that these pathways were not 
affected by prenatal maternal intake of quercetin during gestation.  
Prenatal quercetin exposure and liver iron storage  
Previously, it has been shown that quercetin chelates iron in vitro (2, 3) and attenuates 
iron induced liver injury in vivo (14). We assessed the amount of total iron at 12 weeks of 
age in the liver and spleen, which are respectively the major and minor iron storage 
organs. In the liver, iron levels were indeed significantly increased in case of in utero 
quercetin  exposure  (94.74  ±  5.3  ng/  mg  versus 62.9  ±  5.0  ng/  mg  for  control  animals,  
P=0.002, n=5 for both diets, Figure 2A). Iron levels measured in the spleen of mice 
prenatally exposed to quercetin were also higher, although not statistically significant 
(929.5 ± 265.1 ng/ mg versus 724.5 ± 124.3 ng/ mg for control animals, P=0.41, n=5 for 
both diets, Figure 2B).  
 
 
 
 
 
 
 
 
 
 
Figure 2. Prenatal quercetin exposure results in increased iron levels in the liver of 12 week old mice.  
Iron levels were measured in liver (A) and spleen (B) of control (n=5) and quercetin exposed (n=5) mice at 12 
weeks  of  age.  Bars  represent  the  amount  of  total  iron  expressed  as  ng/  mg  tissue.  Error  bars  represent  the  
standard error. **: Pч0.01  
 
The  increased iron  storage  in  the  liver  of  12  week  old  mice  prenatally  exposed to  quercetin  
could be the result of a long-lasting change in iron homeostasis. Therefore, we examined the 
expression of iron homeostasis related genes using quantitative real-time PCR. Hepcidin 
showed a slightly, though not significant increase in expression in mice prenatally exposed to 
quercetin (n=10) compared with the control group (n=5, Figure 3A). The same was found for IL-
6 that normally regulates hepcidin production (15), which showed a slight, although not 
significant increased expression in quercetin exposed mice (n=10) compared to control mice 
(n=5, Figure 3B).  However, when comparing the overall median of hepcidin and IL-6 expression 
with the individual data in the quercetin exposed and control group, we found that in case of 
the control group only 1 in 5 mice had an expression of hepcidin or IL-6 above the median, 
while in the quercetin exposed group this was 6 out of 10 mice. Other cytokines, namely IL-1ɴ, 
a component of IL-1, which induces ferritin expression resulting in an increased storage of iron 
(15), and IL-10, which stimulates the uptake of iron via the transferrin-receptor (15), showed a 
statistically significant increase in expression in quercetin exposed mice (n=10, IL-1ɴ: P=0.05; IL-
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10: P=0.02, Figure 3C, E) compared to controls (n=5). Although the gene expression of hepcidin 
and ILs involved in iron homeostasis were generally increased in adult mice prenatally exposed 
to quercetin, they were not all statistically significant increased. Interestingly, gene expression 
of IL-1ɴ was not altered in bone marrow of 12-week old mice prenatally exposed to quercetin  
(IL-1ɴ: -1.2-fold change, P=0.5; no microarray data were available for IL-6, IL-10 and hepcidin as 
the expression signal could not be detected). 
As iron overload could result in oxidative stress, 8-oxo-dG levels were measured in the 
livers of mice prenatally exposed to quercetin (n=5) compared to controls (n=5).  
Interestingly, mice prenatally exposed to quercetin had lower 8-oxo-dG levels (14.6 ± 
1.5 x 10-6 8-oxo-dG/ dG versus 26.8 ± 2.0 x 10-6 8-oxo-dG/ dG for control, P=0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Prenatal quercetin exposure induces hepcidin and interleukins involved in iron uptake in the liver of 
12 week old mice. 
mRNA expression levels of  hepcidin (A), IL-6 (B), IL-1ɴ (C), IL-10 (D) were measured in the liver of 12 week old 
mice  from  the  control  group  (n=5)  and  the  quercetin  exposed  group  (n=7).  Bars  represent  the  normalized  
average fold change (calculated as 2ͲȴȴCT) of hepcidin and interleukin genes quantified by quantitative real-time 
PCR. Error bars represent the standard error. *: Pч0.05. 
Prenatal quercetin leads to long-term epigenetic changes 
As quercetin exposure early in development exerted long-term changes in the 
expression of certain genes, we assumed that these effects might be mediated 
through epigenetic modifications. Therefore, we employed an assay in which the 
methylation-sensitive endonuclease McrBC cleaves methylated DNA, but leaves 
unmethylated CpGs intact. By subsequent PCR amplification, one could quantify the 
unmethylated repetitive elements. Using this assay, we determined the methylation 
status of Major and Minor satellites, intracisternal-A-particle (IAP-GAG), long interspersed 
nucleotide elements (LINE1) and short interspersed nucleotide elements (SINEB1 and 
SINEB2), which constitute almost 37.5 % of the mouse genome (1), in bone marrow cells. 
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Overall, bone marrow cells of adult mice prenatally exposed to quercetin (n=3) showed 
moderate hypermethylation of the repetitive elements observed as lower level of PCR 
products after McrBC digestion compared with the control group (n=3, Figure 4A). 
Especially, the SINEB1 elements were hypermethylated (P=0.01).  
In the fetuses, quercetin exposure exerted no effect on the gene expression. Still, to 
investigate whether global epigenetic modifications had already occurred in utero, we 
studied the methylation status of the repetitive DNA elements in the liver of control (n=4) 
and quercetin exposed fetuses (n=4) at E14.5. Indeed, we did not observe any difference 
in the methylation status of repetitive elements between the diet groups at this particular 
developmental time point (Figure 4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The effect of quercetin on DNA methylation of repetitive elements.  
A. Long-term effect of prenatal exposure to quercetin on DNA methylation of repetitive elements in bone 
marrow cells of quercetin exposed mice (n=3) compared to control mice (n=3). B. Short-term effect of prenatal 
exposure to quercetin on DNA methylation of repetitive elements in fetal liver of quercetin exposed fetuses 
(n=4)  compared  to  control  fetuses  (n=4)  at  day  14.5  of  gestation.  The  degree  of  methylation  of  repetitive  
elements: long interspersed nucleotide elements (LINE1), short interspersed nucleotide elements (SINEB1 and 
SINEB2), intracisternal-A-particle (IAP-GAG), and Major and Minor satellites were determined by methylation-
sensitive McrBC-real-time PCR assay. Bars represent the normalized average expression level of the 
unmethylated repetitive elements between the quercetin-exposed (black bars) and the control group (white 
bars). Error bars represent the standard error. *: Pч0.05. 
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Discussion 
In this study, pregnant mice were exposed to a high dose of quercetin (302 mg/ kg 
feed), which is higher than the average daily dietary intake of quercetin in humans (4–
68 mg per day) (17). However, we do not expect that this dose has been toxic to the 
fetuses as Prater et al. (18) showed that a high dose of quercetin (333 mg/ kg feed) 
administered to mice throughout their pregnancy, did not have teratogenic effects on 
the fetuses. Moreover, the quercetin dose administered to mice in our study is 
comparable with quercetin supplement intake: the daily dose of quercetin supplements 
lies between 200-1800 mg quercetin (manufacturers’ recommendations) (19, 20). These 
high dose supplements are freely available in pharmacies and drugstores. Besides, it has 
also been shown that daily quercetin supplementation results in increased plasma 
quercetin levels (19), suggesting that the fetus could also be exposed to increased 
concentrations of quercetin and its metabolites.  
In this study, we show that prenatal exposure to quercetin results in an adapted iron 
homeostasis as seen in the significantly increased iron storage in the liver of adult mice. 
We assumed that the effects seen in adult mice prenatally exposed to quercetin were 
most probably the result of a disturbed iron homeostasis in utero with persisting 
consequences for iron homeostasis and erythropoiesis later in life.  
At gestational day 14.5 no clear effects of quercetin on erythropoiesis or iron levels could 
be observed. Iron levels measured in the liver of mothers and gene expression levels of 
liver hepcidin did not indicate any differences between control and quercetin exposed 
mothers, suggesting that mothers fed a diet containing iron chelators did not suffer from 
severe iron depletion during gestation. In addition, maternal iron deficiency normally 
results in a reduced fetal weight (21). However, E14.5 fetuses exposed to quercetin had an 
average weight comparable to control. High placental weight is usually also associated 
with iron deficient pregnancies (22), but no difference in placental weight were noticeable 
between quercetin exposed and control fetuses. Finally, the average weight at day 5 after 
birth did not differ between control and quercetin exposed mice. Taken together, this 
would suggest that the situation created by quercetin exposure did not result in severe 
iron deficiency and did not cause early termination of gestation, as the litter size both at 
day 14.5 of gestation and at birth did not differ between both diet groups.  
However, mother mice exposed to quercetin did have increased expression of Ho1, 
which could suggest that quercetin did decrease the amount of available iron and 
therefore the mother had to make more iron available for the fetuses by degradation of 
heme. Indeed, during a normal gestation, when the mother needs to cope with the 
increasing iron requirement of the fetus, she first addresses her own iron stores. Only 
when the fetal demands are too high or there is maternal iron deficiency, hematocrit 
levels  will  decrease  (23),  because  iron  is  made  available  by  increased  degradation  of  
heme. Degradation of heme by Ho1 results in the formation of bilirubin, (12), and 
bilirubin levels were increased in the amniotic fluid of fetuses exposed to quercetin. 
Please note that this increase was not statistically significant, but fetal bilirubin is 
transfered via the placenta to the mother (24), suggesting that the levels of bilirubin 
actually formed in the fetus could have been even higher. However, as increased levels 
of bilirubin are normally found in anemic fetuses (24), and because we did not see any 
differences in globin expression or RBC composition in fetuses exposed to quercetin, we 
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assume that quercetin exposure at this time point in gestation had a very mild effect 
that cannot be distinguished from a non-anemic situation. In addition, it should also be 
emphasized that the iron requirement of the fetus increases throughout the pregnancy 
(25). Therefore, pronounced effects of quercetin may not be present at this time point 
in gestation. Moreover, as flavonoids have shown to accumulate in fetal tissue (7), the 
direct effects of quercetin exposure may be visible at a later time point of gestation. 
Nonetheless, we had chosen day 14.5 of gestation to sacrifice the pregnant mice, since 
at that time point the switch from primitive to adult erythroid lineage and 
concomitantly the switch from fetal to adult hemoglobin occurs (26-28). However, 
exposure to quercetin did not have any effects on these events.  
Once born, pups were no longer exposed to high levels of quercetin. We assumed that 
this resulted in the increased availability of dietary iron, which could be experienced as 
an iron overload as we suspect that these animals were ‘developmentally programmed’ 
to cope with lower iron levels in utero. The mismatch between the in utero environment 
and postnatal life with regard to iron availability resulted in a differently regulated iron 
homeostasis in mice prenatally exposed to quercetin. However erythropoiesis was not 
affected, since we did not observe any differences in globin status and RBC maturation 
in the bone marrow. Interestingly, Ho1 gene expression in the spleen was significantly 
up-regulated, suggesting increased RBC turnover. However, as there were no observed 
differences  in  bone  marrow  maturation  or  the  amount  of  red  blood  cells  (7.2  ±  0.1  x  
1012/ L versus 7.0 ± 0.1 x 1012/ L for control group, P=0.53, n=39 for quercetin group and 
n=41 for control group), we assumed that the increase in Ho1 gene expression is the 
result of an increase in hemoglobin per RBC. Indeed, there were 1) a slight elevation in 
hemoglobin  level  of  reticulocytes  (1.03  ±  0.01  fmol  versus 0.96  ±  0.01  fmol  in  control  
group, P=0.07, n=39 for quercetin group and n=41 for control group) and 2) an increase 
in  the  mean corpuscular  volume of  red  blood cells  (mean ±  SE,  46.33  ±  0.50  fL  versus 
44.96 ± 0.45 fL for control group, n=39 for quercetin group and n=41 for control group) 
compared with control mice, which both indicate that more hemoglobin is formed by 
RBCs of mice prenatally exposed to quercetin.  
In addition, gene expression profile analysis of bone marrow cells did not show any 
alterations in gene expression of genes involved in erythropoiesis or iron homeostasis 
between prenatally exposed and control mice. Only the expression of Steap4 was 
significantly decreased in mice prenatally exposed to quercetin. Steap4 has been shown 
to function as a ferrireductase, capable of increasing the uptake of iron by cells in vitro. 
It has also been postulated that Steap4 could play a role in the pathologic deposition of 
iron  in  many  tissues  (29).  Decreased  expression  of  Steap4 by  prenatal  exposure  to  
quercetin thus limits the iron uptake by the bone marrow, probably to protect the bone 
marrow from excessive iron uptake, which could induce oxidative stress. 
The increase in iron availability after birth could activate pathways to overcome the iron 
‘overload’ as it is toxic to cells (4, 30). Indeed, expression of hepcidin and IL-1ɴ, IL-6 and 
IL-10, all involved in the storage of iron, were up-regulated resulting in increased 
storage of iron in the liver. It is remarkable to see that this pathway is activated, as it is 
normally triggered during chronic inflammation induced anemia (4, 15).  An overview of 
the mechanism by which we assume that iron accumulation occurs in the liver of mice 
prenatally exposed to high levels of quercetin is given in Figure 5. 
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Figure  5.  Overview of the hypothesis.  
Prenatal quercetin exposure results in a relative iron excess after birth because iron chelation by quercetin ceases, 
which  will  activate  pathways  to  overcome  the  iron  ‘overload’  as  it  is  toxic  to  cells.  Since  these  pathways  are  
permanently activated in adult life, iron will accumulate in the liver. Iron accumulation in cells occurs through the 
up-regulation of several interleukins (IL1ɴ, IL6 and IL10) involved in the storage of iron. The increase in IL-1 and IL-6 
will up-regulate the expression of hepcidin by the liver, resulting in iron retention by limiting the iron efflux. In 
addition, IL-1 and IL-6, but also IL-10, is known to increase the production of ferritin (Ft), increasing the iron storage 
capacity of cells. Moreover, IL-6 and IL-10 increase the uptake of heme and hemoglobin (Hb). IL-10 also induces the 
production of hemeoxygenase-1 (Ho1) by the spleen, resulting in the release of iron from heme. In addition, it 
increases the uptake of transferrin (Tf) bound iron. The increase in gene expression is indicated by 3 different 
arrows which represent a fold change of approximately 5, 20 and 60, respectively. 
 
As quercetin exposure early in development was found to exert long-term changes in the 
expression of certain genes, we assume that these effects might be mediated through 
epigenetic modifications. Our results show that prenatal exposure to quercetin was 
associated with a moderate hypermethylation of repetitive elements (SINEB1, SINEB2, 
LINE1, Major and Minor satellites) in bone marrow cells at 12 weeks of age. However the 
methylation status of these repeats was not affected directly by quercetin exposure 
during fetal development, therefore we assume that this occurred at a later time point. 
However, one should keep in mind that for some experiments performed in this study 
numbers of animals were on the low side. 
The expression of inflammation related cytokines was enhanced, although there was no 
apparent inflammation present. Therefore, future studies should further elucidate the 
critical window of exposure, as this study suggests that quercetin exerts an effect after day 
14.5 of gestation in mice. Furthermore, it also needs to be investigated whether these 
mice would react differently if inflammation would indeed be triggered at adult age.  
Besides quercetin, other iron chelators which are administered to overcome iron overload 
resulting from for instance chronic blood transfusion (31, 32), should be used with caution 
during pregnancy.   
Maternal quercetin intake during pregnancy and iron homeostasis at adulthood 
   
101 
Acknowledgments 
The authors sincerely thank Edwin Moonen for performing the iron storage measurements, 
Lou Maas for the 8-oxo-dG measurements and Eric Ruijters for the global methylation assay. 
 
This work was supported by grant number 06A031 from the American Institute for Cancer 
Research. 
†Supplementary data 
The supplementary data can be viewed at: 
 http://www.sciencedirect.com/science/article/pii/S0300483X11004562. 
Supplementary Table 1. Gene expression profile by Q-PCR of globins in the liver of quercetin 
exposed fetuses at embryonic day 14.5. 
 
Supplementary Table 2. Red blood cell composition in blood of quercetin exposed fetuses at 
embryonic day 14.5. 
 
Supplementary Table 3. Go term analysis of the mRNA expression of bone marrow cells of 12 
week old mice prenatally exposed to quercetin. 
 
Supplementary data. Identification of relevant genes by Gene Ontology terms. Statistical 
analysis of microarray data. 
Chapter 5 102 
References 
1. Ross, J. A., and Kasum, C. M. (2002) Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu 
Rev Nutr 22, 19-34 
2. Ferrali, M., Signorini, C., Caciotti, B., Sugherini, L., Ciccoli, L., Giachetti, D., and Comporti, M. (1997) 
Protection against oxidative damage of erythrocyte membrane by the flavonoid quercetin and its relation 
to iron chelating activity. FEBS Lett 416, 123-129 
3. Kitagawa, S., Sakamoto, H., and Tano, H. (2004) Inhibitory effects of flavonoids on free radical-induced 
hemolysis and their oxidative effects on hemoglobin. Chem Pharm Bull (Tokyo) 52, 999-1001 
4. Munoz, M., Villar, I., and Garcia-Erce, J. A. (2009) An update on iron physiology. World J Gastroenterol 15, 4617-4626 
5. Cao, G., Sofic, E., and Prior, R. L. (1997) Antioxidant and prooxidant behavior of flavonoids: structure-activity 
relationships. Free Radic Biol Med 22, 749-760 
6. Laughton, M. J., Halliwell, B., Evans, P. J., and Hoult, J. R. (1989) Antioxidant and pro-oxidant actions of the 
plant phenolics quercetin, gossypol and myricetin. Effects on lipid peroxidation, hydroxyl radical generation 
and bleomycin-dependent damage to DNA. Biochem Pharmacol 38, 2859-2865 
7. Todaka, E., Sakurai, K., Fukata, H., Miyagawa, H., Uzuki, M., Omori, M., Osada, H., Ikezuki, Y., Tsutsumi, O., 
Iguchi, T., and Mori, C. (2005) Fetal exposure to phytoestrogens--the difference in phytoestrogen status 
between mother and fetus. Environ Res 99, 195-203 
8. Vanhees, K., de Bock, L., Godschalk, R. W., van Schooten, F. J., and van Waalwijk van Doorn-Khosrovani, S. B. 
(2011) Prenatal exposure to flavonoids: implication for cancer risk. Toxicol Sci 120, 59-67 
9. Godfrey, K. M., and Barker, D. J. (2000) Fetal nutrition and adult disease. Am J Clin Nutr 71, 1344S-1352S 
10. Vanhees, K., Coort, S., Ruijters, E. J., Godschalk, R. W., van Schooten, F. J., and van Doorn-Khosrovani, S. B. 
(2011) Epigenetics: prenatal exposure to genistein leaves a permanent signature on the hematopoietic 
lineage. FASEB J 25, 797-807 
11. Langie, S. A., Kowalczyk, P., Tudek, B., Zabielski, R., Dziaman, T., Olinski, R., van Schooten, F. J., and 
Godschalk, R. W. (2010) The effect of oxidative stress on nucleotide-excision repair in colon tissue of 
newborn piglets. Mutat Res 695, 75-80 
12. Maines, M. D. (1988) Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical 
applications. FASEB J 2, 2557-2568 
13.  Koury,  M.  J.,  and  Ponka,  P.  (2004)  New insights  into  erythropoiesis:  the  roles  of  folate,  vitamin  B12,  and 
iron. Annu Rev Nutr 24, 105-131 
14. Zhang, Y., Li, H., Zhao, Y., and Gao, Z. (2006) Dietary supplementation of baicalin and quercetin attenuates 
iron overload induced mouse liver injury. Eur J Pharmacol 535, 263-269 
15. Weiss, G. (2009) Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 1790, 682-693 
16. Waterston, R. H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J. F., Agarwal, P., Agarwala, R., Ainscough, R., 
Alexandersson, M., An, P., Antonarakis, S. E., Attwood, J., Baertsch, R., Bailey, J., Barlow, K., Beck, S., Berry, 
E., Birren, B., Bloom, T., Bork, P., Botcherby, M., Bray, N., Brent, M. R., Brown, D. G., Brown, S. D., Bult, C., 
Burton, J., Butler, J., Campbell, R. D., Carninci, P., Cawley, S., Chiaromonte, F., Chinwalla, A. T., Church, D. 
M., Clamp, M., Clee, C., Collins, F. S.,  Cook, L. L.,  Copley, R. R., Coulson, A., Couronne, O., Cuff, J.,  Curwen, 
V., Cutts, T., Daly, M., David, R., Davies, J., Delehaunty, K. D., Deri, J., Dermitzakis, E. T., Dewey, C., Dickens, 
N. J., Diekhans, M., Dodge, S., Dubchak, I., Dunn, D. M., Eddy, S. R., Elnitski, L., Emes, R. D., Eswara, P., 
Eyras, E., Felsenfeld, A., Fewell, G. A., Flicek, P., Foley, K., Frankel, W. N., Fulton, L. A., Fulton, R. S., Furey, T. 
S., Gage, D., Gibbs, R. A., Glusman, G., Gnerre, S., Goldman, N., Goodstadt, L., Grafham, D., Graves, T. A., 
Green,  E.  D.,  Gregory,  S.,  Guigo,  R.,  Guyer,  M.,  Hardison,  R.  C.,  Haussler,  D.,  Hayashizaki,  Y.,  Hillier,  L.  W.,  
Hinrichs, A., Hlavina, W., Holzer, T., Hsu, F., Hua, A., Hubbard, T., Hunt, A., Jackson, I., Jaffe, D. B., Johnson, 
L. S., Jones, M., Jones, T. A., Joy, A., Kamal, M., Karlsson, E. K., Karolchik, D., Kasprzyk, A., Kawai, J., Keibler, 
E., Kells, C., Kent, W. J., Kirby, A., Kolbe, D. L., Korf, I., Kucherlapati, R. S., Kulbokas, E. J., Kulp, D., Landers, 
T.,  Leger,  J.  P.,  Leonard,  S.,  Letunic,  I.,  Levine,  R.,  Li,  J.,  Li,  M.,  Lloyd,  C.,  Lucas,  S.,  Ma,  B.,  Maglott,  D.  R.,  
Mardis, E. R., Matthews, L., Mauceli, E., Mayer, J. H., McCarthy, M., McCombie, W. R., McLaren, S., McLay, 
K., McPherson, J. D., Meldrim, J., Meredith, B., Mesirov, J. P., Miller, W., Miner, T. L., Mongin, E., 
Montgomery, K. T., Morgan, M., Mott, R., Mullikin, J. C., Muzny, D. M., Nash, W. E., Nelson, J. O., Nhan, M. 
N., Nicol, R., Ning, Z., Nusbaum, C., O'Connor, M. J., Okazaki, Y., Oliver, K., Overton-Larty, E., Pachter, L., 
Parra, G., Pepin, K. H., Peterson, J., Pevzner, P., Plumb, R., Pohl, C. S., Poliakov, A., Ponce, T. C., Ponting, C. 
P., Potter, S., Quail, M., Reymond, A., Roe, B. A., Roskin, K. M., Rubin, E. M., Rust, A. G., Santos, R., 
Sapojnikov, V., Schultz, B., Schultz, J., Schwartz, M. S., Schwartz, S., Scott, C., Seaman, S., Searle, S., Sharpe, 
T., Sheridan, A., Shownkeen, R., Sims, S., Singer, J. B., Slater, G., Smit, A., Smith, D. R., Spencer, B., Stabenau, 
A., Stange-Thomann, N., Sugnet, C., Suyama, M., Tesler, G., Thompson, J., Torrents, D., Trevaskis, E., Tromp, 
Maternal quercetin intake during pregnancy and iron homeostasis at adulthood 
   
103 
J., Ucla, C., Ureta-Vidal, A., Vinson, J. P., Von Niederhausern, A. C., Wade, C. M., Wall, M., Weber, R. J., 
Weiss, R. B., Wendl, M. C., West, A. P., Wetterstrand, K., Wheeler, R., Whelan, S., Wierzbowski, J., Willey, 
D., Williams, S., Wilson, R. K., Winter, E., Worley, K. C., Wyman, D., Yang, S., Yang, S. P., Zdobnov, E. M., 
Zody, M. C., and Lander, E. S. (2002) Initial sequencing and comparative analysis of the mouse genome. 
Nature 420, 520-562 
17. Skibola, C. F., and Smith, M. T. (2000) Potential health impacts of excessive flavonoid intake. Free Radic Biol 
Med 29, 375-383 
18.  Prater,  M.  R.,  Laudermilch,  C.  L.,  Liang,  C.,  and  Holladay,  S.  D.  (2008)  Placental  oxidative  stress  alters  
expression of murine osteogenic genes and impairs fetal skeletal formation. Placenta 29, 802-808 
19. Egert, S., Wolffram, S., Bosy-Westphal, A., Boesch-Saadatmandi, C., Wagner, A. E., Frank, J., Rimbach, G., 
and Mueller, M. J. (2008) Daily quercetin supplementation dose-dependently increases plasma quercetin 
concentrations in healthy humans. J Nutr 138, 1615-1621 
20. Mennen, L. I., Walker, R., Bennetau-Pelissero, C., and Scalbert, A. (2005) Risks and safety of polyphenol 
consumption. Am J Clin Nutr 81, 326S-329S 
21. Gambling, L., Charania, Z., Hannah, L., Antipatis, C., Lea, R. G., and McArdle, H. J. (2002) Effect of iron 
deficiency on placental cytokine expression and fetal growth in the pregnant rat. Biol Reprod 66, 516-523 
22.  Hindmarsh,  P.  C.,  Geary,  M.  P.,  Rodeck,  C.  H.,  Jackson,  M.  R.,  and  Kingdom,  J.  C.  (2000)  Effect  of  early  
maternal iron stores on placental weight and structure. Lancet 356, 719-723 
23. Gambling, L., Czopek, A., Andersen, H. S., Holtrop, G., Srai, S. K., Krejpcio, Z., and McArdle, H. J. (2009) Fetal 
iron status regulates maternal iron metabolism during pregnancy in the rat. Am J Physiol Regul Integr Comp 
Physiol 296, R1063-1070 
24. Sikkel, E., Pasman, S. A., Oepkes, D., Kanhai, H. H., and Vandenbussche, F. P. (2004) On the origin of 
amniotic fluid bilirubin. Placenta 25, 463-468 
25. Bothwell, T. H. (2000) Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr 72, 257S-264S 
26. Palis, J. (2008) Ontogeny of erythropoiesis. Curr Opin Hematol 15, 155-161 
27. Keller, G., Lacaud, G., and Robertson, S. (1999) Development of the hematopoietic system in the mouse. Exp 
Hematol 27, 777-787 
28. Kingsley, P. D., Malik, J., Emerson, R. L., Bushnell, T. P., McGrath, K. E., Bloedorn, L. A., Bulger, M., and Palis, 
J. (2006) "Maturational" globin switching in primary primitive erythroid cells. Blood 107, 1665-1672 
29. Ohgami, R. S., Campagna, D. R., McDonald, A., and Fleming, M. D. (2006) The Steap proteins are 
metalloreductases. Blood 108, 1388-1394 
30. Ganz, T. (2006) Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol 
Educ Program, 29-35, 507 
31. Olivieri, N. F., and Brittenham, G. M. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 
89, 739-761 
32. Taher, A., Sheikh-Taha, M., Sharara, A., Inati, A., Koussa, S., Ellis, G., Dhillon, A. P., and Hoffbrand, A. V. 
(2005)  Safety  and effectiveness  of  100  mg/kg/day  deferiprone in  patients  with  thalassemia  major:  a  two-
year study. Acta Haematol 114, 146-149 
  
 
 
 
 
Chapter 6 
 
 
Maternal intake of quercetin        
during gestation alters ex vivo 
benzo[a]pyrene metabolism and DNA- 
adduct formation in adult offspring 
 
 
 
Vanhees K, van Schooten FJ, Moonen EJ, Maas LM, Barjesteh van Waalwijk 
van Doorn-Khosrovani S, Godschalk RWL 
Mutagenesis. 2012 
Chapter 6 106 
Abstract 
Variation in xenobiotic metabolism can not entirely be explained by genetic diversity in 
metabolic enzymes. We suggest that maternal diet during gestation can contribute to 
variation in metabolism by creating an in utero environment that shapes the offspring’s 
defence against chemical carcinogens. Therefore, pregnant mice were supplemented with 
the natural aryl hydrocarbon receptor (AhR) agonist quercetin (1 mmol quercetin/ kg feed) 
until delivery. Next, it was investigated whether the adult offspring at the age of 12 weeks 
had altered biotransformation of the environmental pollutant benzo[a]pyrene (B[a]P). In 
utero quercetin exposure resulted in significantly enhanced gene expression of Cyp1a1, 
Cyp1b1, Nqo1 and Ugt1a6 in liver of fetuses at day 14.5 of gestation. Despite cessation of 
supplementation after delivery, altered gene expression persisted into adulthood, but in a 
tissue and gender dependent manner. Expression of phase I enzymes (Cyp1a1 and 
Cyp1b1) was up-regulated in liver of adult female mice in utero exposed to quercetin, 
whereas expression of phase II enzymes (Gstp1, Nqo1 and Ugt1a6) was predominantly 
enhanced in lung tissue of female mice. Epigenetic mechanisms may contribute to this 
adapted gene expression, as the repetitive elements (SINEB1) were hypomethylated in 
liver of female mice prenatally exposed to quercetin. Studies on ex vivo metabolism of 
B[a]P by lung and liver microsomes showed that the amount of B[a]P-9,10-dehydrodiol, 
B[a]P-7,8-dihydrodiol and 3-hydroxy-B[a]P did not change, but the amount of 
unmetabolized B[a]P was significantly lower after incubation with lung microsomes from 
offspring that received quercetin during gestation. Moreover, ex vivo B[a]P induced DNA-
adduct formation was significantly lower for liver microsomes of offspring that were 
exposed to quercetin during gestation. These results suggest that prenatal diet leads to 
persistent alterations in phase I and II enzymes of adult mice and may affect cancer risk. 
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Introduction 
A vast amount of research has been performed to determine the effects of genetic 
polymorphisms in enzymes involved in xenobiotic metabolism on inter-individual variation 
in cancer susceptibility (1-4). However, analysis of genetic polymorphisms did not explain 
a large part of the variation and other factors, especially the diet, have been postulated as 
additional contributors to individual reactions after exposure to xenobiotics (5). For 
instance, intake of dietary flavonoids is common in the human diet as they are found in 
fruit, vegetables and beverages such as wine, tea and coffee. They are mostly known for 
their anticancer properties, as they are potent antioxidants (6). Quercetin is the most 
widely consumed flavonoid in the diet. This polyphenolic compound is not only a potent 
free radical scavenger and iron chelator (7, 8), it can also modulate the expression and 
activity of cytochrome P450 (CYP450) and phase II detoxifying enzymes (9-11). The 
expression of phase I and phase II enzymes is important for the metabolism of many 
xenobiotics, including benzo[a]pyrene (B[a]P). B[a]P is produced during the incomplete 
combustion of organic compounds like tobacco, fuels, wood and meat (12-14). On its own, 
B[a]P has no mutagenic or carcinogenic properties (10, 15). However, it can diffuse into 
the cell due to its lipophilic character, bind to the aryl hydrocarbon receptor (AhR) and 
translocate into the nucleus. Here, AhR heterodimerizes with the aryl hydrocarbon 
receptor nuclear translocator (ARNT) and this complex binds to xenobiotic responsive 
elements, leading to the transcription of genes of phase I and II enzymes (10, 16). The 
metabolic activation of B[a]P is thought to be principally performed by cytochrome P450 
(CYP450) enzymes (CYP1A1, CYP1B1), resulting in the formation of the reactive B[a]P-7,8-
dihydrodiol-9,10-epoxide (BPDE), leading to DNA-adduct formation and subsequent 
mutations, thus increasing the risk of cancer. Although it is known that quercetin prevents 
B[a]P induced DNA damage, there is a disagreement about the underlying mechanism (10, 
17-20). Similar to B[a]P, quercetin is a potent ligand for AhR (9) and could thus alter the 
expression of enzymes involved in both activation as well as detoxification of B[a]P. 
A diet rich in fruit and vegetables and therefore containing high amounts of flavonoids is 
thought to protect against cancer development (6). However, the time point of exposure 
to these flavonoids can also contribute to the inter-individual differences (21). Without 
any doubt, maternal diets can affect fetal programming by inducing epigenetic alterations 
that can lead to long-lasting changes in gene expression (21, 22). Due to altered genetic 
imprinting, individuals may acquire distinct responses to carcinogenic exposures and may 
therefore have different risks for developing DNA damage and cancer. The fetal origin of 
adult cancer needs more attention. 
Therefore, in this study we aim to investigate whether gene expression of B[a]P 
metabolizing enzymes can be modulated by prenatal exposure to quercetin (1 mmol (302 
mg)  quercetin/  kg  feed  )  via the maternal diet, starting 3 days before conception until 
delivery. At the adult age of 12 weeks male and female offspring mice were sacrificed and 
phase I and II gene expression was determined. Direct effect of quercetin was investigated 
by determining gene expression levels of phase I and II enzymes in the liver of fetuses at 
day 14.5 of gestation. B[a]P metabolism and DNA-adduct formation was determined ex 
vivo using S9 mix of liver and lung tissue of 12 week old male and female offspring. 
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Material and methods  
Mice and sample collection 
Mice  (129/SvJ:C57BL/6J  background)  approximately  8  weeks  of  age,  received  either  
normal chow (n=8, low phytoestrogen content complete feed for mice breeding, ssniff®, 
Soest, Germany) or the same chow (ssniff®) supplemented with quercetin (n=8, 1 mmol 
(302 mg)/ kg feed) (Sigma, Zwijndrecht, the Netherlands) from 3 days before conception 
until the end of gestation. Male mice were placed in the cage only for the duration of 
copulation. After delivery all mothers and pups received normal chow. Offspring mice 
were anesthetized and sacrificed by cardiac puncture at 12 weeks of age, and liver and 
lung were removed and frozen at -80 oC until analysis.   
To study the direct effects of the maternal diet on fetal phase I and II gene expression, a 
different group of mice were mated overnight. The presence of a vaginal plug the next 
morning was defined as 0.5 day post conception. On day 14.5 of gestation, mice were 
sacrificed to isolate the fetuses and their livers, as AhR mRNA and protein expression 
peaks between gestational day 14 and 16 (23).  
Quantitative real-time polymerase chain reaction 
The  liver  of  fetuses  and  one  half  of  the  lung  and  liver  of  12  week  old  mice  were  
homogenized, using the Ultra-Turrax homogenizer (IKA, Staufen, Germany). Next, RNA 
was isolated using TRIzol Reagent (Invitrogen, Breda, the Netherlands) according to the 
manufacturer’s instructions.  
Using iScript reverse transcriptase (Bio-rad, Hercules, USA), 1 µg RNA was transcribed into 
cDNA.  An  aliquot  of  one  10th of the resulting cDNA was applied for quantitative PCR 
ampliĮcation together with 12.5 µl SYBR Green (Qiagen, Venlo, the Netherlands) and 7.5 
pmol of each primer (see Table 1, Eurogentec, Maastricht, the Netherlands) in a volume of 
25 ʅl. The reactions were carried out using a MyiQ Single Color RT-PCR detection system 
(Bio-rad), under the following conditions: 1 cycle at 95 °C for 3 minutes and then 40 cycles 
at 95 °C for 15 seconds and 60 °C for 1 minute followed by 1 cycle at 95 °C for 1 minute 
and  1  cycle  at  65  °C.  Data  were  analyzed  by  MyiQ  Software  system  (Bio-rad),  Ct  values  
were normalized for an endogenous reference gene (ɴ-actin), compared with the 
calibrator (i.e. average Ct value of control samples) and expressed as fold change (2ͲȴȴCt). 
 
Table 1: Forward and reverse primers used for quantitative real-time PCR 
  Forward primer (5’-3’) Reverse primer (5’-3’) 
Cyp1a1 TGCCCTTCATTGGTCACATG CGTCCCCATACTGCTGACTCA 
Cyp1b1 AACGCAGCCGGTGATTGT TGTACCGACAGCCGAAGCA 
Comt AGAGAAGGAGTGGGCCATGA CCGAATCACTGCATCCATGA 
Gstp1 AGAACCAGGGAGGCAAAGCT CAGGTCCAGCAAGTTGTAATCG 
Nqo1 CAGTTCCCATTGCAGTGGTTT CCTGCTACGAGCACTCTCTCAA 
Ugt1a6 GCTACCCCAAAATGATCTGCTT AATACCATGGGAGCCAGAGTGT 
AhR TGTGCAGAATCCCACATCCG AATCAAGCGTGCATTGGACTG 
ɴ-actin ACGGCCAGGTCATCACTATTG CAAGAAGGAAGGCTGGAAAAGA 
SINEB1 GTGGCGCACGCCTTTAATC GACAGGGTTTCTCTGTGTAG 
SINEB2 GAGATGGCTCAGTGGTTAAG CTGTCTTCAGACACTCCAG 
LINE1 TTTGGGACACAATGAAAGCA CTGCCGTCTACTCCTCTTGG 
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Methylation-sensitive McrBC-real-time polymerase chain reaction (PCR) assay of fetuses 
and adult mice 
Analysis of methylation patterns of the short- and long interspersed nucleotide elements 
(SINEB1, SINEB2 and LINE1) was performed using the methylation-sensitive McrBC-real-time 
PCR assay  (24).  1  ʅg  of  genomic  DNA was  digested  overnight  at  37  °C  using  10  U of  McrBC 
(New England Biolabs, Beverly,  MA, USA), an endonuclease which cleaves DNA containing 5-
methylcytosine, but will not cleave unmethylated DNA. The DNA strand-breaks prevent 
amplification of methylated DNA in the quantitative real-time PCR assay. Two-step quantitative 
real-time  PCR  was  performed  using  IQ  SYBR  Green  Supermix  (Bio-Rad  Laboratories,  
Veenendaal, the Netherlands) with 4 ng of McrBC-digested DNA and 25 pmol of each primer 
(Table 1, Eurogentec, Maastricht, the Netherlands) in a reaction volume of 25 ʅl. The cycling 
conditions consisted of an initial denaturation at 95 °C for 10 minutes, followed by 40 cycles of 
95 °C for 45 seconds, 58 °C for 90 seconds, using the iCycler (Bio-Rad). Data were analyzed by 
MyiQ Software system (Bio-rad),  Ct values were normalized for Ct values of undigested DNA 
and subsequently compared to a calibrator (i.e. average Ct value of 5 control samples for the 
adult  mice  and  of  4  control  samples  for  the  fetuses).  Results  were  expressed  as  relative  
expression (2ͲȴȴCt). An increase in PCR amplification is indicative of hypomethylation, whereas a 
decrease in PCR amplification products indicates hypermethylation. Alterations in DNA 
methylation were assessed in fetal liver and adult liver and lung.   
High-performance liquid chromatography (HPLC) and fluorescence detection of B[a]P 
metabolites 
To mimic lung and liver biotransformation, an aliquot of S9 mix (4 mg of proteins), 
obtained from homogenizing the other half of the lung and liver of 12 week old mice in 
lysis  buffer  (10  mM Tris,  150  mM KCl,  pH 7.4)  using  the  Ultra-Turrax  homogenizer  (IKA),  
was incubated with a mixture consisting of 1 ʅM B[a]P in DMSO and a NADPH-generating 
system (10 mM NADPH, 100 mM glucose-6-phosphate, 40 mM MgCl2, 400 mM Tris (pH 8), 
17.8  ʅg  glucose-6-phoshate  dehydrogenase  and  milli-Q  in  a  final  volume  of  500  ʅl),  
without addition of cofactors for phase II metabolizing enzymes. The incubation was 
carried out at 37 °C for 1 hour. Afterwards, metabolites were extracted using ethyl-
acetate, evaporated and dissolved in methanol. Next, samples were applied to a HPLC 
system equipped with a fluorescence detector (excitation 257 nm, emission 350 nm) and 
an analytical reversed-phase column (ODS Hypersil, length 2.5 cm, I.D. 3 mm, particle size 
5 ʅm; Supelco, Belafonte, USA). Separation was performed with solvent A (100 % 
methanol) and solvent B (40 % methanol, mobile phase), using following elution gradient: 
30 % A and 70 % B (0-29 minutes), 90 % A and 10 % B (30-35 minutes), 30 % A and 70 % B 
(36-40 minutes) while the flow rate was maintained at 0.5 ml/ minutes. 
32P-postlabeling analysis 
To determine the BPDE induced DNA-adduct formation 10 ʅg calf thymus DNA (Sigma) 
was incubated with the S9 mix of lung and liver tissue of 12 week old mice and 1 ʅM of 
B[a]P. The DNA was isolated using a phenol-chloroform extraction method and BPDE DNA-
adduct levels were determined by the nuclease P1 enrichment technique as described by 
Reddy and Randerath (25) with the modifications described by Godschalk et al. (26). In all 
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experiments, three BPDE DNA standards with known BPDE DNA-adduct levels (one adduct 
per 106, 107 and  108 normal nucleotides) were analyzed in parallel for quantification 
purposes. Adduct spots on the chromatograms were quantified using Phosphor-Imaging 
technology (Fujifilm FLA-3000, Rotterdam, the Netherlands) using the Aida Imager 
Analyser (Raytest, Milan, Italy), with a detection limit of approximately 1 adduct per 109 
nucleotides per individual DNA adduct spot. 
Statistical analysis 
Statistical analysis was performed with Statistical Package for Social Sciences (SPSS version 
17  for  Windows,  SPSS  Inc.,  Chicago,  IL,  USA).  Nested  ANOVA  was  used  to  compare  the  
mRNA expression level of phase I and II enzymes in the liver of fetuses. The non-
parametric Mann-Whitney test was used to determine the mRNA expression level of 
phase I and II enzymes in the liver and lung of adults, unconjugated B[a]P metabolites, 
unmetabolized B[a]P and BPDE DNA-adducts formed after incubation with liver or lung S9 
mix of adult mice. To avoid litter effects no more than two adult mice per litter were used 
for analysis. One-way ANOVA was used to test differences in methylation pattern of 
SINEB1, SINEB2 and LINE1 between control and quercetin exposed fetuses and adult mice. 
Results 
Quercetin exposure increased gene expression of phase I and II enzymes in fetuses  
To investigate the effects of quercetin exposure on the fetuses’ gene expression of phase I 
and  II  enzymes,  mice  fetuses  were  exposed  to  quercetin  (1  mmol/  kg  feed) via the 
maternal diet. Pregnant mice were sacrificed at day 14.5 of gestation. Phase I and II gene 
expression levels were examined in the liver of the fetuses (n=5 per diet group). In line 
with the AhR agonistic action of quercetin maternal exposure resulted in a significant 
increase in expression of both phase I (Cyp1a1:  F1,3: 22.5, P=0.004; Cyp1b1:  F1,3: 76.1,  
P<0.001; Table 2) and phase II (Gstp1:  F1,3: 5.2, P=0.07; Nqo1:  F1,3: 20.5, P=0.005 and 
Ugt1a6:  F1,3: 1.8, P=0.004) enzymes, without a statistically significant litter effect. AhR 
gene expression did not change by quercetin exposure.  
 
Table 2. Relative gene expression profile of phase I and II enzymes in the liver of quercetin exposed fetuses at 
day 14.5 of gestation 
 Control (n=5) Quercetin (n=5)   
 Mean ± SE Mean ± SE Diet Litter effect 
Cyp1a1 1.0 ± 0.4 16.5 ± 3.1 F1,3: 22.5; P=0.004 F5,3: 0.9;  P=0.6 
Cyp1b1 1.0 ± 0.4 7.9 ± 1.3 F1,3: 76.1;  P<0.001 F5,3: 0.1; P=1.0 
Comt 1.0 ± 0.4 2.5 ± 0.2 F1,3: 3.8; P=0.1 F5,3: 3.5; P=0.2 
Gstp1 1.0 ± 0.4 2.5 ± 0.4 F1,3: 5.2; P=0.07 F5,3: 3.7; P=0.2 
Nqo1 1.0 ± 0.2 2.5 ± 0.3 F1,3: 20.5; P=0.005 F5,3: 0.5; P=0.7 
Ugt1a6 1.0 ± 0.5 3.9 ± 1.0 F1,3: 1.8; P=0.004 F5,3: 4.3; P=0.6 
AhR 1.0 ± 0.4 1.2 ± 0.1 F1,3: 0.1; P=0.7 F5,3: 9.0 P=0.05 
F-value with corresponding degrees of freedom for respectively diet groups and number of litters 
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Prenatal exposure to quercetin affects gene expression profile of B[a]P metabolizing 
enzymes in adult liver and lung 
As in utero exposure to quercetin up-regulated gene expression of phase I and II enzymes, we 
investigated whether these changes persisted into adulthood. Therefore mice were in utero 
exposed to quercetin (1 mmol/ kg feed) and they were sacrificed at the age of 12 weeks. Basal 
gene expression of phase I and II enzymes was determined in liver and lung tissue of 5 male and 5 
female offspring mice. As shown in Table 3, prenatal exposure to quercetin enhanced gene 
expression in the liver of female offspring mice of phase I enzymes, Cyp1b1 (P=0.01) and Cyp1a1 
(P=0.05), involved in B[a]P metabolism in the liver of female offspring mice. However, the gene 
expression of AhR was significantly induced in the liver of males prenatally exposed to quercetin 
(P=0.009). On the contrary, the expression of phase II enzymes was not altered in the liver.  
In lungs of these mice, no significant changes in phase I  or AhR gene expression levels were 
observed (Table 3). On the other hand, female mice prenatally exposed to quercetin showed 
an increase in expression of the following phase II enzymes in their lung: Gstp1 (P=0.009), Nqo1 
(P=0.009) and Ugt1a6 (P<0.05) compared to control females.  
Also interesting to see were the significant tissue specific differences in gene expression 
between male and female mice (Table 4). In case of the liver, Cyp1b1 (P=0.05), Gstp1 
(P=0.009), Nqo1 (P=0.009) and Ugt1a6 (P=0.02) were differentially regulated in control males 
and females. In the lung, only the expression of Gstp1 (P<0.05) and Nqo1 (P=0.009) differed 
between male and female control mice. Moreover, prenatal exposure to quercetin seemed to 
counteract these gender differences for almost all genes, with an exception for Gstp1 in liver 
(P=0.009) and Nqo1 (P=0.01) in lung. 
 
Table 3. Relative gene expression of phase I and II enzymes in the liver and lung of 12 week old male and 
female offspring mice prenatally exposed to quercetin 
  Males1 (n=5)  Females1 (n=5) 
  Control Quercetin  Control Quercetin 
Liver Cyp1a1 1.0 ± 0.3 1.0 ± 0.1  1.0 ± 0.1 1.5 ± 0.2* 
 Cyp1b1 1.0 ± 0.2 1.9 ± 0.6  1.0 ± 0.3 2.9 ± 0.8** 
 Comt 1.0 ± 0.1 0.9 ± 0.2  1.0 ± 0.2 1.2 ± 0.3 
 Gstp1 1.0 ± 0.4 0.9 ± 0.2  1.0 ± 0.2 1.4 ± 0.4 
 Nqo1 1.0 ± 0.1 4.5 ± 2.9  1.0 ± 0.5 2.4 ± 1.0 
 Ugt1a6 1.0 ± 0.2 1.0 ± 0.3  1.0 ± 0.2 1.0 ± 0.4 
 AhR 1.0 ± 0.1 2.6 ± 0.4**  1.0 ± 0.3 1.5 ± 0.4 
Lung Cyp1a1 1.0 ± 0.5 0.9 ± 0.3  1.0 ± 0.2 0.9 ± 0.1 
 Cyp1b1 1.0 ± 0.2 1.2 ± 0.5  1.0 ± 0.4 1.4 ± 0.2 
 Comt 1.0 ± 0.3 1.5 ± 0.2  1.0 ± 0.1 1.2 ± 0.2 
 Gstp1 1.0 ± 0.1 1.4 ± 0.2  1.0 ± 0.1 2.2 ± 0.3** 
 Nqo1 1.0 ± 0.7 1.6 ± 0.6   1.0 ± 0.2 11.3 ± 3.8** 
 Ugt1a6 1.0 ± 0.3 1.6 ± 0.6  1.0 ± 0.1 2.3 ± 0.4* 
 AhR 1.0 ± 0.4 1.9 ± 0.6  1.0 ± 0.6 1.0 ± 0.2 
1 Control male and female mice were used as reference sample to calculate ȴȴCT for respectively males and 
females. Results represent mean ± SE. Significant differences between diets: *: P<0.05, **: Pч0.01 
Prenatal exposure to quercetin results in long-lasting epigenetic modifications of repetitive 
elements in liver of female mice prenatally exposed to quercetin 
As gene expression of phase I  and phase II  enzymes were altered by prenatal exposure to 
quercetin and were maintained till adulthood, we also investigated whether exposure to 
quercetin could affect the methylation status of the repetitive elements SINEB1, SINEB2 and 
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LINE1. SINE and LINE repetitive elements are normally expressed during early 
embryogenesis, after which their expression rapidly decreases with development. Later in 
life,  expression  of  SINEB1,  SINEB2 and LINE1 is  associated  with  cell  stress,  for  instance  by  
DNA-damaging agents (27, 28). At gestational day 14.5, no changes in methylation of 
repetitive elements were detected in fetuses exposed to quercetin (Figure 1A), suggesting 
that quercetin exposure did not influence methylation status at that point in gestation. 
Although no differences in global methylation status could be detected in the liver at 
gestational day 14.5, SINEB1 in the liver of adult female mice prenatally exposed to 
quercetin was hypomethylated compared to control female mice (P=0.01, Figure 1B). DNA 
methylation of SINEB2 and LINE1 repetitive elements was also decreased in female mice 
prenatally exposed to quercetin, though not significantly when analysed seperately. 
Combined  analysis  of  all  three  repetitive  sequences  also  indicated  that  these  were  
hypomethylated in liver of female offspring that received quercetin in utero, with borderline 
significance (P=0.06). No alterations in methylation were observed for male liver or lung of 
both genders (Figure 1B and 1C). These data suggests that in utero exposure to quercetin 
results in the hypomethylation of the repetitive elements SINEB1, SINEB2 and LINE1 in the 
liver of adult female mice. 
Prenatal exposure to quercetin diminished the B[a]P-induced DNA-adduct formation ex 
vivo using liver microsomes of adult mice  
Prenatal exposure to quercetin resulted in long-lasting alterations in the gene expression 
profile of enzymes involved in B[a]P metabolism in liver and lung of mainly female 
offspring.  However, as mRNA expression levels do not necessarily reflect enzyme activity, 
S9  mix  from  liver  or  lung  tissue  of  5  male  and  5  female  mice  prenatally  exposed  to  
quercetin were incubated ex vivo with B[a]P. S9 mix of liver of mice prenatally exposed to 
quercetin did not show an altered B[a]P metabolism (Table 5). On the other hand, lung S9 
mix of mice prenatally exposed to quercetin resulted in decreased amounts of B[a]P-9,10-
dihydrodiol (9,10-diOH-B[a]P, P=0.007) and B[a]P-7,8-dihydrodiol (7,8–diOH-B[a]P, 
P=0.05).  The  amount  of  9,10-diOH-B[a]P  was  especially  decreased  in  case  of  S9  mix  
derived from male mice prenatally exposed to quercetin compared to control males 
(P=0.03). In addition, the total amount of unmetabolized B[a]P was significantly lower 
(P=0.01) when using lung S9 mix of mice prenatally exposed to quercetin compared to the 
control group, especially in males (P<0.05).  
Despite the clear differences in gene expression between male and female mice, no 
gender differences were observed for B[a]P metabolism, except maybe for the liver S9 mix 
where  9,10-diOH-B[a]P  levels  were  higher  for  control  males  compared  to  their  female  
littermates, but this did not reach statistical significance (P=0.09). The overall profile of 
metabolites strongly differed between lung and liver S9 mix; using S9 mix obtained from 
the lung, the major metabolite was 3-hydroxy-B[a]P (3-OH-B[a]P), which is considered to 
be a detoxification product of B[a]P. No B[a]P DNA-adducts could be detected in calf 
thymus DNA that was added to the S9 mix obtained from lung tissue, regardless of the 
prenatal diet (Table 5). When using liver derived S9 mix, prenatal quercetin exposure 
resulted in a significant decrease in DNA-adduct formation (P=0.04), with no differences 
between genders.  
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Figure 1. Methylation status of SINEB1, SINEB2 and LINE1 repetitive elements in fetal and adult liver and lung 
after (prenatal) exposure to quercetin 
Short-term effects of prenatal exposure to quercetin on DNA methylation of SINEB1, SINEB2 and LINE1 
repetitive elements in fetal liver of quercetin exposed fetuses (n=4, black bars) compared to control fetuses 
(n=4, white bars) at day 14.5 of gestation (A). Long-term effects of prenatal exposure to quercetin on DNA 
methylation of SINEB1, SINEB2 and LINE1 repetitive elements in liver (B) and lung (C) of male and female mice 
prenatally  exposed to  quercetin  (n=5  for  each  gender,  black  bars)  compared with  control  mice  (n=5  for  each  
gender, white bars). The degree of methylation of SINEB1, SINEB2 and LINE1 repetitive elements were 
determined by methylation-sensitive McrBC-real-time PCR assay. Bars represent the normalized average 
expression level of the unmethylated repetitive elements. Error bars represent standard error. Statistical 
significance was determined by One-way ANOVA: *: P<0.05. 
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Discussion 
As genetic polymorphisms (1-4) do not entirely explain the inter-individual differences in 
xenobiotic metabolism, we investigated whether prenatal exposure to the natural 
flavonoid quercetin, which is a potent AhR ligand, could permanently alter the expression 
of enzymes involved in both activation as well as detoxification of B[a]P.  
We found that in utero exposure to quercetin affected the gene expression of phase I and 
II enzymes of the fetal liver at gestational day 14.5. Gene expression of Cyp1a1 and 
Cyp1b1 was significantly increased, indicating that quercetin or its metabolites functioned 
as an AhR ligand in the fetus. However, these alterations in gene expression could also 
have other reasons. For instance, Santini et al. (29) showed that exposure of swine 
granulose cells in vitro to  a  low  dose  of  quercetin  resulted  in  increased  levels  of  17ɴ-
estradiol. As 17ɴ-estradiol is a substrate for CYP1B1 and 1A1 (30) and because fetuses, 
both males and females, are continuously exposed to 17ɴ-estradiol throughout gestation 
via the mother (31) this route of exposure could additionally increase the gene expression 
of phase I enzymes. Moreover, as CYP’s are hemeproteins that contain iron (32), the iron 
scavenging properties of quercetin (7) could result in less CYP activity, therefore enhanced 
gene expression is needed as compensation. Gene expression of the phase II enzymes 
Ugt1a6 and Nqo1 was also significantly enhanced in the liver of quercetin exposed 
fetuses. This increase could theoretically be the result of an increase in CYP activity, 
detoxifying the reactive compounds formed by the phase I reactions. Regardless of the 
underlying mechanism, from our experiments it is clear that supplementation with 
quercetin altered gene expression in utero.  
According to the hypothesis of ‘fetal programming’ impaired maternal nutrition during 
pregnancy results in fetal adaptations that are meant to improve survival. However, when 
these adaptations are permanent, they could also alter the risk for diseases later in life. In 
this study, we investigated whether the changes in phase I and II gene expression due to 
the in utero environment are maintained throughout life. Indeed, 12 week old female 
mice prenatally exposed to quercetin had increased phase I (Cyp1a1 and Cyp1b1) gene 
expression levels in their liver, while the phase II enzymes (Gstp1, Nqo1 and Ugt1a6) were 
predominantly enhanced in lung tissue of these female mice. Interestingly, AhR gene 
expression was only increased in the liver of male mice prenatally exposed to quercetin.  
The assumed AhR-induced up-regulation of Cyp450s seen in the liver due to prenatal 
exposure to quercetin did not occur in the lung. Since the lung develops mainly in the final 
stages of pregnancy and even continues to develop after birth (33),  while the liver is 
largely differentiated before birth (34), the different responses of both tissues to 
quercetin exposure could be due to the difference in maturation state of the organ during 
exposure. The enhanced expression of phase II enzymes in mice prenatally exposed to 
quercetin could be the result of the pro-oxidant capacity of quercetin (35, 36), resulting in 
the up-regulation of phase II enzymes through the Nrf2-pathway (9), which could then be 
maintained throughout life.   
In the control group significant differences were observed between male and female 
offspring regarding the gene expression of certain phase I and II enzymes both in liver as 
well as lung. This has already been reported for several species (37-40). However, prenatal 
exposure to quercetin seemed to reduce this gender difference. Only for Gstp1 (liver) and 
Nqo1 (lung) the gender effect was persistent. Makaji et al. (11) also reported that prenatal 
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intake of flavonoids only resulted in long-term alterations of CYP activity in female rat 
offspring, by making the CYP profile more masculine, as was also observed in our study. 
They suggested that quercetin could influence phase I and II gene expression by regulating 
constitutive androstene receptor or Ah receptor. They also suggested that the gender 
differences in mRNA expression of phase I enzymes seen in adult animals is imprinted by 
the presence (or absence) of increased androgen levels at puberty. 
We suspected that epigenetic modulations underlie the persistent changes in phase I and II 
gene expression. Therefore the potential of quercetin to alter the epigenome was assessed 
and showed that prenatal quercetin exposure resulted in the hypomethylation of repetitive 
elements in liver of adult female mice. Interestingly, most pronounced changes in gene 
expression were observed in liver and lung of female mice prenatally exposed to quercetin. 
However, changes in DNA methylation of repetitive elements were only seen in liver. As we 
did not measure gene specific DNA methylation levels, we can only assume that in utero 
exposure to quercetin resulted in gene specific hypomethylation for the genes or their 
regulators that were up-regulated in liver and lung tissue of male and female mice prenatally 
exposed to quercetin. Since these epigenetic modifications could not be detected in fetuses 
at day 14.5 of gestation, we suggest that they occurred at a later time point in pregnancy or 
even after birth. This is plausible as during the late gestational and early postnatal period, 
tissue maturation results in most epigenetic modifications. Moreover, it has been suggested 
that transcriptional inactivity attracts de novo methylation while transcriptional activity can 
eventually override DNA methylation (41). 
To study the effects of maternal quercetin intake during gestation on B[a]P metabolism by 
adult liver and lung, we used S9 mix of lungs and livers of animals that did not receive B[a]P 
at adult age. In that case, analysis of ex vivo B[a]P  metabolism  using  S9  mix  is  more  
straightforward,  because  there  is  no  bias  by  for  instance  B[a]P  uptake  and  kinetics,  DNA  
repair and altered cell turnover. The identified metabolites formed using liver and lung S9 
mix did not differ between control and quercetin exposed animals. However, due to the 
limited number of metabolites detected, false representation of the B[a]P metabolite profile 
can not be excluded. Although there were no differences in the amount of unmetabolized 
B[a]P for liver S9 mix after the one hour incubation, the BPDE DNA-adduct levels were lower 
for mice prenatally exposed to quercetin. This suggests that prenatal exposure to quercetin 
did not result in an accelerated metabolism of B[a]P (as seen in lung), but in B[a]P 
detoxification, e.g. less formation of DNA reactive metabolites including BPDE.  
No BPDE DNA-adducts could be detected for the lung S9 mix of both control and quercetin 
exposed mice, indicating that the B[a]P-adduct forming ability of the lung is lower 
compared to the liver. Moreover, for the lung less unmetabolized B[a]P was detected after 
incubation, indicating that the conversion of B[a]P to water soluble derivatives was 
significantly increased in offspring that received quercetin during gestation. This suggested 
that more detoxification of B[a]P can take place in the lung of mice prenatally exposed to 
quercetin as a result of the adapted gene expression of phase II enzymes, which is an 
important finding as the lung is the primary target organ for airborne B[a]P (42). This 
finding therefore indicates that prenatal exposure to quercetin could decrease the risk on 
B[a]P induced DNA damage and therefore the susceptibility to lung cancer. 
These results show that prenatal exposure to the natural AhR agonist quercetin leads to 
tissue and gender specific long-lasting alterations in the gene expression of phase I and II 
enzymes of adult mice, probably by epigenetic modifications. This seems to result in 
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increased protection against B[a]P-induced DNA-adduct formation. However, as gene 
expression levels of phase I and phase II enzymes do not reflect actual enzyme activities, 
and because B[a]P metabolism and BPDE DNA-adduct formation experiments occurred ex 
vivo, it is now warranted to continue with similar studies with in vivo exposure to B[a]P of 
adult mice prenatally exposed to quercetin to confirm our theory. 
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Adult chronic illnesses, such as cancer, cardiovascular and respiratory diseases are a major 
burden on human health worldwide (1). Exposure to genotoxins and mutagens are 
thought to play an important role in the etiology of these diseases (2-6). On the other 
hand, a healthy diet is though to protect against genotoxins and mutagens and would 
therefore also protect against these chronic diseases to maintain health. One major 
dietary group receiving a lot of attention regarding the treatment and prevention of adult 
chronic diseases are the flavonoids, because of their potent antioxidant capacity (7-10). 
They comprise a large group of polyphenolic compounds widely distributed in the human 
diet (9), resulting in an average intake from 65 to 250 mg of mixed flavonoids a day (11). 
The most predominant flavonoid in the human diet is quercetin, which is present in for 
instance onions, apples, tea and red wine (9, 12-14). Besides being a potent free radical 
scavenger, it also chelates iron (15, 16). Genistein is another important flavonoid, with 
antioxidant properties and is mainly found in soybeans. However, it also has estrogen-like 
properties due to its structural similarities to 17ɴ-estradiol. Whether it works as an 
estrogen agonist or antagonist depends on the situation (17, 18).  
Due to the health benefits they are presumed to provide, flavonoids are freely available as 
high dose supplements, with a recommended daily dose ranging between 1-2 gram (19, 
20). Additionally, disturbingly is the increase in supplement consumption of woman during 
pregnancy. In the US 78 % of the pregnant woman take dietary supplements (21), which 
includes the intake of folic acid. However, folic acid supplementation in adults has been 
shown to increase the risk on cancer (22). Yet little is known about the biological actions 
of flavonoids in pregnancy and the short-term and/ or long-term effects they exert on the 
offspring’s health. It is known that flavonoids can cross the placenta and may accumulate 
in the fetus (23, 24). Therefore research is needed to assess the safety of intake of 
flavonoid supplements during pregnancy.  
Flavonoids during pregnancy: Infant leukemia 
Excessive intake of flavonoids could play a role in the onset of infant leukemia as they 
are efficient topoisomerase II inhibitors (25, 26). Flavonoids could therefore induce DNA 
double-strand breaks (DSB) and rearrangements in the mixed-lineage leukemia (MLL) 
gene, which is frequently observed in childhood leukemia (26, 27). In Chapter 2 we mated 
AtmͲȴSRI heterozygote mice to obtain pups with a different genetic capacity for the DNA 
repair of DSBs, namely Atm wild-type, AtmͲȴSRI heterozygote and AtmͲȴSRI mutant 
offspring mice and found that prenatal exposure to flavonoids indeed induced Mll 
translocations in the bone marrow of both wild-type and AtmͲȴSRI mutant mice. 
Moreover, AtmͲȴSRI mutant mice did show a higher susceptibility to develop these 
chromosomal aberrations. We also showed that mice with an impaired DNA repair had an 
increased risk on developing other malignancies when prenatally exposed to genistein 
besides an increased risk on infant leukemia, which indicates that the DSB DNA repair 
pathway is relevant for maintaining genomic integrity in the developing fetus.  
The AtmͲȴSRI mutation corresponds to one of the most common Atm mutations found 
to date in humans and these mice have a phenotype which is distinct from Atm knock-
out mice. It is known that AtmͲȴSRI mutant mice have a 50 % chance of developing 
leukemia and lymphoma without additional exposures (28). The age of tumor onset was 
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decreased dramatically by prenatal exposure to genistein and quercetin from an 
average of 18.6 months (28, 29) to only 3 months in our study.  
Although the number of animals in which leukemia could actually be identified was low 
in our study, analysis of Mll translocations established in offspring mice prenatally 
exposed to both flavonoids, suggested that the risk of developing cancer later in life for 
these animals was elevated. 
Flavonoids during pregnancy: Fetal programming 
Besides directly increasing cancer susceptibility, flavonoids are also thought to be 
involved in so-called ‘fetal programming’. This concept defines an attempt of the fetus 
to adapt to adverse conditions encountered in utero, which results in adaptations that 
will be detrimental when these conditions will not prevail later in life (30). A clear 
example of fetal programming by genistein was given by Dolinoy et al. (31),  as  they  
showed that prenatal exposure of agouti mice to genistein resulted in a change in coat 
color, but it also protected the mouse from obesity later in life, which is distinctive for 
these mice. These effects were caused by epigenetic changes, namely hypermethylation 
of a repetitive element upstream of the transcription start site of the Agouti gene and 
the Agouti gene was silenced as a result of this hypermethylation. Formation of altered 
DNA methylation patterns in cells during fetal development by flavonoid intake may 
thus have long-lasting effects, because patterns can be transmitted to daughter cells 
after cell division 
Persistent changes in gene expression 
In Chapter 3, the effect of prenatal exposure to genistein on gene expression and global 
methylation of bone marrow cells of 12 week old male mice was investigated. Prenatal 
exposure to genistein resulted in a pronounced down-regulation of estrogen responsive 
genes and of genes involved in inhibiting hematopoiesis, consequently up-regulating 
erythropoiesis and granulopoiesis in these mice. The effect of genistein on estrogen 
responsive genes was to some extent expected as genistein has structural similarities 
with 17ɴ-estradiol, exerting its effect through the estrogen receptor (18). In addition, 
the effect of genistein on hematopoiesis was also found by Zhou et al. (32) who 
pretreated mice with genistein for 7 days prior to whole-body irradiation, protecting 
them from death due to enhanced regeneration of hematopoietic stem cells. We 
hypothesize that the changes in gene expression were a result of epigenetic 
mechanisms, because hypermethylation of repetitive elements could be distinguished in 
the bone marrow cells of these animals. 
Oxidative stress related processes 
Since flavonoids are well known for their antioxidant properties (9) and they can cross the 
placenta to reach the developing fetus, we investigated whether prenatal exposure to 
genistein and quercetin could also have long-lasting effects on systems that contribute to 
the resistance to oxidative stress, which is involved in the onset of cancer (33). To this end, 
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the antioxidant capacity of liver and lung tissue of adult male mice prenatally exposed to 
genistein or quercetin was assessed in Chapter 4. Quercetin exposure during pregnancy 
resulted in the up-regulation of genes involved in the enzymatic antioxidant defense system 
of  the  liver  of  fetuses  at  day  14.5  of  gestation.  Especially  Nrf2, which functions as an 
important transcription factor responding to oxidative stress, showed increased gene 
expression levels during quercetin exposure. This indicated that despite quercetin’s 
antioxidant property, it probably exerted pro-oxidant effects during in utero exposure. Pro-
oxidant effects have previously also been ascribed to quercetin (34, 35). Genistein exposure 
on the contrary, had no effect on the enzymatic antioxidant defense system at this time 
point in gestation. This could be the result of a less pro-oxidant or even antioxidant effect of 
genistein. However, it has also been reported for genistein that in case of Nrf2 genistein 
impedes its nuclear export and degradation (36), making the up-regulation in gene 
expression unnecessary.  
However, at adult age, mice prenatally exposed to either genistein or quercetin still had a 
differential expression of genes involved in the enzymatic antioxidant defense in their 
liver. This suggests that the adaptations made by the fetus in response to the in utero 
conditions by the increased supply of genistein or quercetin to the mother are maintained 
throughout life. We also investigated the effect of prenatal exposure to genistein or 
quercetin on the non-enzymatic antioxidant defense system and could only find an effect 
of prenatal exposure to genistein in the lung compared to control animals. Oxidative stress 
induced DNA damage, namely direct oxidizing of the DNA (8-oxo-dG levels) or indirect 
DNA damage induced by the lipid peroxidation product MDA (M1dG), was also assessed in 
the liver and lung of adult male mice prenatally exposed to quercetin or genistein. 
Prenatal exposure to genistein but especially to quercetin resulted in lower levels of 
oxidative stress induced DNA damage, however, only in the liver of these animals. As we 
mainly found changes in the gene expression of enzymatic antioxidants in the liver, it 
seems that the pre-emptive trigger of the enzymatic antioxidant defense system appeared 
to be beneficial and protective against oxidative DNA damage in the liver of adult mice 
prenatally exposed to genistein but especially to quercetin.  
This effect was tissue specific as in the lung only modest effects of maternal flavonoid 
supplementation on gene expression of enzymatic antioxidants were observed and 
the non-enzymatic antioxidant defense system was only increased due to prenatal 
genistein exposure. Therefore the minor statistically non significant decrease in 8-oxo-
dG levels and M1dG in the lung of male mice prenatally exposed to either genistein or 
quercetin was as expected.  
This study showed that although genistein and quercetin are mainly known for their 
antioxidant properties, they probably functioned as pro-oxidants during gestation, as has 
been reported previously (35, 37-40), probably due to their accumulation in the fetus (23, 
24), because antioxidant properties mainly occur at lower concentrations. This study also 
showed that genistein and quercetin did not exerted the same effects, with regard to long-
lasting changes in the enzymatic antioxidant defense system; quercetin was more effective 
than genistein. Though it had already been shown that exposure to genistein and quercetin 
during adult life protects against oxidative stress (41, 42), we have now shown that in utero 
exposure also results in protection at adulthood, but it remains to be established whether 
this beneficial effect outweighs the oxidative stress that is induced in utero.  
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Iron chelating properties of quercetin as programming trigger 
Quercetin is known to be a very potent iron chelator (15, 16). Therefore, the effect of 
prenatal quercetin exposure on iron homeostasis was assessed during fetal development 
and at adult age in Chapter 5. First, we investigated whether quercetin exposure in utero 
indeed resulted in iron chelation. However, at day 14.5 of gestation, no differences in the 
total amount of iron measured in amniotic fluid could be detected. Next, since the largest 
amount  of  iron  is  used  for  the  production  of  hemoglobin  (43,  44),  gene  expression  of  
globin genes was assessed. At day 14.5 of gestation, fetuses are undergoing a switch from 
the embryonic hemoglobin, solely produced by primitive erythrocytes, to the adult 
hemoglobin, produced by primitive and definitive erythrocytes (45, 46). The main 
difference between both forms of hemoglobin is their affinity for oxygen. During early 
development, oxygen levels are low due to limited vascularisation to ensure proper 
organogenesis, because at this time point the fetus is the most vulnerable for oxidative 
stress, which could lead to damage or disruption of the fetus (47, 48). Nevertheless, the 
fetus needs to subtract oxygen from the maternal blood. Therefore, in the early phase of 
pregnancy the fetus produces embryonic hemoglobin as it has a higher affinity for oxygen 
compared to adult hemoglobin present in the maternal blood (49, 50). However, once the 
utero-placental circulation is well established (between day 9.5 and 11 of gestation) (47) a 
switch to the adult hemoglobin occurs due to the increase in oxygen concentration (45, 
46, 48). In addition, embryonic hemoglobin is less stable compared to adult hemoglobin 
(48) making it more prone to oxidation, resulting in the formation of methemoglobin, 
which is incapable of binding oxygen. Hence, embryonic hemoglobin also releases iron 
more easily from heme (51). As it has been shown that quercetin exposure results in the 
formation of methemoglobin by entering red blood cells (RBCs) and oxidizing the iron ion 
(15, 16), we expected to see an accelerated switch from the fetal to the adult hemoglobin 
in fetuses exposed to quercetin. Though the results were not significant, we did observe a 
trend in globin gene expression, namely the decrease in gene expression of embryonic 
globins in fetuses exposed to quercetin. However, the gene expression of adult globins 
remained unaltered while the switch from the primitive erythroid lineage towards the 
definitive erythroid lineage was accelerated due to increased quercetin intake by the 
mothers. This could indicate that, thought iron levels were not significantly lower 
quercetin did chelate the iron delivered by the mother, making the amount of iron 
available for hemoglobin production limited. Moreover, these data also suggested that 
quercetin chelated the iron from embryonic hemoglobin, which is less stable, accelerating 
the switch from embryonic to adult hemoglobin. However, the level of adult hemoglobin 
was not elevated as the globin production is dependent on iron availability (52), which we 
suspected to be low. However, the accelerated switch in hemoglobin production seems 
reasonable as the switch in erythroid lineage was also accelerated in these mice, and RBCs 
from the definitive lineage mainly produce adult hemoglobin.   
The amount of iron stored in the liver of adult offspring was much higher in mice 
prenatally exposed to quercetin compared to control animals. We assume that exposure 
to quercetin resulted in lower levels of available iron in utero, to which the fetus adapted. 
Once born, fetuses were exposed to normal levels of iron, because the chelating activity of 
quercetin ceased. However, due to this fetal programming towards a life with lower levels 
of iron, these levels exceeded the levels they perceived as normal. Therefore, pathways 
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were activated to cope with this “iron overload”. Hence, we found an increased gene 
expression of several interleukins and hepcidin, all involved in iron storage normally seen 
with anemia of chronic disease also known as ‘anemia of inflammation’. Interestingly, 
anemia is seen more frequently at advanced age and in people with cancer, where ‘anemia 
of inflammation’ accounts for 77 % of the underlying causes of anemia (53). In addition, a 
decreased gene expression of Steap4, involved in the iron uptake by cells (54), was found in 
bone marrow cells of mice prenatally exposed to quercetin. We assumed that this measure 
was taken to protect the bone marrow from excess iron and subsequent DNA damage.   
These data suggested that although mice were adapted to an in utero situation, with scarcity 
of iron due to quercetin chelation, they did cope with the increased iron availability later in 
life. Moreover, they even decreased the risk on iron induced ROS formation, as a decrease in 
8-oxo-dG  levels  was  found  for  the  liver  of  these  mice.  However,  as  gene  expression  of  
inflammation related pathways were induced in the absence of an inflammatory trigger, one 
could expect that these mice could react differently if inflammation would be triggered. As 
inflammation  is  involved  in  many  chronic  diseases,  including  cancer  (33),  one  can  
hypothesize that although these animals seemed to be protected against oxidative stress 
induced diseases, an inflammatory stressor could alter this protective mechanism towards a 
harmful one, but this needs confirmation.   
Quercetin as AhR agonist modifies xenobiotic metabolism 
AhR-signaling in the liver is of major importance in determining the capacity to 
metabolize certain well known carcinogens. It therefore determines an individual’s risk 
to develop cancer after exposure to genotoxic compounds. We further elucidated the 
potential of quercetin exposure on carcinogen metabolism, more precisely on the 
metabolism of B[a]P (Chapter 6). B[a]P is know to be a potent mutagen and carcinogen 
when metabolically activated. This activation is performed by CYP1A1 and CYP1B1 (55, 
56), which both have been shown to be modulated by quercetin. Moreover, quercetin 
can also modulate phase II enzymes (57-59). However, no straightforward effect of 
quercetin  on  phase  I  and  II  expression  has  been  reported  (56,  57,  60-62).  Here,  we  
showed that exposure to quercetin induced Cyp1a1 and Cyp1b1 gene expression in mice 
fetuses at day 14.5 of gestation. This increase could be due to the fact that CYPs are 
hemoproteins, containing heme-iron (63), which could be chelated by quercetin 
resulting in less CYP activity that needs to be compensated by an increase in gene 
expression. Another explanation is the fact that quercetin can increase the 17ɴ-estradiol 
level, which is a known substrate for Cyp1b1 and Cyp1a1 (64). Moreover, AhR gene 
expression was not induced in these fetuses. However, as in the liver of developing mice 
the AhR mRNA and protein expression peaks between gestational day 14 and 16 (65), it 
may be that the effect of quercetin on AhR gene expression may not be visible at that 
time point. Furthermore, gene expression of Nqo1, Ugt1a6 and Gstp1 was also induced 
in fetuses exposed to quercetin. We suspect that this is the result of the activation of 
the Nrf2-pathway as all three genes are target genes of the transcription factor Nrf2 (66, 
67). Indeed, Nrf2 gene expression was up-regulated in these fetuses (Chapter 4).  
At 12 weeks of age, mice prenatally exposed to quercetin still had an up-regulation in 
the expression of Cyp1b1 in their liver, while the up-regulation of the other genes was 
not maintained throughout life. Interesting to see was that in adult mice, AhR gene 
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expression was increased, which could at least partly explain the increase in Cyp1b1 
expression. We compared male and female littermates and found that female mice 
prenatally exposed to quercetin developed a more masculine profile regarding the 
phase I and II enzymes compared to control female mice. In rats it has also been shown 
that prenatal exposure to quercetin resulted in long-term alterations of CYP activity, 
predominantly in the female offspring. Here, the CYP profile of the female offspring also 
showed to be more masculine compared to control females. It was suggested that 
quercetin exerted these effects by regulating constitutive androstene receptor or Ah 
receptor (58). Indeed, AhR gene  expression  was  slightly  increased  in  female  mice  
prenatally exposed to quercetin.   
Gene expression of phase I and II enzymes demonstrated a different profile in the lung 
of 12 week old mice prenatally exposed to quercetin. Here phase II enzymes (Gstp1, 
Nqo1 and Ugt1a6) were mainly induced. The difference in tissue response to prenatal 
quercetin exposure could be due to the fact that the lung develops mainly in the final 
stages of pregnancy and even continues to develop after birth (68), while the liver is 
largely  differentiated   before  birth  (69).  Hence,  less  gender  effects  were  noticeable  in  
the lung, which is in line with the fact that lung is not a main organ involved in estrogen 
metabolism. However, in fetuses at gestational day 14.5, increased gene expression of 
Nqo1 and Ugt1a6 was detected and was suggested to be the result of the activation of 
the Nrf2-pathway, as quercetin can also function as pro-oxidant (Chapter 4). As the lung 
is directly exposed to oxygen concentrations higher than in most tissues (33), a pre-
emptive oxidative stress trigger in utero  could result in the up-regulation of the Nrf2-
pathway and therefore of phase II enzymes. However, as mentioned above, Nrf2-
pathway was probably only modestly induced in the lung of these mice (Chapter 4).  
Although prenatal exposure to quercetin resulted in an increased expression of phase I 
and II enzymes in liver and lung, differences in ex vivo B[a]P metabolism were only 
found in the lung of mice prenatally exposed to quercetin as they showed a decrease in 
the amount of B[a]P-9,10-dihydrodiol and B[a]P-7,8-dihydrodiol. Moreover, mice 
prenatally exposed to quercetin showed an increase in B[a]P metabolism. However, due 
to the high detoxification of B[a]P towards 3-hydroxy-B[a]P in all diet groups, no BPDE-
induced DNA-adducts could be detected. However, as the lung is the primary target 
organ for airborne B[a]P the increased B[a]P metabolism and phase II gene expression 
suggests that prenatal exposure to quercetin could decrease the susceptibility to 
develop lung cancer in vivo.  
Surprisingly, in case of the liver the ex vivo induction of BPDE DNA-adducts was decreased 
for mice prenatally exposed to quercetin, although they did not show a change in the rate 
of B[a]P metabolism or a changed profile of the 3 major B[a]P metabolites, including the 
7,8-dihydrodiol of B[a]P which is thought to be the precursor of the ultimate genotoxic 
metabolite, BPDE. This suggests that prenatal exposure to quercetin results in the 
protection from B[a]P induced DNA damage in the liver, we suspect due to up-regulation 
of phase I enzymes. Although CYP1A1 and CYP1B1 are mainly thought to be important for 
metabolic activation of B[a]P, we suspect that they also contributed to the detoxification 
of B[a]P, as previously also has been suggested by Uno et al. (70). 
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Fetal programming is regulated via epigenetics 
The changes in gene expression discussed in Chapter 3-6, as a result of in utero exposure 
to genistein or quercetin, are maintained throughout life. We therefore expected 
epigenetic mechanisms to be involved. Therefore, the induction of changes in methylation 
status of repetitive elements due to prenatal exposure to genistein or quercetin was 
investigated, as the mouse genome constitutes almost for 37.5 % out of these repetitive 
elements (71). Results showed that that both flavonoids did not induce changes in global 
methylation (namely, methylation of SINEB1, SINEB2, LINE1, IAP, Major and Minor 
satellites) in the liver of fetuses at gestational day 14.5 (Chapter 3, 5, 6). However, when 
investigating methylation patterns in the bone marrow of 12 week old mice, an overall 
increase in methylation could be distinguished and this especially for SINEB1 and SINEB2 
(Chapter 3, 5). Moreover, in liver and lung tissue of 12 week old mice prenatally exposed 
to genistein or quercetin mild hypomethylation of the repetitive elements SINEB1, SINEB2, 
and LINE1 occurred (Chapter 6). The fact that no changes in methylation could be 
distinguished in fetuses at day 14.5 of gestation could suggest that de novo methylation 
induced by flavonoids took place at a later time point in gestation or even after birth. This 
is plausible as during the late gestational and early postnatal period, tissue maturation can 
result in epigenetic modifications. Moreover, it has been suggested that transcriptional 
inactivity attracts de novo methylation while transcriptional activity can override DNA 
methylation, inducing developmental hypomethylation (72). Besides, the level of exposure 
to genistein and quercetin only increases throughout gestation, enhancing their effects.  
Prenatal exposure to genistein has previously been shown to alter gene expression by 
affecting methylation patterns, namely prenatal exposure of yellow agouti mice altered 
coat color and body weight of agouti mice by inducing hypermethylation of transposable 
repetitive elements upstream of the transcription start site of the Agouti gene  (31).  
Hence, both genistein and quercetin have been shown to inhibit DNA methyltransferases, 
inducing hypomethylation, namely of hypermethylated tumor suppressor genes, to which 
their anticancer effects are ascribed (73, 74). However, prenatal exposure to flavonoids 
resulted in a tissue dependent effect on methylation, namely hypermethylation in case of 
the bone marrow and hypomethylation in case of liver and lung tissue, especially of SINE 
transcripts. During early embryogenesis SINE and LINE repetitive elements are normally 
expressed, after which their expression rapidly decreases with development. Therefore, 
SINEB1, SINEB2 and LINE1 expression later in life is associated with cell stress, for instance 
induced by DNA-damaging agents (75, 76), which we have shown in Chapter 2 quercetin 
and genistein are capable of due to their topoII inhibiting properties. As SINE and LINE 
expression  are  also  associated  with  cancer  (75,  76),  this  could  suggest  that  an  in utero 
flavonoid  trigger  can  result  in  an  increased  silencing  of  SINEB1,  SINEB2  and  LINE1  to  
protect the genome from any future genomic instability. 
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Implications and future research 
As this is only the beginning of understanding how maternal intake of genistein and 
quercetin can affect offspring’s risk on developing cancer later in life, further elaborate 
studies need to be performed:  
x Concerning the epigenetic mechanisms behind the genistein and quercetin 
induced fetal programming. Moreover, the critical window of exposure should 
be assessed.  
x Although genistein and quercetin both are flavonoids, they exert different 
effects. Therefore their specific actions should be further elucidated.  
x At 12 weeks of age it seemed that prenatal exposure to genistein and quercetin 
overall had beneficial effects regarding cancer susceptibility. However, as these 
mice are relatively young, the true contribution of the adaptations made by the 
fetus regarding genistein and quercetin exposure in utero will not be visible at 
this age and additional studies should thus include aging mice. Moreover, the 
effects of fetal programming should also be investigated at a later time point in 
life, when these mice normally are subjected to adult chronic diseases. These 
chronic diseases could also be induced by for instance pro-inflammatory 
triggers.  
x It would also be interesting to investigate what the effects of life-long exposure 
to both flavonoids would be regarding the cancer susceptibility.   
x It would also be valuable to study the effects of prenatal exposure to genistein 
or quercetin on following generations. However, to examine the true 
transgenerational inheritance, the third generation, the first unexposed 
generation, needs to be examined, as the first generation is directly exposed to 
genistein or quercetin and the second generation results from gametes that are 
exposed to genistein or quercetin (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Overview of transgenerational inheritance of effects induced by genistein or quercetin exposure.  
 
When summarizing the results as described in this thesis it can be concluded that prenatal 
exposure to quercetin and genistein resulted in altered fetal programming as compared to 
a non-supplemented diet during pregnancy. During gestation, when fetuses are directly 
exposed to both flavonoids, changes in expression of genes involved in antioxidant 
defense and carcinogen metabolism occurred, suggesting that these fetuses adapted to 
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the in utero environment. However, once born genistein and quercetin exposure ceased, 
but some changes in gene expression were maintained until adult life, while others were 
gained throughout life, showing that the offspring was trying to cope with its new 
‘unexpected’ environment.   
At the age of 12 weeks, prenatal exposure to genistein and quercetin seemed to be 
beneficial as these mice showed to have less oxidative stress induced DNA damage as a 
result of increased enzymatic antioxidant defense system and more efficient iron storage. 
It also seemed that they could better cope with B[a]P induced DNA-damage due to the up-
regulation of phase I and II enzymes. Moreover, the increased methylation in certain 
repetitive elements suggested that these animals were more protected from genomic 
instability, overall suggesting they were less susceptible to develop cancer. On the other 
hand, prenatal exposure to genistein and quercetin induced Mll translocations, increasing 
the risk on leukemia especially in mice with an impaired DNA repair. Additionally, some 
inflammatory cytokines were increased in their basal expression, which could affect the 
inflammatory response.  
A general overview of the effects of prenatal genistein and quercetin exposure on the 
offspring’s risk to develop cancer is depicted in Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. General overview of the effects of prenatal exposure to genistein or quercetin on the offspring’s 
cancer risk discussed in this thesis 
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Chronische ziektes die op volwassen leeftijd optreden, zoals kanker, cardiovasculaire en 
respiratoire aandoeningen zijn een grote last voor de gezondheid van de mens 
wereldwijd (1). Blootstelling aan genotoxische en mutagene stoffen lijkt een belangrijke 
rol te spelen in de ontwikkeling van dit soort ziektes (2-6). Van gezonde voeding wordt 
vermoed dat ze beschermen tegen deze genotoxische en mutagene stoffen en zo ook 
bescherming bieden tegen chronische ziektes en de gezondheid te bevorderen. Een 
voedingscomponent dat veel aandacht krijgt in verband met de behandeling en 
preventie van chronische ziektes zijn de flavonoïden (7-10). Flavonoïden bestaan uit een 
grote groep polyfenolen die wijdverspreid voorkomen in onze voeding (9), waardoor de 
gemiddelde inname varieert tussen 65 en 250 mg flavonoïden per dag (11). Quercetine 
is de meest voorkomende flavonoïd in ons dieet en wordt teruggevonden in uien, 
appels, thee en rode wijn (9, 12-14). Het is een zeer krachtige radicaalvanger en kan ook 
ijzer cheleren (15, 16). Genisteïne is ook een belangrijk flavonoïd dat voornamelijk 
wordt teruggevonden in sojabonen. Naast een antioxidant werking heeft het ook 
oestrogeen agonistische/ antagonistische werkingen, afhankelijk van de situatie, als 
gevolg van structurele overeenkomsten met 17ɴ-oestradiol (17, 18). 
Aangezien flavonoïden momenteel geacht worden voordeling te zijn voor de 
gezondheid, zijn ze vrij verkrijgbaar als voedingssupplementen en dit in hoge dosissen, 
met een aangeraden dagelijkse dosis tussen 1-2 gram (19, 20). Zorgwekkend is de 
toename in supplement inname door zwangere vrouwen. In de VS nemen 78 % van de 
zwangere vrouwen voedingssupplementen (21), waaronder foliumzuur. Nochtans 
verhoogt  de  inname  van  foliumzuur  het  risico  op  kanker  bij  volwassenen  (22).  Er  is  
echter weinig bekend over de biologische werking van flavonoïden tijdens de 
zwangerschap en over de kort en/ of lange termijn effecten die ze kunnen hebben op de 
gezondheid van het kind. Aangezien flavonoïden de placenta kunnen doorkruisen om zo 
te accumuleren in de foetus (23, 24), is het nodig onderzoek te verrichten naar de 
veiligheid van verhoogde flavonoïd inname tijdens de zwangerschap. 
Flavonoïden tijdens de zwangerschap: Kinderleukemie 
Een verhoogde flavonoïd inname wordt ook in verband gebracht met het ontstaan van 
kinderleukemie, omdat ze topoïsomerase II kunnen remmen (25, 26) en zo 
dubbelstrengsbreuken in DNA en herschikkingen van het mixed-lineage leukemia (MLL) 
gen kunnen induceren, wat veel voorkomt bij kinderleukemie (26, 27). In Hoofdstuk 2 
werden AtmͲȴSRI heterozygote muizen gepaard om nakomelingen te verkrijgen met een 
verschillende genetische mogelijkheid om DNA schade te herstellen, namelijk Atm wild-
type, AtmͲȴSRI heterozygote en AtmͲȴSRI mutante nakomelingen. Wij konden vaststellen 
dat prenatale blootstelling aan flavonoïden inderdaad Mll translocaties in het beenmerg 
van zowel wild-type als AtmͲȴSRI mutante muizen veroorzaakte. Bovendien waren Atm-
ȴSRI mutante muizen gevoeliger voor het ontwikkelen van deze chromosomale 
afwijkingen. Ook werd aangetoond dat muizen met een slecht werkend DNA 
herstelmechanisme een verhoogd risico hadden op het ontwikkelen van andere 
aandoeningen buiten kinderleukemie, wanneer ze prenataal blootgesteld waren aan 
genisteïne. Dit geeft aan dat het DNA dubbelstrengsbreuk herstelmechanisme van belang 
is voor het behoud van de integriteit van het genoom in de ontwikkelende foetus.  
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De AtmͲȴSRI mutatie komt overeen met een van de meest voorkomende Atm mutaties 
teruggevonden in de mens. AtmͲȴSRI muizen hebben ook een fenotype dat verschilt van 
Atm knock-out muizen. AtmͲȴSRI mutant muizen hebben 50 % kans op het ontwikkelen 
van leukemie en lymfoma, zonder bijkomende blootstellingen (28). In onze studie lag de 
leeftijd waarop deze muizen tumoren ontwikkelden dramatisch lager wanneer ze 
prenataal blootgesteld waren aan genisteïne en quercetine, namelijk van een 
gemiddelde leeftijd van 18,6 maanden (28, 29) naar slechts 3 maanden.  
Ondanks dat het aantal dieren waarin leukemie vastgesteld kon worden tamelijk laag 
was in onze studie, toonden de Mll translocatie analyse wel aan dat muizen die 
prenataal blootgesteld waren aan een van beide flavonoïden een verhoogd risico liepen 
op het krijgen van kanker op latere leeftijd. 
Flavonoïden tijdens de zwangerschap: Foetale programmering 
Naast het direct verhogen van de gevoeligheid voor het ontwikkelen van kanker wordt 
van flavonoïden ook vermoed dat ze betrokken zijn bij ‘foetale programmering’. Dit 
concept houdt in dat de foetus zich tracht aan te passen aan ongunstige 
omstandigheden dat het tegenkomt in utero, wat kan resulteren in aanpassingen die 
schadelijk zijn wanneer deze omstandigheden niet overheersen tijdens het verdere 
leven (30). Dolinoy et al. (31) geeft een duidelijk voorbeeld van foetale 
programmering door aan te tonen dat agouti muizen die prenataal blootgesteld 
werden aan genisteïne een andere vachtkleur hadden, terwijl ze ook beschermd 
waren tegen obesitas op latere leeftijd,  wat kenmerkend is voor agouti  muizen. Deze 
effecten werden veroorzaakt door epigenetische veranderingen, namelijk door 
hypermethylatie van een repetitief element stroomopwaarts van de transcriptie start 
site van het Agouti gen dat resulteerde in de verminderde expressie van dit gen. De 
verandering in het DNA methylatie patroon tijdens de foetale ontwikkeling door 
blootstelling aan flavonoïden kan dus langdurige effecten hebben, omdat dit patroon 
doorgegeven wordt aan dochtercellen tijdens de celdeling.  
Aanhoudende veranderingen in gen expressie 
In Hoofdstuk 3 werd het effect van prenatale blootstelling aan genisteïne op gen 
expressie en globale methylatie van beenmerg cellen van 12 weken oude, mannelijke 
muizen onderzocht. Prenatale blootstelling aan genisteïne resulteerde overduidelijk in 
een verminderde expressie van oestrogeengevoelige genen en genen betrokken bij het 
remmen van de hematopoëse. Dit had als gevolg dat de erythropoëse en granulopoëse 
toenam in deze muizen. Het effect dat genisteïne uitoefende op de oestrogeengevoelige 
genen was min of meer verwacht, aangezien genisteïne structurele gelijkenissen heeft 
met 17ɴ-oestradiol, waardoor het via de oestrogeenreceptor zijn effect kan uitoefenen 
(18). Daarnaast werd het effect van genisteïne op de hematopoëse ook teruggevonden 
door Zhou et al. (32), waar muizen voorbehandeld werden met genisteïne alvorens ze 7 
dagen later aan een gehele lichaamsbestraling blootgesteld werden. De 
voorbehandeling met genisteïne had een beschermend effect op deze muizen doordat 
het de regeneratie van hematopoëtische stamcellen verbeterde. We vermoeden dat de 
Nederlandse samenvatting 140 
verandering in gen expressie in onze studie het resultaat is van epigenetische 
mechanismen, aangezien de repetitieve elementen een toename in methylatie 
vertoonden in het beenmerg van deze dieren. 
Oxidatieve stress gerelateerde processen 
Flavonoïden zijn voornamelijk gekend omwille van hun werking als antioxidant (9) en ze 
kunnen de placenta doorkruisen om zo de ontwikkelende foetus te bereiken. Daarom 
hebben wij onderzocht of prenatale blootstelling aan genisteïne of quercetine ook lange 
termijn effecten kon hebben op systemen die bijdragen aan de bescherming tegen 
oxidatieve stress, aangezien dit betrokken is bij het ontstaan van kanker (33). Hiervoor 
hebben we de antioxidant capaciteit van lever en long weefsel van volwassen, 
mannelijke muizen die prenataal blootgesteld werden aan genisteïne en quercetine, 
onderzocht in Hoofdstuk 4. Quercetine blootstelling tijdens de dracht resulteerde in een 
verhoogde expressie van genen die betrokken zijn bij het enzymatische antioxidant 
verdedigingssysteem van de lever van foetussen op dag 14,5 van de dracht. Vooral Nrf2, 
een belangrijke transcriptie factor die reageert op oxidatieve stress, toonde een 
verhoogde expressie bij blootstelling aan quercetine. Dit toont aan dat, ondanks 
quercetine’s eigenschappen als antioxidant, het waarschijnlijk een pro-oxidante werking 
uitoefende tijdens de in utero blootstelling. Pro-oxidante effecten zijn reeds eerder 
aangetoond voor quercetine (34, 35). Blootstelling aan genisteïne daarentegen had op 
dit moment van de dracht geen effect op het enzymatische antioxidant e 
verdedigingssysteem. Dit zou kunnen zijn doordat genisteïne een minder sterke pro-
oxidant  is  of  zelfs  eerder  een  antioxidant  werking  had.  Het  is  echter  wel  reeds  
aangetoond dat genisteïne het nucleaire transport en de degradatie van Nrf2 
verhinderd (36), waardoor de verhoogde gen expressie overbodig is.  
Op volwassen leeftijd vertoonde de muizen die prenataal blootgesteld werden aan 
genisteïne of quercetine nog altijd een verandering in de expressie van genen die 
betrokken zijn bij de enzymatische antioxidante verdediging van de lever. Dit suggereert 
dat de foetus zich aanpast aan de in utero omgeving, gecreëerd door de verhoogde 
aanlevering van genisteïne en quercetine door de moeder, en dat deze aanpassingen 
behouden blijven tijdens het leven. We onderzochten ook het effect van prenatale 
blootstelling aan genisteïne en quercetine op de non-enzymatische antioxidant e 
verdediging. Enkel prenatale blootstelling aan genisteïne had een effect op de non-
enzymatische antioxidante capaciteit van de long. Oxidatieve stress-geïnduceerde DNA 
schade, namelijk directe oxidatie van het DNA (8-oxo-dG levels) of indirecte DNA schade 
geïnduceerd door het lipidenperoxidatie product MDA (M1dG)  werd  ook  gemeten  in  de  
lever en longen van volwassen muizen die prenataal blootgesteld werden aan quercetine 
of genisteïne. Zowel prenatale blootstelling aan genisteïne, maar vooral aan quercetine, 
resulteerde in minder oxidatieve stress geïnduceerd DNA schade, maar dit enkel in de 
lever van de dieren. Aangezien we in de lever voornamelijk veranderingen in gen expressie 
van de enzymatische antioxidanten vonden, lijkt het erop dat het preventief stimuleren 
van het enzymatische antioxidant verdedigingssysteem voordelig en beschermend werkt 
tegen oxidatieve DNA schade in de lever van volwassen muizen die prenataal blootgesteld 
waren aan genisteïne, maar vooral aan quercetine. 
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Dit effect was weefselspecifiek, aangezien in de long enkel bescheiden effecten in gen 
expressie van de enzymatische antioxidanten terug te vinden waren ten gevolge van 
toevoeging van flavonoïden aan het dieet van de moeder en de non-enzymatische 
antioxidanten verdedigingssysteem enkel toegenomen was ten gevolge van blootstelling aan 
genisteïne, in vergelijking met de lever. Daarom dat de beperkte, niet statistisch significante, 
daling  in  8-oxo-dG  en  M1dG in de long van volwassen muizen die prenataal blootgesteld 
werden aan genisteïne of quercetine te verwachten was. 
Deze studie toonde aan dat, ondanks het feit dat genisteïne en quercetine voornamelijk 
gekend zijn omwille van hun antioxidante eigenschappen, ze waarschijnlijk als pro-oxidanten 
fungeerden tijdens de dracht, zoals ook al eerder gemeld werd (35, 37-40). Dit is 
aannemelijk aangezien ze accumuleren in de foetus (23, 24) terwijl een antioxidante werking 
optreed bij lagere concentraties. Deze studie toonde ook aan dat genisteïne en quercetine 
niet hetzelfde effect uitoefenden als we kijken naar de lange termijn veranderingen in het 
enzymatische antioxidante verdedigingssysteem. Het effect van quercetine was meer 
uitgesproken dan dat van genisteïne. Hoewel het al eerder was aangetoond dat blootstelling 
aan genisteïne en quercetine op volwassen leeftijd beschermt tegen oxidatieve stress (41, 
42), hebben wij nu aangetoond dat in utero blootstelling ook voor bescherming zorgt op 
volwassen  leeftijd.  Het  moet  echter  nog  vastgesteld  worden  of  dit  voordelige  effect  kan  
opwegen tegen de oxidatieve stress veroorzaakt in utero.  
De ijzer chelerende eigenschap van quercetine als programmeringsstimulus 
Quercetine is een gekende, zeer krachtige ijzer chelator (15, 16).  Dit is  de rede dat het 
effect van prenatale blootstelling aan quercetine op de ijzerhuishouding onderzocht 
werd tijdens de foetale ontwikkeling en op volwassen leeftijd in Hoofdstuk 5. Eerst 
werd onderzocht of in utero blootstelling aan quercetine wel degelijk resulteerde in ijzer 
chelatie, maar op dag 14,5 van de dracht was er echter geen verschil in de totale 
hoeveelheid ijzer meetbaar in het vruchtwater. Aangezien het merendeel van het ijzer 
gebruikt wordt voor hemoglobine vorming (43, 44) werd de gen expressie van globine 
genen bepaald. Op dag 14,5 van de dracht ondergaan foetusen een omschakeling van 
de embryonische vorm van hemoglobine, dat enkel gevormd wordt door primitieve rode 
bloedcellen (RBCs), naar de volwassen vorm van hemoglobine, dat gevormd wordt door 
zowel de primitieve als de definitieve RBCs (45, 46). Het belangrijkste verschil tussen 
beide vormen van hemoglobine is hun affiniteit voor zuurstof. Tijdens de vroege 
ontwikkeling zijn de zuurstof niveaus laag door de beperkte doorbloeding, om een 
optimale orgaanontwikkeling te garanderen. Dit is de periode waarin de foetus het 
meest kwetsbaar is voor oxidatieve stress, wat kan leiden tot beschadiging van de 
foetus en vroegtijdig beëindigen van de zwangerschap (47, 48). Niettemin moet de 
foetus ook zuurstof krijgen via het bloed van de moeder. Daarom vormt de foetus in de 
eerste fase van de zwangerschap embryonische hemoglobine, welke een hogere 
affiniteit voor zuurstof heeft in vergelijking met de adulte hemoglobine, wat gevormd 
wordt door de moeder (49, 50). Eens de utero-placentale circulatie gevormd is (tussen 
dag 9,5 en 11 van de dracht) (47), komt er een overschakeling naar de adulte 
hemoglobine, als gevolg van de toename in zuurstof concentratie (45, 46, 48). Maar de 
embryonische hemoglobine is ook minder stabiel in vergelijking met de adulte 
hemoglobine (48), waardoor het gevoeliger is voor oxidatie, wat resulteert in de 
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vorming van methemoglobine dat niet in staat is zuurstof te binden. Daarbij laat 
embryonische hemoglobine ook makkelijker ijzer vrij van zijn heem groep (51). 
Aangezien het aangetoond is dat blootstelling aan quercetine leidt tot de vorming van 
methemoglobine, doordat quercetine de RBCs ingaat en het ijzer ion oxideert (15, 16), 
verwachtten wij ook een versnelde overgang van embryonische naar adulte 
hemoglobine waar te nemen bij blootstelling aan quercetine. Ondanks dat de resultaten 
niet significant waren, zagen we toch een trend in de expressie van de globine genen, 
namelijk een vermindering in gen expressie van de embryonische globines in foetussen 
die blootgesteld waren aan quercetine. De gen expressie van de adulte globines was 
echter onveranderd, terwijl de overgang van de primitieve RBC lijn naar de definitieve 
RBC lijn versneld was ten gevolg van de verhoogde inname van quercetine door de 
moeders. Dit kan betekenen dat ondanks dat de ijzer niveaus niet significant afgenomen 
waren, quercetine toch het ijzer dat geleverd werd door de moeder cheleerde, 
waardoor  er  minder  ijzer  beschikbaar  was  voor  de  vorming  van  hemoglobine.  Daarbij  
doet deze data ook vermoeden dat quercetine het ijzer van de embryonische 
hemoglobine cheleerde, omdat deze minder stabiel is, waardoor de overgang van 
embryonische naar adult hemogelobine versneld werd. Er was echter geen verandering 
in de hoeveelheid adulte hemoglobine detecteerbaar. Dit kan verklaard worden doordat 
de globine productie afhankelijk is van de hoeveelheid beschikbaar ijzer (52), waarvan 
wij vermoeden dat er minder beschikbaar was. Desondanks lijkt de versnelde overgang 
van embryonisch naar adult hemoglobine aannemelijk aangezien de overgang in RBC lijn 
ook versneld was in deze muizen en RBCs van de definitieve lijn voornamelijk adult 
hemoglobine produceren.  
De hoeveelheid ijzer dat opgeslagen was in de lever van volwassen nakomelingen lag 
veel hoger in muizen die prenataal blootgesteld waren aan quercetine in vergelijking 
met controle dieren. Wij vermoeden dat de foetus zich aangepast heeft aan de lagere 
hoeveelheden bruikbaar ijzer waaraan het in utero blootgesteld was door de chelatie 
van quercetine. Eens geboren worden de foetussen blootgesteld aan een normaal ijzer 
niveau, aangezien de chelerende werking van quercetine wegvalt. Doordat deze 
foetussen echter geprogrammeerd werden voor een leven met een laag ijzer niveau 
voelden deze niveaus aan alsof ze de normale waarden overschreden. Hierdoor werden 
pathways geactiveerd om deze ‘ijzer overlast’ te verwerken. We vonden ook een 
verhoogde gen expressie terug voor verschillende interleukines en hepcidin die allemaal 
betrokken zijn bij de opslag van ijzer wanneer ‘anemie van chronische ziekten’, ook wel 
‘inflammatoire anemie’ genoemd, optreed. Interessant om te weten is dat anemie vaker 
voorkomt op oudere leeftijd en bij personen die lijden aan kanker, waarvan 
‘inflammatoire anemie’ meetelt voor 77 % van de onderliggende oorzaken van de 
anemie  (53). In beenmerg cellen van muizen die prenataal blootgesteld werden aan 
quercetine werd ook een daling teruggevonden in de gen expressie van Steap4, wat 
normaal betrokken is bij de opname van ijzer door cellen (54). Wij vermoeden dat deze 
maatregel genomen was om het beenmerg te beschermen tegen een overmaat aan ijzer 
en de DNA schade die hierdoor veroorzaakt kan worden. 
Deze data doet vermoeden dat de nakomelingen konden omgaan met de toename in 
beschikbaar ijzer tijdens hun leven, ondanks dat ze zich hadden aangepast aan de in 
utero omstandigheden, waar ijzer schaars was door de chelatie door quercetine. Sterker 
nog, er werden minder reactieve zuurstof soorten (ROS) gevormd door ijzer aangezien 
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lagere 8-oxo-dG levels teruggevonden werden in de lever van deze muizen. Maar omdat 
de expressie van genen betrokken bij inflammatie ook verhoogd was in afwezigheid van 
een inflammatoire stimulus, zou het kunnen dat deze muizen anders zullen reageren als 
inflammatie zou plaats vinden. Aangezien inflammatie betrokken is bij vele chronische 
ziektes, waaronder kanker (33), lijkt het erop dat, ondanks dat deze dieren beschermd 
zijn tegen oxidatieve stress gerelateerde ziektes, een inflammatoire stimulus dit 
beschermend mechanisme misschien kan veranderen in een schadelijk mechanisme. Dit 
moet echter nog bevestigd worden. 
Quercetine als AhR agonist wijzigt het xenobiotisch metabolisme 
AhR-signalering in de lever speelt een belangrijke rol in het metabolisme van bepaalde, 
gekende carcinogenen. Zo bepaalt het het risico van een individu op het ontwikkelen 
van kanker na blootstelling aan genotoxische stoffen. Daarom hebben wij uitgezocht of 
blootstelling aan quercetine het carcinogeen metabolisme kon beïnvloeden, meer 
bepaald het metabolisme van B[a]P (Hoofdstuk 6). B[a]P is een gekend, krachtig 
mutageen en carcinogeen dat metabolisch geactiveerd moet worden. Deze activatie 
wordt uitgevoerd door CYP1A1 en CYP1B1 (55, 56), die beiden gereguleerd kunnen 
worden door quercetine. Quercetine kan zelfs fase II enzymen reguleren (57-59). 
Desondanks is er geen eenduidig effect van quercetine op fase I en II enzyme expressie 
gemeld (56, 57, 60-62). In deze studie toonden we aan dat blootstelling aan quercetine 
Cyp1a1 en Cyp1b1 gen expressie verhoogde in foetussen op dag 14,5 van de dracht. 
Aangezien CYPs hemoproteïnes zijn, die ijzer bevatten in hun heemgroep (63), kan het 
zijn dat de toename in gen expressie het resultaat is van de chelerende werking van 
quercetine. Dit kan namelijk resulteren in een mindere CYP activiteit wat 
gecompenseerd wordt door een toename in gen expressie. Een andere verklaring kan 
zijn dat quercetine het 17ɴ-oestradiol niveau verhoogt, wat ook een substraat is voor 
Cyp1b1 en Cyp1a1 (64). AhR gen expressie was bovendien niet verhoogd in foetussen. 
Dit kan zijn omdat in de lever van ontwikkelende muizen foetussen de AhR mRNA  en  
proteïne expressie een piek kent tussen dag 14 en 16 van de dracht (65), waardoor het 
effect van quercetine op de AhR gen expressie misschien nog niet zichtbaar is op dit 
tijdstip. Daarbuiten was de gen expressie van Nqo1, Ugt1a6 and Gstp1 wel verhoogd in 
foetussen die blootgesteld waren aan quercetine. Wij vermoeden dat dit het resultaat is 
van de activatie van het Nrf2-pathway, aangezien deze 3 genen doelgenen zijn van de 
transcriptie factor Nrf2 (66, 67). Nrf2 gen expressie was inderdaad verhoogd in 
foetussen blootgesteld aan quercetine (Hoofdstuk 4).  
Op 12 weken vertoonde de muizen die prenataal blootgesteld waren aan quercetine 
nog altijd een verhoogde expressie van Cyp1b1 in  hun  lever,  terwijl  de  verhoogde  
expressie van de overige genen niet behouden bleef over tijd. Interessant om te zien 
was dat in volwassen dieren de gen expressie van AhR verhoogd was, wat de toename in 
Cyp1b1 gen expressie kan verklaren. Wanneer mannelijke en vrouwelijke muizen van 
eenzelfde nest met elkaar vergeleken werden, vonden we dat vrouwelijke muizen die 
prenataal blootgesteld waren aan quercetine een mannelijker fase I en II enzyme profiel 
ontwikkelden in vergelijking met vrouwelijke controle muizen. In ratten werd ook 
aangetoond dat prenatale blootstelling aan quercetine lange termijn veranderingen in 
CYP activiteit veroorzaakte, voornamelijk in de vrouwelijke nakomelingen. Het CYP 
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profiel van de vrouwelijke nakomelingen toonde ook in dit geval een mannelijker profiel 
in vergelijking met controle vrouwen. Er werd vermoed dat quercetine zijn effecten 
uitoefende via de regulatie van de androstene of Ah receptor (58). Inderdaad, AhR gen 
expressie was licht verhoogd in vrouwelijke muizen die prenataal blootgesteld waren 
aan quercetine. 
Gen expressie van fase I en II enzymen toonde een ander profiel in de longen van 12 
weken oude muizen die prenataal blootgesteld waren aan quercetine. In dit geval was 
de  gen  expressie  van  de  fase  II  enzymen (Gstp1, Nqo1 and Ugt1a6)  verhoogd.  Het  feit  
dat beide weefsels anders reageren op prenatale blootstelling aan quercetine kan 
verklaard worden doordat de longen zich voornamelijk ontwikkelen tijdens de laatste 
fase van de zwangerschap en zelfs nog verder ontwikkelen na de geboorte (68), terwijl 
de lever grotendeels gevormd is voor de geboorte (69). De minder aanwezige 
geslachtseffecten in de long kunnen ook het gevolg zijn van de minder belangrijke rol 
die de long speelt in het metabolisme van oestrogeen. Desondanks vertoonden de 
foetussen op dag 14,5 van de dracht wel een toename in Nqo1 en Ugt1a6 gen expressie, 
waarvan wij vermoeden dat dit het resultaat was van de activering van het Nrf2-
pathway, aangezien quercetine ook als pro-oxidant kan werken (Hoofdstuk 4). Aangezien 
de long blootgesteld wordt aan hogere zuurstof concentraties in vergelijking met andere 
weefsels (33) kan een preventieve oxidatieve stress stimulus in utero resulteren in de 
verhoogde expressie van de Nrf2-pathway en zo ook van de fase II enzymen. Maar, zoals 
hierboven aangegeven, was het Nrf2-pathway slechts matig geïnduceerd in de longen van 
muizen die prenataal blootgesteld waren aan quercetine (Hoofdstuk 4). 
Hoewel prenatale blootstelling aan quercetine resulteerde in een verhoogde expressie van 
fase I en II enzymen in lever en longen, werden er slechts enkele veranderingen 
teruggevonden in het ex vivo B[a]P metabolisme van de longen van muizen die prenataal 
blootgesteld werden aan quercetine. Dit was zichtbaar als een afname in B[a]P-9,10-
dihydrodiol en B[a]P-7,8-dihydrodiol. Bovendien hadden muizen die prenataal 
blootgesteld waren aan quercetine een verhoogd B[a]P metabolisme. Omwille van de 
hoge detoxificatie van B[a]P tot 3-hydroxy-B[a]P konden er echter geen BPDE-
geïnduceerde DNA-adducten gedetecteerd worden in geval van alle 3 de dieetgroepen. 
Aangezien de long het doelorgaan is voor vluchtig B[a]P zou de toename in B[a]P 
metabolisme en fase II gen expressie erop kunnen wijzen dat prenatale blootstelling aan 
quercetine de gevoeligheid voor het ontwikkelen van longkanker in vivo kan verminderen. 
In de lever was verrassend genoeg te zien dat ex vivo inductie van BPDE DNA-adducten 
verminderd was wanneer muizen prenataal blootgesteld waren aan quercetine. 
Desondanks was er geen verandering in de snelheid waarmee B[a]P gemetaboliseerd 
werd of in het profiel van de 3 belangrijkste B[a]P metabolieten, waaronder de 7,8-
dihydrodiol van B[a]P wat een voorloper is van de uiteindelijke genotoxische metaboliet 
BPDE. Dit wijst erop dat prenatale blootstelling aan quercetine resulteert in de 
bescherming tegen B[a]P geïnduceerde DNA schade in de lever, waarschijnlijk door een 
verhoogde expressie van fase I enzymen. Ondanks dat CYP1A1 en CYP1B1 belangrijk zijn 
voor  de  activering  van  B[a]P,  vermoeden  wij  dat  ze  ook  bijdragen  aan  B[a]P  
detoxificatie, wat voorheen ook voorgesteld werd door Uno et al. (70). 
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Foetale programmering wordt gereguleerd via epigenetica 
De verandering in gen expressie ten gevolge van in utero blootstelling aan genisteïne of 
quercetine, besproken in Hoofdstuk 3-6, werd behouden doorheen het leven van de 
muis. Wij vermoeden dus dat epigenetische mechanismen betrokken zijn. Daarom 
werden in dit onderzoek de veranderingen in methylatie status van repetitieve 
elementen ten gevolge van prenatale blootstelling aan genisteïne en quercetine 
nagegaan, aangezien het muizen genoom voor 37,5 % uit repetitieve elementen bestaat 
(71). De resultaten toonden aan dat beide flavonoïden geen veranderingen in globale 
methylatie (namelijk methylatie van SINEB1, SINEB2, LINE1, IAP, major en minor 
satellieten) veroorzaakten in de lever van foetussen op dag 14,5 van de dracht 
(Hoofdstuk 3, 5,  6). Wanneer echter het methylatie patroon van het beenmerg van 12 
weken oude muizen onderzocht werd, was een algemene toename in methylatie 
zichtbaar, vooral in geval van SINEB1 en SINEB2, wanneer muizen prenataal blootgesteld 
waren aan genisteïne of quercetine (Hoofdstuk 3, 5).  In  lever  en  long  weefsel  van  12  
weken oude muizen die prenataal blootgesteld waren aan genisteïne of quercetine 
bleken de repetitieve elementen SINEB1, SINEB2 en LINE1 licht gehypomethyleerd te 
zijn (Hoofdstuk 6). Het feit dat er nog geen verandering in methylatie vastgesteld kon 
worden in foetussen op dag 14,5 van de dracht kan betekenen dat de novo methylatie 
veroorzaakt door flavonoïden op een later tijdstip in de dracht of zelfs na de geboorte 
pas plaatsvindt. Dit is aannemelijk aangezien tijdens de laatste fase van de dracht en 
tijdens de vroege postnatale periode weefsel maturatie plaatsvindt, waardoor 
epigenetische modificaties plaatsvinden. Bovendien wordt beweerd dat transcriptionele 
inactivatie de novo methylatie aantrekt, terwijl transcriptionele activitie de novo 
methylatie kan uitschakelen, met het laatste resulterend in hypomethylatie tijdens de 
foetale ontwikkeling (72). Daarbij neemt het niveau van blootstelling aan genisteïne en 
quercetine ook enkel toe doorheen de dracht, waardoor hun effect enkel versterkt wordt. 
Eerder is al aangetoond dat prenatale blootstelling aan genisteïne de gen expressie kan 
veranderen door het methylatie patroon te beïnvloeden. Meer bepaald gele agouti 
muizen die prenataal blootgesteld waren aan genisteïne vertoonden een verandering in 
vachtkleur en lichaamsgewicht doordat een repetitief element stroomopwaarts van de 
transcriptie start site van het Agouti gen  gehypermethyleerd  was  (31).  Daarbij  is  voor  
zowel genisteïne als quercetine aangetoond dat ze in staat zijn DNA methyltransferases 
te remmen om zo hypomethylatie te veroorzaken, meer bepaald van 
gehypermethyleerde tumor suppressor genen, waaraan hun beschermend effect tegen 
kanker ook wordt toegeschreven (73, 74).  Er is  echter ook een weefsel effect zichtbaar 
wat de methylatie betreft. Hypermethylatie komt voor in het geval van het beenmerg 
terwijl de lever en long hypomethylatie ondergaan, met name de SINE transcripten. In 
het begin van de embryogenese worden SINE en LINE repetitieve elementen normaal 
uitgedrukt, waarna hun expressie snel afneemt. Naderhand wordt de expressie van 
SINEB1, SINEB2 en LINE1 geassocieerd met cellulaire stress. Dit kan veroorzaakt worden 
door DNA beschadigende stoffen (75, 76) zoals genisteïne en quercetine, aangezien zij 
een topoïsomerase II remmende werking hebben, wat aangetoond werd in Hoofdstuk 2. 
Aangezien SINE en LINE expressie geassocieerd is met kanker (75, 76) kan dit betekenen 
dat een flavonoïden stimulus in utero SINEB1,  SINEB2  en  LINE1  expressie  kan  
onderdrukken om zo te beschermen tegen genoom instabiliteit op latere leeftijd.  
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Implicaties en verder onderzoek 
Omdat dit slechts het begin is van inzicht te verkrijgen in hoe genisteïne en quercetine 
inname door de moeder een effect kan hebben op het risico van de nakomelingen om 
kanker te ontwikkelen op latere leeftijd, moeten verdere studies uitgevoerd worden: 
x Betreffende het epigenetische mechanisme dat betrokken is bij de genisteïne 
en quercetine veroorzaakte foetale programmering. De ‘critical window’ van de 
blootstelling moet achterhaald worden.  
x Ondanks dat genisteïne en quercetine beide flavonoïden zijn, oefenen ze toch 
verschillende effecten uit. Daarom moet hun specifieke werking verder 
onderzocht worden.  
x Als  de  muizen  12  weken  oud  zijn,  lijkt  het  alsof  prenatale  blootstelling  aan  
genisteïne en quercetine over het algemeen voordelige effecten heeft 
veroorzaakt ten opzichte van de gevoeligheid voor kanker. Deze muizen zijn 
echter nog relatief jong, waardoor de werkelijke bijdrage van de aanpassingen 
gemaakt  door  de  foetus  als  reactie  op  de  in utero blootstelling aan genisteïne 
en quercetine misschien nog niet zichtbaar zijn op deze leeftijd. Daarom dat 
toekomstige studies op oudere muizen uitgevoerd moeten worden. Onderzoek 
naar het effect van foetale programmering zou ook op latere leeftijd moeten 
gebeuren, wanneer deze muizen te maken krijgen met chronische ziektes. Deze 
chronische ziektes zouden ook geïnduceerd kunnen worden aan de hand van 
pro-inflammatoire stimuli.  
x Het zou ook interessant zijn te kijken naar het effect van levenslange 
blootstelling aan genisteïne en quercetine met betrekking tot de gevoeligheid 
voor het ontwikkelen van kanker. 
x Het zou ook waardevol zijn te kijken naar het effect van prenatale blootstelling 
aan genisteïne en quercetine in volgende generaties. Echter, om de werkelijke 
erfelijkheid te bepalen, zou de derde generatie, de eerste niet blootgestelde 
generatie, onderzocht moeten worden. De eerste generatie is namelijk direct 
blootgesteld geweest aan genisteïne of quercetine, terwijl de tweede generatie 
ontstaat uit voortplantingscellen die blootgesteld zijn aan genisteïne of 
quercetine (Figuur 1).  
 
 
 
 
 
 
 
 
 
 
 
Figuur 1. Overzicht van hoe de effecten geïnduceerd door genisteïne of quercetine blootstelling overgeërfd  
kan worden door volgende generaties.  
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Wanneer alle resultaten beschreven in deze thesis opgesomd worden, kan geconcludeerd 
worden dat prenatale blootstelling aan quercetine en genisteïne de foetale programmering 
veranderd in vergelijking met een niet-gesupplementeerd dieet tijdens de zwangerschap. 
Tijdens de dracht, wanneer de foetussen direct blootgesteld zijn aan flavonoïden, treden 
veranderingen op in de gen expressie van genen die betrokken zijn bij het antioxidante 
verdedigingssysteem en bij het carcinogeen metabolisme. Dit doet vermoeden dat 
foetussen zich aanpasten aan de in utero omgeving. Eens geboren viel de blootstelling aan 
genisteïne en quercetine weg. Sommige veranderingen in gen expressie bleven echter 
behouden tot op volwassen leeftijd, terwijl andere verkregen werden doorheen het leven, 
wat erop wijst dat de nakomelingen zich probeerden aan te passen aan de nieuwe 
‘onverwachte’ omgeving. 
Op de leeftijd van 12 weken lijkt het dat prenatale blootstelling aan genisteïne en 
quercetine voordelig blijkt te zijn, aangezien de muizen minder oxidatieve stress 
geïnduceerde DNA schade hadden ten gevolge van een verhoogde enzymatische 
antioxidante verdedigingssysteem en omdat ze op een meer efficiëntere manier ijzer 
opsloegen. Het lijkt ook dat ze onder deze condities beter overweg konden met B[a]P 
geïnduceerde DNA schade door de verhoogde expressie van fase I en II enzymen. Daarbij 
vertoonden deze muizen ook een verhoogde methylatie van bepaalde repetitieve 
elementen dat erop wijst dat deze dieren meer beschermd waren tegen genoom 
instabiliteit, waardoor ze minder gevoelig leken voor het ontwikkelen van kanker. Aan de 
andere kant veroorzaakte prenatale blootstelling aan genisteïne en quercetine ook Mll 
translocaties waardoor het risico op leukemie verhoogd was, zeker voor muizen met een 
beperkt DNA herstel. Daarbij was ook de basale expressie van een aantal inflammatoire 
cytokines verhoogd, wat de inflammatoire respons kan beïnvloeden. 
Een algemeen overzicht van het effect van prenatale blootstelling aan genisteïne en 
quercetine op het risico voor de nakomeling om kanker te ontwikkelen, wordt 
weergegeven in Figuur 2. 
 
 
 
 
 
 
 
 
 
 
 
Figuur 2. Algemeen overzicht van het effect van prenatale blootstelling aan genisteïne en quercetine op het 
risico voor de nakomelingen om kanker te ontwikkelen beschreven in deze thesis.  
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